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Abstract 
Medulloblastomas are the most common solid malignant childhood brain tumour. 
Integrated genomic data has identified four distinct medulloblastoma sub-groups (Wnt, 
Shh, Group 3 and Group 4), which have different characteristic genetic abnormalities, and 
result in different clinical outcomes. Group 3 has the poorest prognosis, is the most 
frequently metastatic and characteristically over-expresses c-Myc. Lactate dehydrogenase 
A, known for its key role in metabolic functions, is a downstream target of c-Myc and 
HIF1α.  I hypothesised LDHA inhibition would result in a decrease in lactate concentrations 
and a change from a glycolytic to an oxidative phosphorylation metabolic phenotype, 
leading to decreased medulloblastoma viability, proliferation and motility.  
I found that LDHA expression was significantly elevated in Group 3 medulloblastomas. 
Furthermore I showed that oxamate (a structural analogue of pyruvate) significantly 
inhibited medulloblastoma cell line LDHA activity, lactate production, aerobic glycolysis, 
proliferation and motility under normoxic and hypoxic conditions (1% O2) and also 
upregulated oxidative phosphorylation under normoxic conditions. Additionally, at low 
concentrations, oxamate inhibited LDHA activity and lactate production in the non-
neoplastic paediatric astrocyte cell line CC2565 but it had no significant effects on the 
amount of viable, metabolically active cells or their motility under normoxic or hypoxic 
conditions. Despite showing 80% LDHA knockdown, our LDHA siRNA transfections did not 
have any significant downstream effects on MB cell line metabolism, growth or motility. 
Unfortunately our studies are inconclusive as to whether LDHA alone is a suitable 
therapeutic target for medulloblastoma. Oxamate may inhibit multiple LDH family 
members or >80% LDHA knockdown may be required. The results of further investigations 
will be critical as LDHA may prove to be an inadequate target for MB and a broader LDH 
family inhibitor or lactate inhibitor may be more appropriate. However these studies, 
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combined with extensive research into the literature, support the concept and provide 
proof of principle that targeting aerobic glycolysis and lactate production in 
medulloblastoma is worthwhile therapeutic avenue worth pursuing further. 
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GSK3β  Glycogen synthase kinsase 3 beta 
HBSS  Hanks' balanced salt solution 
HIF  Hypoxic inducible factor 
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HK2  Hexokinase 2 
HLRCC  Hereditary leiomyomatosis and renal cell cancer 
ICC  Immunocytochemistry 
IDH  Isocitrate dehydrogenase 
IHC  Immunohistochemistry 
IMT-1  Immature thymocyte antigen-1 
IPA  Isopropanol 
KATP  Potassium adenosine triphosphate 
LCA  Large-cell anaplastic 
LDH  Lactate dehydrogenase 
LDHA  Lactate dehydrogenase A 
LDHB  Lactate dehydrogenase B 
LDHC  Lactate dehydrogenase C 
LDHD  Lactate dehydrogenase D 
LEF  Lymphoid enhancer-binding protein 
LRP  Low-density lipoprotein receptor-related protein 
MAPK  Mitogen activated protein kinase 
MB  Medulloblastoma 
MBEN  Medulloblastoma with extensive nodularity 
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MCT1  Monocarboxylate transporter 1  
MMP  Matrix metalloproteinase 
M-PER  Mammalian protein extraction reagent 
MRI  Magnetic resonance imaging 
NAC  N-acetyl-l-cysteine 
NAD  Nicotinamide adenine dinucleotide 
NADPH  Nicotinamide adenine dinucleotide phosphate 
NDPK-A Nucleoside diphosphate kinase A 
NHS  National health service 
NK  Natural killer 
NKG2D  Natural-killer group 2, member D 
NQO1  NAD(P)H dehydrogenase [quinone] 1 
NSC  Neural stem cell 
OCA-S  Oct-1 coactivator S 
OXPHOS Oxidative phosphorylation 
PAGE   Polyacrylamide gel electrophoresis 
PCR  Polymerase chain reaction 
PES  Phenazine ethosulfate 
PBS  Phosphate buffer saline 
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PDGF  Platelet derived growth factor 
PDGFRB Platelet derived growth factor receptor B 
PDK1  Pyruvate dehydrogenase kinase, isozyme 1 
PFA  Paraformaldehyde 
PGC-1α  Peroxisome proliferator-activated receptor-gamma coactivator- 1 alpha 
PLGA  Poly-D, L-lactide-co-glycolide 
pHe  Extracellular pH 
PI3K  Phosphatidylinositol-4, 5-bisphosphate 3-kinase 
PPARγ  Peroxisome proliferator-activated receptor gamma 
Ptc  Patched 
Rb  Retinoblastoma protein 
RCF  Relative centrifugal force 
rhEGF  Recombinant human epidermal growth factor 
RNA  Ribonucleic acid 
ROS  Reactive oxygen species 
RPM  Revolutions per minute 
SEM  Standard error mean 
Ser  Serine 
SHH  Sonic hedgehog 
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shRNA  Small hairpin ribonucleic acid 
siRNA  Small interfering ribonucleic acid 
SIRT  Sirtuin 1 
Smo  Smoothened 
SNCAIP  Synuclein alpha interacting protein 
ssRNA  Single stranded ribonucleic acid 
STR  Short tandem repeat 
Sufu  Suppressor of fused homolog 
T  Thymine 
TBS  Tris-buffered saline 
TBST  Tris-buffered saline and tween 20 
TCF-4  T-cell factor 4 
TGF-β2  Transforming growth factor beta 2 
THBS-1  Thrombospondin 1 
TNFα  Tumour necrosis factor alpha 
U  Uracil 
uPA  Urokinase plasminogen activator 
uPAR  Urokinase plasminogen activator receptor 
VEGF  Vascular endothelial growth factor 
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WB  Western blot 
WHO  World health organisation 
WNT  Wingless 
WT  Wild type  
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Chapter 1: Introduction 
1.1 LDHA 
A review, “The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential 
in Brain Tumour”, was published in Brain Pathology 1 and constitutes much of this initial 
introductory review component of the thesis. 
 
1.1.1 Lactate dehydrogenase (LDH) 
Lactate dehydrogenase is a tetrameric metabolic enzyme, belonging to the 2-hydroxy acid 
oxidoreductase family, which increases the rate of the simultaneous inter-conversion of 
pyruvate to lactate and nicotinamide adenine dinucleotide (NAD)H to NAD+ by 14 orders of 
magnitude 2 (Figure 1.1). The reaction involves the transfer of a hydride ion from NADH to 
the C2 carbon of pyruvate 3 and is commonly used by cells for anaerobic respiration. There 
are four LDH genes: LDHA, LDHB, LDHC (Figure 1.2) and LDHD. LDHA, LDHB and LDHC are 
isoenzymes which use or produce L-lactate, the major enantiomer found in vertebrates, 
whereas LDHD acts on or produces the D-isomer of lactate. 
 
Figure 1.1 The reaction catalysed by LDH. 
LDH catalyses the reversible conversion of 
pyruvate and NADH to lactate and NAD+ 
respectively. 
 
The human LDHA gene is located on chromosome 11p15.4, the transcribed protein is the 
inactive M subunit  which has 332 amino acids, a predicted molecular weight of 37 kDa and 
24 splice variants; the human genome also contains several non-transcribed LDHA 
pseudogenes 4,5. Evolutionarily, LDHA and LDHB are thought to have arisen from the 
31 
 
duplication of a single LDHA-like LDH gene 6. LDHC, a testes-specific gene, is also thought to 
have evolved in mammals from the duplication of the LDHA gene after the A-B duplication 
6.  
 
  
 Figure 1.2 LDH homo- and tetramer formation 
The LDH isoenzymes LDH-1, LDH-2, LDH-3, LDH-4 and LDH-5 are made up of different ratios 
of LDH-M and LDH-H subunits, transcribed from LDHA and LDHB respectively. The LDHC 
tetramer is only made up of LDHC subunits. 
 
The product of the LDHA gene is known as the M subunit as it is predominantly found in 
skeletal muscle, while the product of the LDHB gene is known as the H subunit as it is 
predominantly found in the heart. Four LDH subunits assemble randomly to create an 
active LDH enzyme. Unlike the other LDH genes, which can form only homo-tetramers, 
LDHA and LDHB can form homo- or hetero-tetramers. There are five isoenzymes of LDH 
which can be made from the M and H subunits: LDH-1 (4H), LDH-2 (3H, 1M), LDH-3 (2H, 
2M), LDH-4 (1H, 3M), and LDH-5 (4M) (Figure 1.2). LDH-1 and LDH-5 have identical active 
site regions and only differ in 81 out of 332 amino acid positions, most of which are found 
in the first 22 and last 38 residues and have a minimal effect on the overall structure 7. The 
N-terminus of LDHA is important for structural stability as deletion of up 10 amino acids 
from the N-terminus increases instability, flexibility, inactivity and sensitivity to denaturing 
environments 8. Although structurally they are very similar, each LDH isoenzyme has 
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different kinetic properties and studies suggest that their distinct kinetics are due to 
differences in charged surface residues bordering the active site 7. Each LDHA subunit has a 
net charge of -6 and a higher affinity for pyruvate, preferentially converting pyruvate to 
lactate and NADH to NAD+ whereas each LDHB subunit has a net charge of +1 and a higher 
affinity for lactate, preferentially converting lactate to pyruvate and NAD+ to NADH 7,9.  
 
1.1.2 The role of LDHA in cellular metabolism 
Under normal physiological conditions, pyruvate is generated from glucose by glycolysis 
and enters the citric acid cycle in the mitochondria where it is oxidatively decarboxylated to 
form acetyl-CoA which is used to fuel oxidative phosphorylation, theoretically generating 36 
net adenosine triphosphate (ATP) per molecule of glucose. However when oxygen becomes 
scarce, cells are unable to use oxidative phosphorylation to efficiently generate ATP. In this 
scenario glycolysis becomes the main generator of ATP, producing 2 net ATP per molecule 
of glucose. However, NAD+ is required to enable the sixth step of glycolysis as 
glyceraldehyde phosphate dehydrogenase (GAPDH) uses NAD+ to convert glyceraldehyde 3-
phosphate (GADP) to D-1, 3-bisphosphoglycerate (1, 3BPG). NAD+ is usually regenerated 
through oxidative phosphorylation by the electron transport chain, so when the oxygen 
supply is restricted NAD+ is regenerated from NADH by LDHA in order to maintain glycolysis, 
generating lactate as a by-product; this is known as anaerobic glycolysis (Figure 1.3). 
Although it is less efficient, anaerobic glycolysis is 100 times faster than oxidative 
phosphorylation enabling it to fulfil the short term energy requirements in the absence of 
sufficient oxygen at the expense of a greater consumption of glucose.  
 
Different tissues in the body have different metabolic rates, energy requirements and 
functions which are often reflected in their LDHA: LDHB ratio. For example, approximately 
40% of lactate in the circulation is released by skeletal muscle whereas the liver and kidneys 
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predominantly absorb lactate from the circulation and oxidise it to synthesise glucose 10. 
Brain metabolism is clearly complex as it responds dynamically to changes in blood glucose 
and lactate concentrations. A study of six normal physically active males found that at rest 
the brain oxidises approximately 10% of blood L-lactate, fuelling 8% of cerebral energy 
requirements, but still releases a small amount of net L-lactate 11. However in response to 
physical exertion and hyperlactatemia, the brain takes up net L-lactate 11,12 which 
contributes up to 60% of brain metabolism with cerebral lactate oxidation thought to use 
33% of lactate 10,12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Anaerobic glycolysis.  
LDHA is required to maintain glycolysis and ATP production in the absence of sufficient 
oxygen by regenerating NAD+ form NADH. Lactate is generated as the end by-product of 
this reaction. The reaction consumes 2 ATP but creates 4 ATP, generating 2 net ATP per 
molecule of glucose. 
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Cancer cell metabolism is modified when compared with that of normal cells and is known 
as the Warburg effect or aerobic glycolysis, first observed by Otto Warburg in the 1920s 13. 
Cancer cells use LDHA to elevate the rate of glycolysis, and ATP and lactate production even 
when oxygen is available 14. Studies suggest the switch to an aerobic glycolysis metabolic 
phenotype benefits cancer cells by avoiding generation of oxidative stress by the electron 
transport chain 15. Furthermore by using aerobic glycolysis to generate ATP, cancer cells can 
use other metabolites (intermediates and products of reactions catalysed by metabolic 
enzymes) in anabolic reactions to synthesise the lipids, fatty acids and nucleotides required 
for rapid cell proliferation 16,17. In contrast to oxidative phosphorylation (OXPHOS), the 
intermediates of the citric acid cycle are not utilised for ATP production but instead used for 
rapid biosynthesis 16,17. As discussed in previous reviews, this abnormal metabolism used by 
cancer cells is an attractive target for cancer-specific therapies 18,19. Numerous metabolic 
enzymes, which catalyse the reactions in metabolic pathways, have been investigated as 
therapeutic targets for cancer 20. The advantage of LDHA as a therapeutic target is that it is 
not implicated in OXPHOS, meaning inhibition of LDHA activity would have minimal impact 
on the metabolism of non-neoplastic cells. 
 
1.1.3 Regulation of LDHA synthesis 
The LDHA promoter region has long been known to contain the consensus sequences for, 
and be regulated by, major transcription factors; hypoxia-inducible factor 1 (HIF1) and c-
Myc 21-24. More recently, forkhead box protein M1 (FOXM1) 25 and Kruppel-like factor 4 
(KLF4) 26 were identified as transcriptional regulators of LDHA, however LDHA regulation is 
complex and far from completely understood. LDHA transcription is also known to be 
influenced by many factors including lactate 27, Cyclic adenosine monophosphate (cAMP) 28, 
estrogen 29, ErbB2 and heat shock factor 1 30 and is likely to be influenced by other 
unknown factors (Table 1.1). 
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Table 1.1 List of genes and proteins reported to regulate LDHA 
Gene/ protein Mechanism of LDHA regulation Reference 
HIF1 Transcription regulation of LDHA 21,22 
C-Myc Transcription regulation of LDHA 23,24 
FOXM1 Transcription regulation of LDHA 25 
KLF4 Transcription regulation of LDHA 26 
cAMP Transcription regulation of LDHA 28 
Estrogen Transcription regulation of LDHA 29 
ErbB2 Transcription regulation of LDHA 30 
Heat shock factor 1 Transcription regulation of LDHA 30 
FGFR1 Post transcriptional regulation of LDHA 31 
SIRT2 Post transcriptional regulation of LDHA 32 
 
 
HIF1α is the alpha subunit of transcription factor HIF1 which is usually degraded under 
normoxic conditions by prolyl hydroxylase. However under hypoxic conditions HIF1α is 
stabilised and forms the HIF1 transcription factor with the constitutively expressed subunit 
HIF1β. HIF1 promotes the transcription of target genes involved in metabolism (including 
LDHA), angiogenesis and apoptosis, which support cell survival in hypoxic environments. 
However HIF1α is also often stabilised in cancers, including brain tumours 33, by other 
factors such as over-expression of  pyruvate kinase isozymes M2 (PKM2), Ras, Proto-
oncogene tyrosine-protein kinase Src and ErbB2 and constitutive activation of the 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3k)/ Protein kinase B (Akt) / mammalian 
target of rapamycin (mTOR) pathway 34,35. Furthermore, over-expression of HIF1α is 
associated with LDHA over-expression and a significantly poorer survival in some cancers 
36,37. Promotion of LDHA transcription by HIF1 has also been shown to be enhanced when 
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cAMP binds to the cAMP response element (CRE) in the LDHA promoter region 21. However, 
LDHA regulation by HIF1 is clearly complex as studies have shown that LDHA creates a 
positive feedback loop, up-regulating HIF1α expression under normoxic conditions, by 
enhancing lactate production, which inhibits prolyl hydroxylase 27. On the other hand, 
studies in HT29 cells have shown HIF1α expression was up-regulated more in LDHA 
knockdown clones than control clones under hypoxic conditions, but unusually they also 
found that the up-regulation of HIF1α in the LDHA silenced clones did not correlate with 
the expression of other HIF1 regulated genes; Carbonic Anhydrase IX (CAIX) and vascular 
endothelial growth factor (VEGF) 38.   
 
The c-Myc proto-oncogene is known as a “master regulator” as it regulates many key cell 
processes including cell cycle, growth, proliferation and apoptosis and is usually tightly 
controlled. For example, during exercise, c-Myc expression and therefore LDHA expression 
is down-regulated by peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α) 
in oxidative muscle fibres, to promote lactate uptake and lactate oxidation to maintain 
lactate homeostasis 39. However, c-Myc expression is often upregulated in brain tumour 
cells, including the most metastatic subgroup of medulloblastoma (MB) (group 3) 40, and 
has been shown to transform rat fibroblasts by up-regulating LDHA 23,24. LDHA has also been 
shown to cooperate with Rcl, another c-Myc target gene of unknown function, to induce 
anchorage-independent cell growth in vitro and to induce tumour formation in vivo 41. The 
over-expression of c-Myc can also enhance LDHA expression by promoting HIF1α 
stabilisation under normoxic conditions and enhancing HIF1α expression under hypoxic 
conditions. Again, the regulation of LDHA by c-Myc is not straight-forward; studies in gastric 
cancer suggest LDHA may be involved in a negative feedback loop, since inhibition of LDHA 
increases c-Myc expression 42. Although HIF1 and c-Myc have long been known to be LDHA 
transcription factors there are still many aspects which are unclear and the precise 
37 
 
mechanism in which they work and how their transcription of LDHA is regulated should 
continue to be actively investigated. 
 
Recent studies have found that LDHA is also transcriptionally regulated by FOXM1 25. 
FOXM1 is an oncogenic transcription factor elevated in many types of cancer and is known 
to regulate the cell cycle, invasion, metastasis and angiogenesis 43,44. Cui et al (2014) 
conducted studies that demonstrated that FOXM1 binds to the LDHA promoter region, up-
regulates LDHA mRNA transcription, LDHA protein expression, glucose consumption and 
lactate production 25. Furthermore, inhibition of LDHA activity diminished the enhanced 
glucose consumption and lactate production effects of FOXM1 over-expression while in vivo 
studies established that up-regulation of FOXM1 promoted LDHA expression, cancer 
growth and metastasis 25. Another recent study on tissue and cell lines found LDHA 
expression was significantly positively correlated with pancreatic tumour progression and 
de-differentiation, whereas KLF4, a transcription factor normally expressed in terminally 
differentiated epithelial cells, was significantly negatively correlated 26. Further examination 
found that KLF4 suppression significantly increased LDHA expression whereas KLF4 over-
expression significantly inhibited aerobic glycolysis,  tumour growth and LDHA expression 
both in vitro and in vivo 26. Shi et al (2014) went on to find two KLF4 binding sites between -
371 and -367 bp, and -1310 and 1306 bp of the LDHA promoter region 26. These recent 
studies show promise and it would be interesting to see if the results are corroborated in 
different tissues, including brain tumours, as FOXM1 is a marker of poor prognosis in MB 45 
and regulates glioma tumourigenicity 46. KLF4 is also suppressed in MB 47 and mutated in 
meningioma 48. 
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1.1.4 Post-translational regulation of LDHA 
Like many enzymes, LDHA post-translational activity is regulated by phosphorylation and 
acetylation of amino-acid residues. The oncogenic receptor tyrosine kinase FGFR1, 
expressed in meningioma and glioma 49, has been shown to directly phosphorylate LDHA at 
Y10 and Y83 31. Y10 phosphorylation of LDHA, which is common in many human cancers, 
promotes active, tetrameric LDHA formation whereas phosphorylation of Y83 promotes 
NADH substrate binding 31. Recently, Zhao et al (2013) have also shown that deacetylation 
of LDHA at lysine-5 is regulated by SIRT2 deacetylase in pancreatic cancer 32. Furthermore, 
they found that the acetylation of LDHA at K5 lead to degradation of LDHA and proposed 
that it was caused by chaperone-mediated autophagy (CMA) through interaction with 
HSC70 chaperone and lysosomes 32. Continued research on the mechanism of LDHA 
deactivation and degradation could aid in the development of novel therapeutic agents. 
 
LDHA has many other roles in non-neoplastic and neoplastic cells which are described in 
detail in the following text and summarised in Figure 1.4. The genes highlighted in the text, 
which have been reported to be associated with the function of LDHA, have also been 
compiled in Table 1.2. Most of the research into the function of LDHA has been 
demonstrated in non-Central Nervous System (CNS) tumours, some of which commonly 
metastasise to the brain, however links to primary CNS tumours will also be a focus in this 
review.  
 
1.1.5 The role of LDHA in the cell cycle 
It has been known since the 1960s that LDH expression fluctuates as cells progress through 
the cell cycle 50,51. In 1991 Pan et al found that LDHA expression in normal human T and B 
lymphocytes increases when the cells are activated and proliferating, demonstrating that 
LDH isoenzymes can be used as proliferative markers 52. They also observed that LDHA 
39 
 
expression intensity was at its greatest level when majority of T and B lymphocytes were in 
S/G2/M phase and that LDHA expression decreased as the cells returned to their resting 
state 52. LDH has since been used as a marker of cell proliferation and mobilisation of CD34+ 
cells for stem cell apheresis 53,54. More recent studies have begun to clarify the role of LDHA 
in the cell cycle. For example,  inhibition of LDHA activity induced G2/M cell cycle arrest by 
down-regulating the CDK1/cyclin B1 pathway in cell lines 55, while  S-phase transition was 
significantly induced by over-expression of LDHA 56. The mechanism by which LDHA affects 
the cell cycle warrants additional exploration. 
 
1.1.6 LDHA as a transcription factor 
In the 1980s it was reported that although LDHA is predominantly found in the cytoplasm, it 
is also localised in the nucleus of many tumours and binds to ssDNA and mRNA 36,57-60. Pioli 
et al (2002) showed that LDHA specifically binds to the AU-rich element of GM-CSF 
(granulocyte-macrophage colony-stimulating factor) RNA and interacts directly with AUF1 
(a regulator of mRNA) 60. Furthermore, LDHA has been shown to up-regulate DNA synthesis 
catalysed by the DNA polymerase-α complex up to fivefold 61 and bind translationally active 
RNA in polysomes 60. LDHA with tyrosine phosphorylation has also been reported as 
localised to the nucleus, suggesting tyrosine phosphorylation may play an essential role in 
LDHA function in the nucleus 62. Together these studies suggest LDHA has a role in 
transcription, but the mechanism is still unclear and few specific targets have been 
identified. Although most of these studies were conducted over two decades ago, their 
importance must not be forgotten and should be investigated in more depth using modern 
technologies. 
 
L-LDH is critical in the organisation of the Oct-1 coactivator S (OCA-S) transcription complex 
which regulates S-phase histone 2B (H2B) transcription in a NADH/NAD+ dependent manner 
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63-65. The OCA-S complex was sensitive to cellular redox levels as H2B transcription 
decreased when NAD+ was depleted 63. Redox status and therefore metabolic status could 
be linked to gene switching, a mechanism that is commonly seen in prokaryotes and 
requires further exploration in relation to human DNA transcription. Collectively these 
studies suggest one way in which LDHA could regulate transcription is through regulating 
the cellular redox state. However, these studies have not specifically identified whether 
LDHA or LDHB is involved predominantly; or whether they have different enzymatic 
influences on the OCA-S transcription complex.  
 
 
Figure 1.4 Schematic showing processes that are reportedly affected by LDHA. 
LDHA transcription is regulated by the genes and proteins listed in Table 1.1. LDHA has 
been reported to be involved with the processes listed in the orange box. LDHA has also 
been reported to indirectly influence the processes listed in the red box via aerobic 
glycolysis and lactate production. 
 
1.1.7 Other roles of LDHA  
LDHA has been shown to be an integral part of the sarcolemmal ATP-sensitive K+ (KATP) 
channel in the heart, associating with the KATP channel subunits, SUR2A and Kir6.2, at the 
C-terminus and N-terminus respectively. KATP channels are closed in response to high 
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intracellular ATP but open during ischemia to prevent apoptosis. The generation of lactate 
by LDHA during ischemia allows the channel to open in the presence of ATP, protecting the 
cell from death due to calcium accumulation 66. In this way LDHA is able to couple KATP 
channel activity with the metabolic status of the cell and protect against cell death by 
ischemia. Interestingly, KATP channel expression is elevated in glioma and studies have 
shown that inhibition of KATP channels resulted in decreased glioma cell proliferation 67. 
The same group went on to discover that LDHA is part of the Nucleoside Diphosphate 
Kinase - A (NDPK-A) isoform of the liver cytosolic substrate channelling complex 68. 
Furthermore, they found that LDH also has a role in regulating the activity of the liver 
cytosolic substrate channelling complex in response to the metabolic status of the cell. 
Knockdown of LDHA and LDHB revealed that LDHA up-regulates the activity of AMPK and 
CK2, other components of the substrate-channelling complex, whereas LDHB inhibits their 
activity 68. Together these studies show how LDHA plays a critical role in the regulation of 
channel complexes in the heart and liver in response to the metabolic status of the cell. It is 
possible that LDHA could play similar roles in many other channel complexes. Other roles of 
LDHA also includes acting as a molecular chaperone or as an association molecule during 
the differentiation of thymocytes 69.  
 
1.1.8 LDHA in the brain and cerebral spinal fluid 
The brain is a very complex organ with high energy needs which change over a lifespan. 
Studies have shown that the human brain uses high levels of aerobic glycolysis during foetal 
growth and development, which increases during childhood, but then switches to oxidative 
phosphorylation which is seen predominantly in the adult brain 70. The ratios of LDHA to 
LDHB, which determine either aerobic glycolysis or oxidative phosphorylation, were 
examined in human foetuses at different stages of gestation. They found that LDHB 
expression decreased from 18% at 16 weeks to 15% at 40 weeks, compared to 23% in adult 
42 
 
brains. LDHA Increased from 8% at 16 weeks to 16% at 40 weeks, compared to 6 % in adult 
brains 71. More recent studies have examined the distribution of LDHA and LDHB within 
various regions of the brain. Studies in mouse and rat brains showed that LDHB mRNA 
expression was predominant throughout the brain with the exception of strong LDHA 
expression in the hippocampal regions CA1, CA2 and CA4, the ventromedian hypothalamic 
nucleus, and the dorsal raphe nucleus as well as moderate expression in the cerebral cortex 
72,73. Moreover, a study of 33 neurologically normal young adults using MRI and PET scans 
found that aerobic glycolysis was significantly elevated in a few regions, particularly the 
medial and lateral parietal and prefrontal cortices whereas the cerebellum and medial 
temporal lobes had significantly lower levels of aerobic glycolysis than the rest of the brain 
74. Recent studies have shown that the regions of the brain with the highest levels of 
aerobic glycolysis also express increased levels of genes relating to synapse formation and 
growth, suggesting aerobic glycolysis could be used in brain development to support the 
biosynthesis required for growth, similarly to cancer cells 70. Others have also suggested 
that the varying levels of aerobic glycolysis within the human brain could be linked to the 
ratio of neurons to non-neuronal cells 74. Aerobic glycolysis provides astrocytes with the 
high energy requirements of the membrane bound Na+/K+-ATPase pump, at the cell 
surface, to take up glutamate from the synapse 75. According to the astrocyte-neuron 
lactate shuttle theory, the glucose metabolised to lactate by astrocytes is secreted and 
metabolised by neurons, which have no direct access to glucose 76. LDHA clearly has an 
active role within the brain and lactate has also recently been implicated as a neural 
intracellular messenger 77, but further research is required to determine its precise role. 
 
Interestingly several mouse model studies have suggested that loss of aerobic glycolysis in 
the brain is linked to Alzheimer’s disease. APP/PS1 (APPswe, PSEN1dE9) double transgenic 
mice are used as a model for Alzheimer disease and studies showed that 12 month old 
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APP/PS1 mice had decreased PDK1 (pyruvate dehydrogenase kinase isozyme 1), a promoter 
of aerobic glycolysis, and LDHA expression in their frontal cortex compared to age-matched 
controls 78. Furthermore, knockdown of LDHA or PDK1 in B12, a rat CNS cell line, increased 
their sensitivity to Aβ and other neurotoxins 78. Aβ deposition promotes dysfunction of 
mitochondria, ROS (reactive oxygen species) generation, and eventually leads to nerve cell 
death. By elevating PDK1 and LDHA expression and promoting aerobic glycolysis the brain is 
protected 78. Furthermore, a neuroimaging study in humans found that the regions of the 
brain most susceptible to amyloid toxicity also exhibited high levels of aerobic glycolysis 79, 
this has been suggested to be a preventative protective measure against Aβ deposition and 
loss of this protective mechanism may lead to Alzheimer disease 78. However a study in 
prematurely and normally ageing mice found failure of oxidative phosphorylation, thought 
to be caused mainly by mitochondrial DNA point mutations, and elevated brain lactate 
concentrations caused by increased LDHA transcription correlated with an ageing 
phenotype 73.  
 
Changes in cerebral spinal fluid (CSF) LDH isoenzyme (Figure 1.2) concentrations can be 
used as an indicator of neurological pathologies. For example, normal CSF contains very low 
concentrations of LDH-1 and LDH-2 LDH isoenzymes whereas LDH4 is elevated in 
tuberculous meningitis; LDH3 in pyogenic meningitis and Guillain-Barré syndrome; LDH2 in 
viral encephalitis and LDH1 in hydrocephalus 80,81. Elevated CSF concentrations of LDH are 
also seen in patients with ischemic stroke and head injuries 82,83. Furthermore, a study of 
leptomeningeal metastases from solid and haematological tumours found that CSF LDH 
concentrations could be used to help diagnosis and monitor the patient’s response to 
treatment 83. There are several hypotheses for the cause of increased CSF LDH 
concentrations including: disruption of the blood brain barrier (BBB) which allows an 
increased outflow of serum, release of LDH from cytolytic cells, elevated synthesis of LDH in 
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response to vascular damage or reduced removal of LDH 82. Further research is required to 
determine mechanisms of CSF LDH up-regulation and to determine its reliability as a 
prognostic marker for brain tumours. 
 
1.1.9 LDHA and tumour malignancy 
Abnormal LDHA up-regulation and LDHB down-regulation is a common characteristic of 
tumours, which promotes a metabolic switch to aerobic glycolysis, generating lactate as a 
by-product. Elevated lactate concentrations have been shown to predict tumour 
malignancy, recurrence, survival and metastasis in cancer patients 84-86. Serum LDH 
concentrations have also been shown to be a good prognostic marker of many types of 
cancer 37,87-89. LDHA over-expression is also associated with many other poor prognostic 
factors including tumour hypoxia 22, angiogenesis 90, proliferation and glucose uptake 58 as 
well as resistance to chemotherapy 91 and radiotherapy 92. Furthermore, in non-small cell 
lung cancer, which commonly metastasizes to the brain, LDHA expression and NF-κB are 
synergistically associated with death and recurrence 93. Several studies have also 
demonstrated that LDHA has a role in tumour formation, maintenance, and progression 
41,94,95; however there has not been adequate research into the use of LDHA as a prognostic 
marker for brain tumours. 
 
1.1.10 The role of LDHA in tumour growth and survival  
Several studies, including in vivo research, have attenuated LDHA expression initiated by 
various mechanisms and reports predominantly indicate that LDHA suppression inhibits 
tumour cell proliferation and survival 38,42,94,96. However Langhammer et al (2011) found 
that the growth of clones with LDHA silenced were not impeded in vitro, but the same 
LDHA silenced clones had an impaired growth rate in vivo, compared to the control cell 
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lines 38. Additionally cell lines which rely more on glutaminolysis and fatty acid synthesis, 
are not affected by LDHA inhibition whereas cell lines which rely on the pentose phosphate 
pathway and glycolysis,  are affected 97.Therefore the importance of LDHA in cell growth 
and survival is likely to be dependent on tumour metabolic phenotype, reliance on LDHA 
and microenvironmental influences. 
 
Predominantly, studies have found that LDHA indirectly promotes tumour survival through 
protection from ROS, as the inhibition of LDHA forces cells to use oxidative phosphorylation 
in order to generate ATP and mitochondrial ROS production is usually elevated as a result 
94,95,98. Multiple in vitro and in vivo xenograft mouse model studies have found that LDHA 
knockdown cells treated with N-acetyl-l-cysteine (NAC), an antioxidant which breaks 
disulphide bonds, prevented or partially prevented the induced generation of ROS and 
apoptosis 96,99,100. Furthermore, Sheng et al (2012) showed that the knockdown of LDHA and  
generation of ROS, which regulates the intracellular calcium concentration 101, caused a loss 
of mitochondrial membrane potential, release of cytochrome C, activation of caspase 9 and 
caspase 3 and finally apoptosis 99. In vivo xenografts of breast cancer cell lines also found 
that cell lines with LDHA knocked down had elevated Bax, cleaved PARP, cleaved caspase-9, 
cytosolic cytochrome C and superoxide anion expression but decreased Bcl-2 expression 
and mitochondrial membrane potential 100. One group has specifically looked at the effect 
of LDHA inhibition in p53+/+ and p53-/- tumours 102. They found that LDHA inhibition in 
both p53+/+ and p53-/- caused increased ROS and decreased ATP which lead to apoptosis, 
although p53+/+ cell lines were more sensitive to LDHA silencing, but no effect was seen on 
the viability of non-neoplastic cell lines ARPE19 (retinal epithelia) and WI38 (diploid lung 
fibroblasts) 103. The increased sensitivity to  LDHA inhibition in p53+/+ colorectal epithelial 
cancer cells, was caused by a p53 dependent increase in cellular NADH:NAD+ ratio which 
resulted in down-regulation of the activity of the p53 NAD+ dependent deactylator SIRT1 
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and therefore up-regulated acetylated, active tumour suppressor p53 103. Furthermore, 
LDHA suppression increased sensitivity of p53+/+ cancer cells to EO9, a redox 
dependent pro-drug reduced by NADPH-quinone oxidoreductase 1 (NQO1) 103. 
 
LDHA may also inhibit apoptosis more directly. Indeed, an immunohistochemical study of 
melanoma by Zhuang et al (2010) revealed, not only did LDHA expression increase as the 
disease progressed but, it was strongly associated with the expression of the anti-apoptotic 
proteins Mcl-1 and Bcl-XL 104. Furthermore, knockdown of LDHA has been shown to 
increase PARP expression, decrease XIAP, Bcl-2 and Bcl-XL expression, and attenuate the 
tumourigenicity of the pancreatic cell line BXPC-3, reducing the tumour size and weight in 
vivo xenograft models 56. 
 
Interestingly, recent studies have demonstrated that LDHA is inhibited in the Isocitrate 
dehydrogenase (IDH) subgroup of glioma which has characteristically slow progression, 
greater survival rates and better prognosis than the other GBM subgroups 105. It had 
previously been shown that 2-hydroxyglutarate (2-HG), produced by IDH mutant tumours, 
promotes HIF1α degradation 106. Further in vitro and in vivo xenograft studies by 
Chesnelong et al (2014) established that LDHA, a HIF1α responsive gene, was under-
expressed in different grades of IDH mutated gliomas 105. Even brain tumour stem cell 
(BTSC) lines which once had IDH mutations but lost their mutant IDH allele and no longer 
produced 2-HG had silenced LDHA. These results led to the discovery that the LDHA 
promoter was heavily methylated 105. Furthermore, addition of mutant IDH to human 
astrocyte cell lines was also associated with methylation of LDHA promoter. To corroborate 
their findings they analysed data from The Cancer Genome Atlas and REMBRANDT public 
databases, they found that low expression of LDHA and high methylation of the LDHA 
promoter was found in IDHmt glioblastoma (GBM) patients and glioma patients whose 
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tumours over-expressed LDHA had a median survival of 16 months whereas patients whose 
tumour under-expressed LDHA had a median survival of >50 months 105.  As LDHA has 
previously been shown to be important in tumour growth and progression in many other 
tumours, the silencing of LDHA in gliomas with IDH mutations may be responsible in part 
for the characteristically slow progression of gliomas with IDH mutations. These findings 
should prompt further studies to establish if LDHA correlates with tumour growth in other 
types of brain tumour. 
  
There are several other possible mechanisms in which LDHA may promote tumour growth. 
LDHA may be involved in promoting the cancer stem cell phenotype; Zhang et al (2012) 
have shown that LDHA significantly correlates with Oct-4, a gene involved with embryonic 
stem cell self-renewal 42. They conducted in vitro and in vivo studies using lentivirus-
mediated siRNA against LDHA and found it reduced Oct-4 expression and tumourigenicity 
42. LDHA over-expression may also promote tumour growth by preventing necrosis in 
hypoxic environments; Lewis et al (2000) noted that tumours created from cell lines over-
expressing c-Myc or c-Myc target genes LDHA and Rcl were not significantly necrotic 
compared to tumours from cell lines over-expressing c-Myc target genes Rcl and VEGF 41.  
These observations show promise and should be investigated in both primary and 
secondary brain malignancies. 
 
1.1.11 The role of LDHA in tumour migration and metastasis 
Secondary brain metastases are the most common type of adult brain tumour and the 
incidence is rising. Many cancers can metastasise to the brain but the most common are 
melanoma, breast, lung, kidney, and colon cancer. LDHA expression correlates with 
metastasis and poor patient prognosis in many tumours 58,86,89,104,107,108. The most frequently 
reported mechanism by which LDHA modulates cell migration and invasion is through the 
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generation of lactate, as lactate alone has been shown to correlate with the invasive ability 
of many tumours 96. Lactate causes acidification of the microenvironment which promotes 
tumour cell invasion by inducing apoptosis of normal cells and pH-dependent activation of 
metalloproteinases (MMPs) and cathepsins which degrade the extracellular matrix and 
basement membranes 109-112. Goetze and others have used Transwell® Boyden chamber 
assays to show that addition of exogenous lactate increased the migration of tumour cells 
in a concentration-dependent manner 113. Sheng and others have also shown that 
knockdown of LDHA reduced the expression of MMP-2 and metastatic potential, using cell 
lines and xenograft mouse models 99. Furthermore, they found that the knockdown of LDHA 
caused an increase in the tumour suppressor E-cadherin and therefore cell-cell adhesion, 
and a loss of focal adhesion kinase (FAK), and VEGF both of which are also associated with 
tumour metastasis, considerably implicating LDHA as a regulator of invasion 99. There have 
been a few studies of LDHA and lactate in high grade glioma migration. Seliger et al (2013) 
found that the knockdown of LDHA resulted in a decrease in lactate concentration which 
caused a reduction of THBS-1 and TGF-β2 expression and reduced migration by 
approximately 40% compared to the control siRNA 114. Furthermore, addition of lactate or 
synthetic THBS-1 rescued TGF-β2 expression and glioma migration 114. In another study it 
was found that MMP-2, a promoter of migration and invasion which is over-expressed in 
high-grade glioma, is also up-regulated by LDHA through lactate induction of TGF-β2 111.  
 
Arseneault et al (2013) reported another mechanism in which LDHA may regulate cell 
migration. They found that elevated mitochondrial ROS production, caused by LDHA 
targeted knockdown using shRNA, is associated with compromised actin dynamics, 
oxidation of tropomyosin isoform Tm5 and decreased cell motility in the melanoma derived 
cell line MDA-MB-435 115. In wound healing and transwell migration assays, migration of 
clonal MDA-MB-435 cell lines with knocked down LDHA was considerably decreased. 
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Furthermore, addition of antioxidant NAC increased migration of a LDHA knockdown cell 
line in a concentration-dependent manner. Together their studies suggest that LDHA may 
influence cell migration through mitochondrial ROS production, tropomyosins and redox 
regulation 115. Collectively, these studies suggest that LDHA-targeted therapy could reduce 
tumour invasion and migration, which severely decreases a patient’s chance of survival, 
especially in the context of primary brain tumour. 
 
Table 1.2: List of genes and proteins reported to be associated with LDHA activity 
Gene/ protein Association with LDHA function Reference 
AUF Gene Transcription 60 
DNA polymerase- α complex Gene Transcription 61 
OCA-S Gene Transcription 63-65 
ATP-sensitive K+ channel Channel complex regulation 66 
SUR2A Channel complex regulation 66 
Kir6.2 Channel complex regulation 66 
Nucleoside Diphosphate Kinase 
- A (NDPK-A) 
Channel complex regulation 68 
AMPK Channel complex regulation 68 
CK2 Channel complex regulation 68 
Immature thymocyte antigen-1 
(IMT-1) 
Molecular chaperone 69 
Bax Apoptosis 100,55 
PARP Apoptosis 100, 56 
Caspase 9 Apoptosis 99, 100 
Caspase 3 Apoptosis 99 
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Bcl-2 Apoptosis 100, 56 
P53 Apoptosis 103 
Bcl-XL Apoptosis 104, 56 
XIAP Apoptosis 56 
Mcl-1 Apoptosis 104 
Rcl Tumour growth / survival 41 
IDH Tumour growth / survival 105 
Oct-4 Tumour growth / survival/ Cancer stem 
cell 
42 
MMP-2 Tumour migration / metastasis 99,111 
E-cadherin Tumour migration / metastasis 99 
FAK Tumour migration / metastasis 99 
THBS-1 Tumour migration / metastasis 114 
TGF-β2 Tumour migration / metastasis 111,114 
Tropomyosin isoform (Tm5) Tumour migration / metastasis 115 
VEGF Tumour angiogenesis 99,116-118 
VEGFR2 Tumour angiogenesis 116 
NKG2D ligands: ULBP-1 and 
MICB 
Tumour evasion of immune response 119 
Lactate Transcription regulation of LDHA, 
tumour angiogenesis, tumour 
migration / metastasis, tumour evasion 
of immune response 
27,111,113,114,120-
122 
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1.1.12 The role of LDHA in angiogenesis 
Angiogenesis is a hallmark of many tumours, including GBMs, and is stimulated by 
angiogenic factors including VEGF and IL-8. Koukourakis et al (2003, 2006, and 2011) have 
published a number of immunohistochemical studies showing an association between 
LDHA expression and activation of the VEGF pathway 36,90,91,116,118. They found that a high 
level of LDHA in the cytoplasm correlated significantly with cytoplasmic VEGF expression 36 
while LDHA expression was significantly associated with phosphorylated VEGFR2 in both 
tumour-associated vasculature and tumour cells 116. Another group used a tissue microarray 
and found that high LDHA and VEGF expression in tumour and stroma was a prognostic 
factor for gastric tumours 117. However these associations could be partly due to VEGF and 
other angiogenic factors also being a target of the LDHA transcription factors, HIF1 and c-
Myc. Furthermore, other immunohistochemical studies by Koukourakis et al (2005 and 
2006) found a significant correlation between LDHA, HIF1α and an aggressive phenotype. 
However there was no association found between LDHA expression and VEGF or vascular 
density 107,118. 
 
Interestingly, an acute acidic extracellular pH, which can be caused by elevated lactate 
production, has been shown to promote up-regulation of IL-8 and VEGF independently of 
hypoxia 123-127. Studies in wound healing mouse models have shown that sustained, local 
and systemic lactate release from subcutaneous implants of poly-D, L-lactide-co-glycolide 
(PLGA) promotes angiogenesis and accelerates wound closure 120. A study where Hunt-
Schilling wound cylinders were implanted into rats established that increased extracellular 
lactate concentrations in wounds caused an elevation of interleukin-1β, VEGF (2 fold) and 
TGF-β1 (2-3 fold), a 50% increase in collagen deposition and a 90% reduction of insulin-like 
growth factor-1 121. Another study in HUVEC (Human umbilical vein endothelial cells) cells 
cultured with 10 mM lactate found that VEGF and VEGFR2 were significantly up-regulated 
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122. Furthermore, the VEGF expressed in the presence of lactate was of a more active form, 
as VEGF PAR-modification decreased from 76% in the control to 21% in lactate treated cells 
122. Another group developed a novel in vivo microscopy technique in order to 
simultaneously measure tissue oxygen partial pressure (pO2), pH and VEGF promoter 
activity in human glioma cells 124. They found that VEGF expression was independently 
regulated by pH and tissue pO2. Furthermore hypoxia and acidic pH did not have a 
synergistic effect on VEGF transcription 124. 
 
LDH concentrations may also be useful to predict whether patients will benefit from VEGF 
targeted therapies 128. A study of tissues from 179 colorectal cancer patients showed that 
patients treated with an anti-angiogenic drug (Vatalanib) and cytotoxic chemotherapy 
(oxaliplatin/5-fluorouracil (FOLFOX))  combination had an improved response rate and 
progression free survival if their tumour expressed elevated LDHA compared to patients 
with tumours expressing low levels of LDHA 91. Furthermore, a clinical trial of the anti-
angiogenesis drugs bevacizumab and cediranib on advanced colorectal cancer patients 
established that patients with high concentrations of serum LDHA (treated with cediranib) 
had better overall survival (OS) whereas patients with low concentrations of serum LDHA 
(treated with bevacizumab) had a better OS, although these results were not significant 129. 
Several studies suggest LDHA could be involved in the promotion of angiogenesis, but 
further research is required to determine the exact mechanism that could then be targeted 
for therapies in the future. 
 
1.1.13 The role of LDHA in tumour evasion of the immune response 
It has been reported that a poor lymphocyte response occurring at the invading tumour 
edge is associated with carcinomas expressing high levels of LDHA 116. In addition, low 
lymphocyte response was associated with 17 out 20 non-Hodgkin’s lymphoma patients who 
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had a medium or high LDHA expression 37. Again, it is thought that lactate generation, 
promoted by LDHA, is the predominant cause of LDHA-mediated inflammation 130 and 
evasion of the immune response 123 by inhibiting monocyte migration 113 and differentiation 
to dendritic cells 131 and by inhibiting cytotoxic T cell and dendritic cell cytokine release 132. 
Like tumour cells, activated T cells are highly proliferative and use glycolysis as their primary 
energy source. However, in the high lactate environment surrounding the tumour, 
activated T cells cannot secrete their own lactate, which depends on the intra- to 
extracellular concentration gradient of lactate 132,133. Conversely regulatory T cells do not 
use glycolysis as their primary energy source and are not affected by the high lactate 
concentrations 134.  
 
In brain tumours, a study in GBMs revealed that LDHA, secreted by the tumour, induced the 
transcription and expression of natural killer group 2 member D (NKG2D) ligands, ULBP-1 
(UL16 binding protein 1 ) and MICB (major histocompatibility complex (MHC) class I chain-
related B), on circulating monocytes and tumour infiltrating myeloid cells 119. Chronic 
exposure to NKG2D ligands expressed by monocytes down-regulates the expression of 
NKG2D receptors on natural killer cells, preventing their ability to lyse NKG2D ligand-
expressing tumour cells 135. Previous studies in glioma have shown that TGF-β can also 
decrease NKG2D expression on NK cells in vitro 136. As discussed previously, lactate 
production by LDHA activates TGF-β in glioma 111; therefore it is possible that LDHA also 
activates TGF-β to promote evasion of the immune response; this phenomenon should be 
investigated further. 
 
1.1.14 LDHA and the tumour microenvironment 
Due to excessive tumour growth, the tumour microenvironment is often hypoxic and acidic 
which can effect protein expression. Oxygen levels often vary within a tumour, for example, 
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GBMs have oxygenated areas around the tumour vasculature, as well as areas of oxygen 
deprived cells and necrosis. GBMs are well known to display intratumour heterogeneity 
which is caused, in part, by the microenvironment and also makes them more adaptable to 
small fluctuations within the microenvironment. As mentioned previously, hypoxia 
promotes transcription of LDHA by HIF-1 and up-regulation of LDHA causes lactate 
production, decreasing pH levels. Sørensen et al (2005 and 2007) have conducted 
experiments to closely examine LDHA mRNA expression in response to various oxygen and 
extracellular pH (pHe) conditions. They found that, in a human cervix squamous cell 
carcinoma cell line, after 24 hours LDHA mRNA levels increased slightly as oxygen 
decreased from 21% to 0.01% at pHe 7.5, 7.0 and 6.7. Furthermore, at pHe 6.5 and 6.3, and 
1% oxygen, LDHA mRNA levels were 6-7 fold higher than at 21% oxygen 137,138. When they 
repeated the experiment in a pharyngeal squamous cell carcinoma cell line they found that 
LDHA mRNA expression also gradually increased as oxygen concentrations decreased from 
21% to 0.01% however changes in pHe had little effect on LDHA mRNA expression 138. These 
results indicate that LDHA expression in response to the tumour microenvironment is 
regulated differently in different tumours, which could be linked to the aggressiveness of 
the tumour or metabolic phenotype. 
 
LDHA can influence the tumour microenvironment through generation of lactate which 
lowers extracellular pH. Tumour pH can also be variable within a tumour; using pH-sensitive 
electrodes primary brain tumours have been found to have a mean pH of 6.8 and as low as 
5.9 compared to normal brain tissue which has a pH of 7.1 139. It has also been shown that 
an acidic pH induces glioma stem cell markers and promotes angiogenesis and malignancy, 
furthermore in vitro elevation of pH reversed these effects 140. It is conceivable therefore 
that LDHA is a major manipulator of the tumour microenvironment, via lactate production 
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and decreasing the environmental pH, which promotes a cancer stem cell phenotype, 
angiogenesis, migration and immune evasion. 
 
1.1.15 LDHA as a therapeutic target 
As discussed previously, LDHA is associated with tumour initiation, maintenance, 
progression and poor prognosis in many tumours. High serum LDH concentrations are also 
associated with radio-resistance in both primary and metastatic brain tumours. Moreover 
multiple studies on various cell lines have shown that attenuation of LDHA increases 
apoptosis 94,95 (Figure 1.5), and reduces migration and invasion ability 96,99 demonstrating its 
use as a potential therapeutic target. Mouse model studies have found that LDHA deletion 
is embryonic lethal however when LDHA is switched off, in the Cretm - LDHAfl/fl mouse model 
treated with tamoxifen, mice develop severe, nonlethal haemolytic anaemia 141. 
Furthermore human genetic defects in the LDHA gene are also nonlethal but do cause 
glycogen storage disease type 11 (GSD11). Together these studies suggest that LDHA 
inhibition could be a well-tolerated therapy that will impede tumour growth and 
metastasis. 
 
To demonstrate the possible benefits of targeting LDHA as a therapeutic target, as well as 
using LDHA targeted siRNA and shRNA, many studies have also used oxamate; an analogue 
of pyruvate that prevents LDH converting pyruvate to lactate and has been shown to work 
synergistically with other current therapies. Zhou et al (2010) showed that human breast 
cancer cells which had become resistant to the chemotherapeutic agent Taxol, had 
increased levels of LDHA expression when compared to their parental cells 133. 
Furthermore, they found that down-regulation of LDHA by using both LDHA-targeted siRNA 
and oxamate increased the sensitivity of the Taxol resistant cells to Taxol and promoted 
apoptosis133.  
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Figure 1.5. Schematic showing the reported mechanism in which LDHA inhibitors cause 
apoptosis in cancer cells. 
Reported inhibitors of LDHA, listed in Table 1.3, obstruct aerobic glycolysis and the process 
listed in Figure 1.4. Cancer cells are then forced to use oxidative phosphorylation and 
pyruvate enters the mitochondria. This leads to reactive oxygen species (ROS) generation 
and apoptosis. 
 
Miskimins et al (2014) conducted studies with oxamate and phenformin on six different 
cancer cell lines. Phenformin inhibits complex I in the mitochondria electron transport 
chain, causing excess ROS production and is also associated with high incidence of lactic 
acidosis, however oxamate reduced the lactic acidosis side effect and furthermore, it had a 
synergistic anti-cancer effect when treated in combination with phenformin, reducing 
tumour size, glucose uptake, ATP generation and increasing tumour apoptosis in vivo 142. 
Oxamate  also increased the sensitivity of nasopharyngeal cancer cell lines to ionizing 
radiation, synergistically enhancing apoptosis and suppressed the growth of tumour 
xenografts 55.  
 
One of the problems with oxamate is that it has limited cell penetration; therefore 
relatively high doses are required to have any significant effect. However Galloflavin, a 
synthesised LDHA and LDHB inhibitor, has high levels of cell penetration. Galloflavin 
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inhibited the growth of well differentiated (MCF-7), chemotherapy resistant (MCF-Tam) and 
aggressive triple negative (MDA-MB-231) breast cancer cell lines, despite their metabolic 
differences, with their mean IC50 around 125 µM 
143. However this is still a higher 
concentration than commonly used in chemotherapeutics. Preliminary toxicity data is, 
however, promising, as 400 mg kg-1 body weight injected i.p. into mice was not lethal 144.  
Furthermore, the highest tested dose of Galloflavin (250 µM) caused a <30% reduction of 
ATP and lactate production of normal human lymphocytes and lymphoblasts but had a mild 
effect on their growth and survival 143.  
 
Gossypol, a derivative of cotton seed oil, inhibits LDHA and LDHC and is highly soluble at 
physiological pH 145. Furthermore, it has been shown to have cytotoxic effects against a 
range of tumours, including glioma cell lines 146. Coyle et al (1994) found that gossypol 
treatment of mouse xenograft models decreased the mean weight of tumours by more 
than 50% and furthermore, the most sensitive glioma cell lines had higher LDHA expression 
levels 146. Moreover, gossypol has been shown to be well tolerated in clinical trials and has 
also shown promise in recurrent malignant glioma trials (Bushunow et al, 1999) 147-150. Two 
more clinical trials with gossypol and GBM have been completed (NCT00540722 and 
NCT00390403) but the results are currently unavailable. FX11 [3-dihydroxy-6-methyl-7-
(phenylmethyl)-4-propylnaphthalene-1-carboxylic acid] is a promising new gossypol-
derived specific LDHA small molecule inhibitor, that has recently become commercially 
available. Studies on human lymphoma and pancreatic cancer xenografts have shown that 
FX11 inhibited tumour progression and induced significant oxidative stress and necrosis 94.  
 
Recently, over 900 plant extracts commonly used in medicine have been screened and their 
ability to inhibit LDHA evaluated. 46 herbs, including Cinnamon, Pink Rose Buds/Petals, 
Rhodiola Root, Witch Hazel Root and Wintergreen, significantly inhibited LDHA, with IC50s 
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<0.07 mg/ml. However, Chinese Gallnut (Melaphis chinensis gallnut), Bladderwrack (Fucus 
vesiculosus), Kelp (Laminaria japonica) and Babul (Acacia arabica) had the lowest IC50s of 
less than 0.001mg/ml 151. Further investigations are required to identify the active 
compounds within these plants extracts which could be used in future therapies. High 
throughput screening also identified quinoline 3-sulfonamides as NADH-competitive LDHA 
inhibitors.  Lead compounds had a 10- to 80- fold selectivity for LDHA over LDHB and IC50s 
were 2 - 10nm, but regrettably the use of quinolone 3-sulfonamides are unacceptable in 
vivo due to their pharmacokinetic properties; having a low in vivo clearance and being 
incompatible with oral bioavailability 97. 
 
Table 1.3: List of reported LDHA inhibitors 
LDHA inhibitor Reference 
Oxamate 55,133,142 
FX11 94 
Galloflavin 143,144 
Gossypol 146-150 
Quinoline 3-sulfonamides 97 
N-hydroxyindole-based (NHI) inhibitors 152 
Bifunctional ligands 153 
Mn(II) complexes 154 
 
 
Other groups have designed and synthesised specific LDHA inhibitor compounds. For 
example, Granchi et al (2011) have developed N-hydroxyindole-based (NHI) inhibitors of 
LDHA which they showed to inhibit pancreatic ductal adenocarcinoma growth, particularly 
under hypoxic conditions 152 and work synergistically with gemcitabine (first line standard 
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treatment) 155. They also found that the novel NHI LDHA inhibitors significantly reduced 
MMP-2 and MMP-9 expression under hypoxia which they hypothesise to be the cause of 
the attenuated cell migration and invasion observed 155. Moorhouse et al (2011) designed 
novel bifunctional ligands which inhibit LDHA, by synthesising “NADH-like” and “substrate-
like” azido and alkyne functionalised fragments and linking them together to form 31 novel 
compounds. The compound which showed the most promise for further development had 
a relatively low IC50 of 14.8 mM, and a 9-fold better activity against LDHA than sodium 
oxamate 153. Another group found that Mn(II) complexes, good functional mimics of 
catalase, inhibit LDHA and also decreased HIF1α expression in the HepG-2 cell line 154. 
Together, these studies show that designing small drug-like molecules to target LDHA is 
achievable and able to hinder tumour growth and maintenance but many still require 
further development to improve their specificity and potency.  
 
Targeting LDHA and tumour metabolism downstream of pyruvate generation is an 
attractive option for cancer therapies as the effect on the metabolism of normal cells 
should be minimal. Although studies have clearly demonstrated the therapeutic potential 
of inhibiting LDHA in cancer patients, most current inhibitors (Table 1.3) affect more than 
one of the LDH genes, have low potency and require unacceptably high doses (which may 
also be affecting other unknown non-specific targets) to achieve the desired effect and 
therefore are not suitable for clinical use. As described above, many groups are in the early 
stages of identifying and designing compounds which could eventually be used as LDHA 
inhibitors in clinical trials however it is of note that most novel LDHA inhibitors appear to be 
focused on targeting the LDHA enzyme activity rather than the protein expression itself. 
Nonetheless, studies showing synergistic effects of LDHA inhibitors in combination with 
other therapeutics such as radiation, phenformin, taxol and gemcitabine are promising. 
Although a few studies of LDHA in brain tumours have shown promise the extent of these 
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studies is severely lacking. Brain tumours are often more difficult to treat than other 
cancers as therapeutic drugs often have limited propensity to cross the protective blood-
brain barrier (BBB). However to our knowledge, no groups have tested whether any 
potential LDHA inhibitors are able to cross the BBB. 
 
1.1.16 Conclusions 
LDHA is clearly more than just a metabolic gene which is over-expressed in cancer and the 
true extent of its function and the exact mechanism in which it operates in non-neoplastic 
and neoplastic cells is only just beginning to come to light. Extensive studies have shown 
that LDHA is involved directly and indirectly in many aspects of tumour growth, migration, 
invasion and maintenance in a wide range of tumours (Figure 1.4). Despite the promising 
findings of a few studies presented here, the significance of LDHA in normal brain function 
and brain tumour initiation and progression is an area of research which is not receiving 
enough attention. More research conducted on the less studied roles of LDHA should also 
be encouraged as findings will no doubt benefit the ongoing search for suitable LDHA 
inhibitors which could be used in future clinical trials. It is also imperative to keep the issue 
of crossing the BBB in mind when designing LDHA inhibitors. 
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1.2  Medulloblastoma (MB) 
Brain and other CNS tumours are the second largest cause of cancer related deaths in 
children, after leukaemia, with MBs accounting for 20% of paediatric brain tumours making 
them the most common type of solid, malignant childhood brain tumour 156. MBs have 
been defined by the World Health Organisation (WHO) as a malignant, invasive embryonal 
tumour of the cerebellum with preferential manifestation in children, predominantly 
neuronal differentiation, and inherent tendency to metastasise via CSF pathways 156. As 
MBs are embryonal tumours, incidence decreases with age; children between 1-9 years 
have an incidence rate of 6 per million people whereas adults have an incidence rate of 0.6 
157. Approximately 650 and 500 children are diagnosed with MB every year in Europe and  
the USA respectively 157-159 and although the current five year event free survival is >80% for 
low-risk children, and 60–70% for high-risk children 160, the quality of life of the individuals 
after treatment is often significantly reduced.  
 
1.2.1 Medulloblastoma histology 
MB has long been described as a heterogeneous disease which has played a large part in 
hindering progression of MB therapies. Four histological variants divergent from “classic” 
MB have been described: desmoplastic/nodular (D/N), MB with extensive nodularity 
(MBEN), large-cell variant and anaplastic 156 (Figure 1.6). These subgroups are often divided 
into two groups; the desmoplastic MBs (D/N and MBEN) associated with a better prognosis, 
and large-cell anaplastic MBs (LCA) associated with a poorer prognosis 161-163. 
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Figure 1.6 Medulloblastoma histology 
A) Classic MB histology with small cells, mild nuclear polymorphism and a high nuclear to 
cytoplasm ratio. B) D/N MB tissue contains nodules (N) and internodular (IN) regions. 
Nodules are differentiated neurocytic cells expressing neuronal proteins. Internodular 
regions contain undifferentiated embryonal cells and reticulin-positive strands of collagen. 
C) MBEN MB have N and IN regions like D/N MB, but N regions are more numerous and 
often filled with streaming cells along a fibrillary background (arrow). D) Anaplastic MB has 
widespread regions of many apoptotic bodies, marked nuclear pleomorphism, cell 
wrapping and a high mitotic count. E) Large cell MB has monomorphic cells with large 
nuclei and prominent nucleoli, this pattern is often found with anaplastic regions within the 
same tumour, and hence they are classed together in the LCA group 163. 
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1.2.2 Medulloblastoma subgroups  
 
Figure 1.7 Comparison of the four molecular sub-groups of MB  
The four subgroups: Shh, Wnt, Group 3 and Group 4 characteristically occur in different age 
groups, have different rates of metastasis, prognosis, genetic abnormalities and gene 
expression profiles 40. 
 
In the last few years there have been some major breakthroughs in MB research. Data 
collection from many large cohort studies in multiple laboratories which used integrated 
genomics, microarrays, gene expression profiling and sequencing to examine recurrent 
mutations, miRNA profiles and DNA copy number aberrations has identified four main 
subgroups of MB: Sonic Hedgehog (Shh), Wingless (Wnt), Group 3 and Group 4 164-168. These 
subgroups were determined by similarities and differences in MB transcriptomes and are 
likely to contain more subsets within them. As depicted in Figure 1.7, and described in 
further detail below, each sub-group has disparate features including demographics, clinical 
outcomes, characteristic genetic abnormalities, gene expression and rates of metastasis 
Group 3 
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40,164,166,167. It is thought that MBs within the same subgroup, with similar transcriptomes, 
will behave in a biologically similar way and therefore respond similarly to therapies 40. The 
Shh and Wnt subgroups were named after the defected signalling pathway thought to drive 
MB pathogenesis within the respective subgroup. The Group 3 and Group 4 subgroups 
were given generic names as it is currently unclear what significant common feature or 
signalling pathway drives the pathogenesis of these subgroups.  
 
Several, more practical, methods for identifying MB subgroups in the clinic have been 
suggested. Magnetic resonance spectroscopy (MRS) can be used to distinguish between 
SHH and Group 3/4 medulloblastoma 169. Immunostaining for several markers can be used 
to determine which subgroup an individual’s MB belongs to including GAB1 for SHH, β-
catenin for WNT, NPR3 for Group 3 and KCNA1 for Group 4 164,165,170. The expression of 22 
subtype specific signature genes in RNA extracted from fresh frozen MB tissue can also be 
used to identify MB subgroups using nanoString nCounter technology 171. However, as 
many features can overlap between the subgroups, transcriptome analysis is currently the 
most accurate method but unfortunately the classification of MB samples using 
transcriptome analysis and gene expression signatures requires large sample sizes and 
standard references for comparisons which is not practical in a clinical setting. 
 
1.2.3 Sonic hedgehog (Shh) subgroup 
MBs in the Shh subgroup have defects in the Sonic Hedgehog pathway (Figure 1.8) and 
account for approximately 30% of MBs 172. Shh acts as a morphogen in the ventral spinal 
cord during development and also acts as a mitogen which promotes the proliferation of 
granule neuron precursor (GNP) cells 173. The Shh pathway is activated when secreted Shh 
ligand binds to the Patched (Ptc) receptor; this activates the Smoothened receptor (Smo) 
which is normally constitutively suppressed. The Smo receptor then activates glioma-
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associated oncogene (Gli) 1, Gli2, and Gli3, a family of transcription factors. The cleavage of 
Gli3 into its truncated repressor form is suppressed, this enables Gli1 and Gli2 to promote 
transcription of target genes including Gli1, creating a positive feed-back loop 174. Gli1 
promotes the transcription of target genes that promote cell proliferation which is 
important during development and also promotes tumour growth 175.  
 
 
Figure 1.8 The Shh signalling pathway 
In the presence of Shh, Gli1 and Gli2 promote transcription of cell self-renewal genes. In the 
absence of Shh, Gli3 suppresses transcription of target genes including CD133, Cyclin D and 
Bcl-2 176. 
Key: Smo, Smoothened; Shh, Sonic Hedgehog; Ptc, Patched; Gli, Glioma-associated 
oncogene. 
 
Patients with Gorlin syndrome (caused by a germline mutation in Ptc) have a strong 
predisposition to MB, usually with MBEN histology 177,178 an observation which first led to 
investigations into the Shh pathway in MB. However up to 25% of sporadic MBs also have 
mutations in the Shh pathway all of which promote constitutive activation of Shh signalling.  
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Mutations found in the Shh pathway of Shh MBs include inhibition of suppressor of fused 
homolog (Sufu), an inhibitor of the Shh pathway, inactivating Ptc, activating Smo, 
amplification of Gli1 and Gli2 168,179,180. The deletion of the Ptc gene, located on 
chromosome 9q22 and the 9q chromosome, also occurs in some Shh MBs and is exclusive 
to this subgroup 164.  
 
The Shh subgroup is one of the most well defined subgroups as well-established mouse 
models of Shh MB have been around for over 10 years 181,182. Almost all D/N and MBEN MBs 
are thought to belong to the Shh subgroup; however some Shh MBs also display classic MB 
or LCA histology 164,170,172. Shh MBs have a gender ratio of about 1.5:1 male: female, and are 
uncommonly metastatic 40,164. The general 5 year survival for Shh MB patients is  75% 40, 
however, it is a heterogeneous subgroup as some infants (0-3 years) have been cured with 
chemotherapy alone 183 whereas patients with MYCN and Gli2 amplifications have a poorer 
prognosis despite high doses of chemotherapy and radiotherapy 184.  
 
1.2.4 Wingless (WNT) subgroup 
MBs in the Wnt subgroup have defects in the Wnt signalling pathway (Figure 1.9) and are 
the least common, accounting for 10% of MBs 185-188. Abnormalities within the Wnt/β-
catenin signalling pathway lead to its constitutive activation and up-regulation of β-catenin 
which promotes cell survival and proliferation. In the absence of Wnt, the β-catenin 
destruction complex (Axin, adenomatous polyposis coli (APC), glycogen synthase kinase 3 
beta (GSK3β) and casein kinase 1 (CK1)), phosphorylates β-catenin. The phosphorylation of 
β-catenin Ser33 and Ser37 residues provides a binding site for beta transducin repeat 
containing (β-Trcp) ubiquitin ligase, allowing β-catenin to be tagged by ubiquitin and 
degraded in the cytosol by proteasomes 189-191. When Wnt is present, it binds to the frizzled 
receptor and low-density lipoprotein receptor-related protein (LRP) 5 or 6 co-receptor 191. 
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This complex recruits and activates dishevelled (DSH), a scaffolding protein which 
phosphorylates LRP5/6 191 causing recruitment of the β-catenin destruction complex to the 
plasma membrane where Axin binds to LRP5/6 190, inactivating the β-catenin destruction 
complex. β-catenin is then able to accumulate in the cytosol and translocate into the 
nucleus where it activates transcription factors; T-cell factor 4 (TCF-4) and lymphoid 
enhancer-binding protein (LEF) 190,192,193, which switch on target genes (including c-myc) 
which promote cell proliferation, survival and “stemness” 192,194. 
 
Figure 1.9 The Wnt signalling pathway 
A) When Wnt is absent β-catenin is phosphorylated by the β-catenin destruction complex 
and degraded in the cytosol by proteasomes. B) When Wnt binds to the Frizzled receptor 
and LRP5/6 co-receptor, the β-catenin destruction complex is inactivated and β-catenin is 
able to enter the nucleus and activate TCF and LEF transcription factors 190. 
 
Key: APC, adenomatous polyposis coli; β-cat, β-catenin; CBP, CREB-binding protein; CK, 
casein kinase; DKK, Dickkopf; DSH, Dishevelled; GBP, GSK3-binding protein; GSK, glycogen 
synthase kinase; LRP,  LDL receptor-related protein; P, phosphorylation; sFRP, secreted 
Frizzled-related protein; TCF, T-cell factor. 
 
Similarly to the discovery that the Shh pathway was implicated in MB, the Wnt pathway 
involvement was highlighted by an association between patients with Turcot’s syndrome 
and MB 195. Turcot’s syndrome is a familial syndrome consisting of two subtypes, type I 
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involves a mutation in the APC tumour suppressor gene and a greater susceptibility to MB. 
Over 90% of Wnt MBs have mutations in Catenin beta-1 (CTNNB1) (codes for β-catenin) 
which enables a resistance to degradation and promotes accumulation in the nucleus 
163,188,196. Genetic characteristics of Wnt MBs also include Axin inactivation mutations, high 
levels of c-Myc expression, and monosomy six, but few other regions of genetic 
amplification or deletions have been observed. It is also of note that increased expressions 
of genes involved in the Wnt pathway such as β-catenin and c-Myc are also seen in some 
Shh and Group 3 MBs 40,197.  
 
Wnt MBs are not often seen in infants (0-3 years) but can occur in children (3-16 years) and 
adults (>16 years) with a gender ratio of 1:1 male: female. Wnt MBs usually have classical 
histology, are rarely metastatic and have the best prognosis with >95% 5 year survival rates 
198,199. Despite their better prognosis, patients are often given harsh therapy regimes, 
similar to patients with the poorest prognosis. 
 
1.2.5 Group 3 
There is no clear, specific pathway involved in Group 3 MBs but they account for 25% of 
MBs 172. Group 3 MBs have high levels of MYC expression, and seem to be the only 
subgroup with MYC amplification 164,167. There appears to be at least two subsets within the 
Group 3 subgroup; 3a and 3b. Group 3a have MYC amplifications and Group 3b have no 
MYC amplifications.  Group 3a has a very poor outcome and has a high risk of relapse and 
death whereas Group 3b seems to have a better outcome, similar to Group 4 MB 166.  
 
Group 3 MBs have several similarities to Group 4 MBs, such as gain of chromosome 1q, loss 
of chromosome 10q and loss of chromosome 5q, which are all more commonly seen in 
Group 3 MBs than Group 4 MBs 40, isochrome 17q (26% of Group 3 MBs, 66% of Group 4 
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MBs) and amplification and over-expression of MB oncogene OTX2 164. One of the few 
characteristics that appear to be restricted to Group 3 MBs is the formation of PVT1 fusion 
genes occurring through a chromothripsis (chromosome rearrangement) like process 200. 
Group 3 MBs also often over-express a number of genes involved in retinal development 
such as cone-rod homeobox protein (CRX) 201.  
 
Group 3 MBs are more common in males than females, with a 2:1 ratio, and occur in infants 
(0-3 years) and children (3-16 years) but are very rarely found in adults (>16 years) 164. They 
usually have “classic” or LCA histology and have the poorest prognosis as they are the most 
likely to become metastatic. The 5 year survival rate is 45% in infants and 58% in children 
164,172,188. Until recently there have been no mouse models for Group 3 MB, however two 
MYC-driven mouse models of Group 3 MB have recently been developed 202,203, which will 
aid progression of understanding this subgroup and identifying suitable therapeutic targets.  
 
1.2.6 Group 4 
Like Group 3 MBs, there is no clear, specific pathway involved in Group 4 MBs, and it is the 
most prevalent subgroup of MBs accounting for over 30% of all MBs however it is the least 
understood MB subgroup in terms of molecular pathogenesis partly due to no mouse 
models being available 172,204. Amplification of proto-oncogenes MYCN and cyclin-
dependent kinase 6 (CDK6) are common characteristics of Group 4 which are rarely found 
in Group 3 164,166. Within Group 4 MBs, synuclein alpha interacting protein (SNCAIP) is one 
of the highest upregulated genes 200, the most common mutation occurs in the KDM6A 
gene 188,205 and isochrome 17q is the most common cytogenic change. Isolated 17p deletion 
has also been reported in Group 4 as well as Group 3 MBs but very rarely in the Shh and 
Wnt subgroups 164. 
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Group 4 MBs have a 3: 1 male: female ratio, and interestingly 80% of females with Group 4 
MB exhibit loss of one X chromosome 40,164,172. They usually have LCA or classic histology 
and are also frequently metastatic 172. Generally Group 4 MBs are considered to have an 
intermediate prognosis, however depending on their clinical features, Group 4 MB patients 
with average risk have an over 80% 5 year survival rate whereas high risk patients have a 
60% 5 year survival rate 172. Although there are no mouse models of Group 4 MB, there is a 
mouse model which over-expresses MYCN and develops MBs with either Shh or non- Shh 
properties but it is not clear yet whether the non-Shh MBs accurately represent Group 4 
MB 206,207.  
 
1.2.7 Medulloblastoma origin 
The specific origin of MB is still unclear and under much debate. MBs are very heterogenic, 
often expressing many neural lineage phenotypes which suggest they originate from 
multipotent cells. Studies have shown that MBs express nestin, which is used as a marker 
for neural precursor cells, but do not express markers commonly seen in differentiated cells 
208,209. Singh et al (2003) reported that a very small proportion of MBs are brain tumour 
initiating cells (BTIC) which have the ability of self-renewal, proliferation and differentiation 
210.  BTICs with stem cell like properties expressed high levels of CD133, Sox2, Musashi1 and 
Bmi1 which are neural stem cell (NSC) genes, indicating NSC are likely to be the source of 
these BTICs 211. Furthermore Ptc +/- mouse models of Shh MB show increased proliferation 
of NSCs compared to wild type (WT) mice 212.  
 
More recently the consensus is that each of the four MB sub-groups may arise from 
different progenitor cells (Figure 1.10). The origin of Wnt MBs may be from outside the 
cerebellum in the dorsal brainstem as human Wnt MBs tend to be found in the lower 
rhombic lip and embryonic dorsal brainstem more often than the upper rhombic lip, 
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moreover, mouse models suggest they originate from the lower rhombic lip of the 
cerebellum 213. Shh MBs occur within the cerebellar hemispheres, and mouse models of Shh 
MB have suggested that cerebellar granule neural precursors (CGNPs) from the cerebellar 
external granule cell layer (EGL) 213,214 or from the cochlear nuclei of the brain stem 215 are 
cells of origin for the Shh MB subgroup. Shh MBs have also been shown to originate from 
NSC populations within the subventricular zone 216. Mouse models of Group 3 MBs suggest 
that they also originate from CGNPs from the EGL or Prominin1-positive, lineage-negative 
NSCs 202,203 but it is still unknown which cells Group 4 MBs originate from. 
 
 
Figure 1.10 Origin of medulloblastoma progenitor cells 
Wnt MBs are thought to arise from the rhombic lip, Shh MBs from CGNPs or NSCs within 
the sub ventricular zone, Group 3 MBs from CGNPs or Prominin1-positive, lineage-negative 
NSCs and the origin of Group 4 MBs is still unknown 217,218. 
 
1.2.8 Medulloblastoma metastasis 
Approximately 30% of MB patients present with metastatic spread at the time of diagnosis 
219. Metastasis is a key prognostic marker which indicates poor progression-free survival 220, 
the most metastatic subgroup is Group 3 and unsurprisingly is also the subgroup with the 
poorest prognosis. Unlike the highly invasive brain tumour GBM, in which single cells invade 
along perivascular spaces and myelinated structures 221, MB cells are thought to migrate 
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forward together in a “roman army movement” and disseminate from the cerebellum, 
through the leptomeninges  and CSF down the spinal cord (Figure 1.11) 222,223. According to 
Northcott et al (2011), 17.9% of WNT, 19.1% of Shh, 46.5% of Group 3 and 29.7% of Group 
4 MB tumours metastasise 164.  
 
 
Figure 1.11 Migration of medulloblastoma from the cerebellum to the spinal cord  
A): The flow of CSF around the brain - CSF from the choroid plexus flows through the third 
ventricle, into the fourth ventricle past the cerebellum, where migratory MB tumour cells 
join the CSF circulation, before entering the subarachnoid space and descending the spinal 
cord 224 B) Left: An MRI scan of a four-year old with MB 225. Right: An MRI of a 5-year old 
showing MB nodular metastasis of the spinal cord 226.  
 
Although primary MBs are the origin of MB metastases, studies have found that MB 
metastases contained many more genetic mutations than the matched primary MB, and 
A 
B 
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the primary MB also had mutations not seen in the metastatic MB 227. MB cell lines (DAOY, 
Madsen, UW228-2 and 3), which invade at an average rate between 167 and 235 µm per 
day in vitro, over-expressed activated MMP-1 and MMP-2, which degraded the ECM and 
displayed collagen type I proteolytic activity 228. Furthermore MMP inhibitors Marimastat 
and 1,10-ophenanthroline suppressed the invasion of these MB cell lines by approximately 
50% 228. Another study used oligonucleotide expression profiling to identify 59 genes which 
are upregulated in metastatic MB, the most significant of which were platelet derived 
growth factor receptor B (PDGFRB) and members of the down-stream Ras/mitogen 
activated protein kinase (MAPK) pathway 229,230. Further research has shown that Imatinib 
can block MB invasion and metastasis by inhibiting PDGFR activation and PDGF induced 
transactivation of epidermal growth factor receptor (EGFR).  MB invasiveness is also 
decreased by single and fractionated doses of radiation in a dose dependent manner 231. 
Once tumours metastasise they become very difficult to treat and metastasis is the direct 
or indirect cause of most cancer related deaths 232 therefore therapies need to be targeted 
at genetic abnormalities seen in both the primary and metastatic MBs in order to optimise 
success.  
 
1.2.9 Current Therapies 
Current treatment options for MB are surgical resection followed by radiation therapy 
(cranio-spinal radiotherapy in children ≥ 3 years of age), and high doses of chemotherapy 
(regimens typically include a combination of three of the following during or after radiation 
therapy; cisplatin, lomustine, vincristine, cyclophosphamide and topotecan 233), all of which 
are not MB specific therapies. In order to spare patients with a better prognosis from the 
maximum radiation dose, patients are stratified into high risk or average-risk groups 
depending on clinical features including; age at diagnosis, MB histology, the presence of 
metastases and post-operative residual tumour 234. Although these treatments can reduce 
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the overall tumour mass, and increase long-term survival from 20-40% to 60-70% in the last 
10 years 235-237, considerable damage is caused to normal healthy tissue, especially to the 
developing brain and spinal cord, often leaving patients with life-long physical, neurological 
and intellectual disabilities 238. Molecular sub-group affiliation is not presently part of the 
risk stratification but will be included increasingly in future clinical trials as it is clear that 
each subgroup of MB responds differently to current treatments and patients will require 
subgroup specific therapy in the future 239,240. 
 
Targeted therapy using small molecular Smo inhibitors has been trialled in patients with 
Shh MB. However, only patients with Ptc or some Smo mutations responded and the 
response was short-lived in recurrent Shh MB and after long term exposure to Smo 
inhibitors, mutations occurred in Smo which prevented drug binding 241-244. Nonetheless, 
several other agents which target the Wnt pathway and other key signalling pathways in 
MB are under investigation in on-going clinical trials 245. Unfortunately, the increasing 
stratification of patients will also make it increasingly difficult to recruit large enough 
patient cohorts to generate statistically significant data. 
 
1.2.10 Medulloblastoma metabolism 
MBs in patients have been shown to have a glycolytic metabolic phenotype, using MRS and 
18fluorodeoxyglucose positron emission tomography (18FDG-PET), and furthermore MBs 
with increased glucose uptake correlated with a poorer survival rate 246,247. Interestingly, a 
recent study using MRS has shown elevated lactate levels were associated with a Group 3 
/4 subgroup profile 169. Research suggests localised primary MBs grow more slowly and are 
under anaerobic stress whereas metastatic MBs have metabolite profiles of increased 
growth and decreased cell death 246. MBs also have elevated expression of 
monocarboxylate transporter 1 (MCT1) which transports lactate and pyruvate across the 
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plasma membrane, also indicating a glycolytic phenotype 248.  Moreover MCT1 is inhibited 
by miR-124, which is commonly down-regulated in MB and ectopic expression of miR-124 
has been shown to inhibit MB proliferation by blocking cell cycle progression at G1 248.  
Cellular metabolism can be influenced by many pathways including many implicated in MB. 
The Wnt signalling network has been shown to manipulate metabolism by increasing 
glycolysis and decreasing oxidative phosphorylation 249-251. Wnt signalling has been shown 
to induce Snail (a transcription regulator) which inhibits cytochrome C oxidase, preventing 
mitochondrial respiration and promoting a glycolytic phenotype 252. C-Myc which is over 
expressed in Group 3 MB and activated downstream of Wnt and EGF signalling pathways, is 
also known to promote glycolysis in many cancers 40,192,253,254. C-Myc upregulates glutamate 
catabolism through the citric acid cycle, by transcriptionally repressing miR-23a and miR-
23b to elevate mitochondrial glutaminase (GLS) (converts glutamine to glutamate) 255. C-
Myc also induces glutamine transporters SLC7A5 and ASCT2 at the mRNA level 255 and, as 
previously mentioned (chapter 1.1.4), upregulates LDHA expression 24. 
 
Mouse models have shown that during normal development of the cerebellum CGNPs are 
stimulated by Shh to undergo aerobic glycolysis 256-258. Furthermore Shh and 
phosphoinositide 3-kinase (PI3K) signalling has been shown to stimulate aerobic glycolysis 
in CGNPs in a hexokinase-2 (HK2) dependent manner 257. Another Shh driven axis used by 
CGNPs during neurogenesis to stimulate aerobic glycolysis has also been shown, where Shh 
inhibits the tumour suppressor retinoblastoma protein (Rb) to induce peroxisome 
proliferator-activated receptor gamma (PPARγ) activity by E2F1 (a key proliferation 
regulator) 256. Both of these Shh signalling pathways have also been shown to be activated 
in Shh MBs 256,257. Inhibition of aerobic glycolysis by deleting HK2 in Shh MB mouse models 
(hGFAP-cre; SmoM2; Hk2fl/fl mice) reduced MB malignancy by promoting differentiation 
and reducing proliferation 257. Inactivation of Rb and / or PPARγ also inhibited CGNP 
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proliferation and promoted Shh MB cell death 256. PPARγ expression is also seen in other 
MB sub-groups, implying this pathway could be activated more generally in MB 256. Shh 
MBs (in vitro and in vivo mouse models) also exhibit elevated lipid synthesis implicated in 
aerobic glycolysis 258.  
 
Taken together, these reports suggest many of the MB sub-group specific abnormalities 
influence tumour metabolism to promote aerobic glycolysis. This indicates MB metabolism 
could be a promising therapeutic target for some or even all MB subgroups. As described 
previously in this chapter, LDHA is a metabolic enzyme, integral to aerobic glycolysis, which 
has been identified as a potential tumour specific therapeutic target for glycolytic tumours. 
LDHA has also been associated with tumour progression and metastasis in numerous 
tumours. Group 3 MBs are the most metastatic subgroup of MB and over express C-MYC, a 
transcription factor for LDHA, so are the most likely MB subgroup to respond to LDHA 
targeted therapy. However as of yet there have been very few studies on targeting aerobic 
glycolysis in MB and none investigating the role of LDHA in MB or the potential of LDHA as a 
therapeutic target for MB.  
 
1.2.11 Medulloblastoma and hypoxia 
Hypoxia is a common feature of solid tumours, such as MB, and stabilises HIF-1α and HIF-2α 
transcription factors, influencing many cell functions as mentioned previously (chapter 
1.1.4). The presence and importance of hypoxia in MB is unclear as there have been no 
direct studies on hypoxia markers in MB in vivo and there have also been surprisingly few in 
vitro studies on the effects of hypoxia on MB. However, as mentioned previously (chapter 
1.2.7), MBs are thought to arise from NSC and hypoxia is an important feature of the stem 
cell niche. One group has shown HIF-1α maintains MB stem cells through Notch1 signalling 
259 and furthermore, hypoxic conditions have been shown to increase CD133 (frequently 
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found on BTICs) expression 1.6 fold in the MB cell line DAOY 260. Hypoxia has also been 
shown to induce significant transcriptional changes in MB cell lines, affecting stem cell 
maintenance and neuronal development pathways 261. 
 
MBs often become metastatic and moreover increased metastasis has been correlated with 
hypoxia in many other tumours 262,263. One group found that intermittent hypoxia (18-20 
cycles of 48h 1% O2 followed by 48h 21% O2) lead to increased MB cell line migration, 
invasion and angiogenesis through over expression of urokinase plasminogen (uPA) and its 
receptor (uPAR) which is known to promote epithelial-mesenchymal transition (EMT) 264. 
They also found that intermittent hypoxia caused an increase in the activation of ERK, 
expression of Bcl2 and Bcl-xL (anti-apoptotic proteins) and caused a decrease in expression 
of Bax and Bad (pro-apoptotic proteins) in MB cells 264.  However further research is 
necessary to increase our understanding of the effects of hypoxia on metabolism and 
migration in MB. 
 
1.3 Oxamate  
Catalytic aminolysis of oxalate, which competes with lactate to inhibit lactate 
dehydrogenase lactic acid oxidation, gives oxamate. As mentioned previously in “The 
Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain 
Tumour” 1, chapter 1.1.16, oxamate is a structural analogue of pyruvate (Figure 1.12) which 
competes with pyruvate to inhibit lactate dehydrogenase. Colowick et al (1961) found that 
oxamate inhibited HeLa cell growth, glycolysis and glucose uptake, furthermore these 
effects were reversed when pyruvate was present in the media, indicating lactate 
dehydrogenase was the primary site of action for oxamate 265. Subsequent studies aimed to 
establish the specificity of oxamate for lactate dehydrogenase and whether it was also 
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inhibiting pyruvate entry into the citric acid cycle and oxidative phosphorylation. Studies in 
Sarcoma 37 ascites tumour cells and Ehrlich ascites tumour cells reported that oxamate did 
not significantly inhibit oxygen consumption or oxidative phosphorylation ≤ 80 mM; 
however cell respiration was inhibited at higher concentrations 266,267. Colowick et al (1965) 
went on to demonstrate that α-Ketoglutarate an intermediate of the citric acid cycle, which 
can substitute for pyruvate in the citric acid cycle, did not reverse the growth inhibition 
caused by 80 mM oxamate 268. This indicated that the decrease in growth observed was due 
to the inhibition of the glycolysis pathway via lactate dehydrogenase and not the citric acid 
cycle and oxidative phosphorylation. It has also been reported that oxamate causes 
inhibition of hexokinase and aspartate aminotransferase activity however at low 
concentrations of oxamate the effects are small and unlikely to have any significant effects 
on glycolysis 266,269. Together these reports indicate that oxamate concentrations ≤80 mM 
primarily target lactate dehydrogenase and that lactate dehydrogenase inhibition is the 
principal cause of any functional effects observed. Studies have also shown that the IC50 
(concentration which inhibited 50% cell growth) for oxamate after 48h treatment varies 
considerably between cell lines. The IC50 in human mammary epithelial cells (HMECs) was 
88 mM and in human breast adenocarcinoma cell lines 78 mM for MCF7 and 54 mM for 
MCF10A and 40 mM MDA-MB-231 270.  
 
Figure 1.12 Sodium oxamate and sodium pyruvate 
Sodium oxamate inhibits LDHA activity as it is a structural analogue of pyruvate. Left; 
Structural formula of sodium oxamate. Right; Structural formula of sodium pyruvate. 
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1.4 Conclusions 
Cell proliferation and survival depends on cell metabolism, furthermore, inhibition of 
aerobic glycolysis in MB has been shown to inhibit MB growth in mouse models 256,257. The 
devastating and debilitating nature of MB is predominantly due to the migratory nature of 
the tumour and the highly toxic treatment regime. There is a strong link in the literature 
between metastasis, lactate, hypoxia and metabolism which has not yet been fully explored 
in MB. The role of LDHA in MB metabolism and metastasis could make it an attractive, 
specific therapeutic target for multiple or even all MB subgroups. I believe that MB 
metabolism is highly glycolytic and that this influences MB growth and migration. I posit 
that the more migratory MB subgroups express higher levels of LDHA, therefore exporting 
higher levels of lactate into the microenvironment, promoting migration and invasion and 
inhibition of LDHA will therefore disrupt MB aerobic glycolysis, causing a decrease in cell 
proliferation and migration.  
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1.5 Plan of investigation 
1.5.1 Hypotheses 
1. LDHA expression is elevated in MB compared to non-neoplastic cells and higher 
LDHA expression is associated with the more aggressive and metastatic MB 
subgroups Group 3 and Group 4. 
2. Inhibition of LDHA will decrease MB lactate production, cell proliferation, and 
motility 
3. Under hypoxic conditions MB cell metabolism will depend on upregulated LDHA 
expression therefore the inhibition of LDHA will have a greater effect on MB 
metabolism, motility and proliferation compared to normoxic conditions 
1.5.2 Aims of study 
1. To characterise the expression of LDHA in MB in vitro. 
2. To examine the downstream effects of sodium oxamate on LDHA activity, MB 
metabolism, proliferation, and motility in vitro. 
3. To examine the downstream effects of LDHA siRNA on LDHA expression and 
activity, MB metabolism, proliferation, and motility in vitro. 
1.5.3 Objectives 
1. To characterise LDHA expression in MB subgroups using databases, in MB tissue 
using immunohistochemistry (IHC) and in paediatric MB cell lines using Western 
blotting (WB), flow cytometry (FC) and immunocytochemistry (ICC) under normoxic 
and hypoxic conditions (1% O2, 5% CO2). 
2. To inhibit LDHA activity in paediatric MB cell lines using sodium oxamate and 
conduct downstream analysis to: 
a. Investigate the role and activity of LDHA in MB metabolism using pyruvate, 
lactate, glycolysis stress test and mito stress test assays. 
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b. Investigate the role of LDHA in MB proliferation using trypan blue growth 
curves, MTS assays, and cell cycle analysis. 
c. Investigate the role of LDHA in MB motility using live cell imaging, scratch 
wound assays and cell tracking analysis. 
3. To knockdown LDHA expression in paediatric MB cell lines using siRNA and conduct 
downstream analysis to: 
a. Investigate the role and activity of LDHA in MB metabolism using pyruvate 
and lactate assays. 
b. Investigate the role of LDHA in MB proliferation using MTS assays. 
c. Investigate the role of LDHA in MB motility using live cell imaging and 
scratch wound assays. 
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Chapter 2: Materials and methods 
2.1 Data mining with R2 genomics and visualisation platform 
Datamining using the R2 database was used to determine the relative expression of LDHA, 
LDHB and LDHC mRNA within the MB subgroups and non-neoplastic CNS tissue. The R2 
genomics and visualisation platform is a user friendly database, available online 
(http://r2.amc.nl), which contains publically accessible datasets (Figure 2. 1) 271.  
LDHA, LDHB and LDHC expression was analysed from a selection of CNS tissues available 
from the Normal Various - Roth - 504 – MAS5.0 - u133p2 dataset which contains 504 
samples and is the largest publicly available normal human tissue dataset. LDHA, LDHB and 
LDHC expression was also analysed in MBs using the Tumor Medulloblastoma - Gilbertson - 
76 - MAS5.0 - u133p2 dataset which contains 76 MB samples which have been categorised 
into the relevant MB subgroups. Microarrays cannot measure absolute expression however 
the relative expression of mRNA can be compared between two or more datasets if they 
have used the same chiptype and the signal intensities were normalised by the same 
algorithm. The Tumor Medulloblastoma - Gilbertson - 76 - MAS5.0 - u133p2 and Normal 
Various - Roth - 504 – MAS5.0 - u133p2 datasets both used the same chiptype (u133p2 
(Affymetrix®)) and algorithm (MAS5.0 (Affymetrix)) so were eligible for comparison using 
the R2 genomics and visualisation platform. The MAS5.0 algorithm uses many calculations 
to determine the relative expression of mRNAs based on background correction, perfect 
match probe correction, summarisation and normalisation to 100 housekeeping genes. 
LDHA, LDHB and LDHC expression was compared between non-neoplastic CNS tissues and 
MB subgroups. Data was exported from the R2 database and analysed using GraphPad 
Prism software. 
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Figure 2. 1 R2 genomics and visualisation platform analysis software 
The R2 genomics and visualisation platform software was used to mine and analyse LDHA 
expression in non-neoplastic CNS tissues and MB subgroups. The data sets to be analysed 
can be selected from a drop down menu and the gene of interest selected. 
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2.2 Cell culture  
2.2.1 Cell line maintenance 
Table 2. 1 Cell lines  
List of cell lines and culture mediums used as recommended. * With human serum (Sigma 
Aldrich, UK, Lot # SLBM0231V) instead of FBS. 
Cell line Origin Culture media Source 
UW402 Human, Medulloblastoma, 
1st published 2001, 272,273 
DMEM (Gibco, UK) 
supplemented with 10% 
FBS (Sigma Aldrich, UK) 
Dr John Silber, 
University of 
Washington, Seattle. 
Res256 Human, Medulloblastoma, 
16 year old, male, 1st 
published 2005, 272,274 
DMEM (Gibco, UK) 
supplemented with 10% 
FBS (Sigma Aldrich, UK) 
Dr John Silber, 
University of 
Washington, Seattle. 
DAOY Human, Medulloblastoma, 
4 year old, male, 1st 
published 1985, 272,275 
EMEM (ATCC) 
supplemented with 10% 
FBS (Sigma Aldrich, UK) 
ATCC, UK 
CC2565 Human, Foetal Astrocyte, 
17 weeks gestation, 
initiated 27.2.14 (Lot # 
0000402839) 
ABM (Lonza, UK) 
supplemented with AGM 
SingleQuots ® (Lonza, UK) 
Lonza, UK 
SC1800 Human, Adult Astrocyte ABM (Lonza, UK) 
supplemented with 
supplemented with AGM 
SingleQuots ® (Lonza, UK)* 
ScienCell research 
laboratories, cultured 
by Samah Jassem, 
PhD student 
A549 Human, Alveolar basal  
epithelial adenocarcinoma, 
used as positive control 
DMEM (Gibco, UK) 
supplemented with 10% 
FBS (Sigma Aldrich, UK) 
Dr Craig Murdoch, 
University of Sheffield 
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All cell culture maintenance and preparation was carried out in a biological level II sterile 
laminar flow cabinet (NUAIRE, UK) using aseptic technique. Apparatus were sterilised using 
an autoclave (Astell, UK) and all surfaces and equipment were cleaned using 70% ethanol 
(100% ethanol, VWR Chemicals diluted 7:3 with dH2O) and LookOut® Mycoplasma Erase 
(Sigma Aldrich, UK) before and after use. The laminar flow cabinet, incubators and all 
surfaces were also cleaned with Presept™ disinfectant (Fisher Scientific, UK), 70% ethanol 
and LookOut® Mycoplasma Erase weekly.  
 
Astrocyte cell lines (Table 2. 1) have a finite life-span in cell culture and were maintained in 
astrocyte basal medium-2 TM (ABM-2TM)  (Lonza, UK) supplemented with astrocyte growth 
medium TM (AGMTM) SingleQuots® containing heat inactivated foetal bovine serum (FBS), 
ascorbic acid, recombinant human epidermal growth factor (rhEGF), gentamicin 
amphotericin-B (GA-1000), insulin and L-glutamine (Lonza, UK), as recommended by Lonza 
(UK), up to 15 passages. All other cell lines (Table 2. 1) were cultured and maintained in 
Dulbecco's Modified Eagle's medium (DMEM) with phenol red, glucose and GlutaMAX TM 
and without sodium pyruvate (Gibco, UK - 61965) or Eagle’s minimum essential medium 
(EMEM) with L-glutamine (ATCC, UK, 30-2003) supplemented with 10% heat inactivated 
FBS (Sigma Aldrich, UK, Lot 083M3396). The concentrations of all components in the culture 
media are compiled in Table 8. 1. All cell lines were maintained in T75 flasks (Greiner bio-
one, UK), in 8 ml of appropriate media, at 37°C, 95% air, 5% CO2 in an air-jacketed, 
humidified, DH autoflow automatic CO2 incubator (NUAIRE, UK). For experiments 
performed under hypoxic conditions, cells were grown at 37°C, 1% O2, 5% CO2 in a Mini 
galaxy A incubator (Wolf Laboratories, UK). All solutions were pre-warmed to 37°C in a 
water bath (Fisherbrand, UK) containing Clear Bath® (Spectrum Laboratories, UK) before 
use in cell culture. Cell growth, confluence and morphology were regularly checked using an 
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Olympus CKX41 inverted phase contrast microscope. Images of cells in culture were taken 
on an Olympus IX71 inverted phase contrast microscope using analySIS® software. 
 
Cells were regularly sub-cultured by aspiration of the media from the flask and washing the 
cells with 1 ml Hank’s balanced salt solution (HBSS) (Gibco, UK), with no calcium or 
magnesium, which rinses off chelators. Cells were detached from the flask by incubating 
the cells in 1 ml TrypLE™ express (Gibco, UK), a cell dissociation enzyme, for 5 minutes. Cell 
culture flasks were tapped to aid with cell detachment from the flask and 2 ml of 
appropriate media was added to deactivate the TrypLE™ express. The entire cell suspension 
was removed from the flask and centrifuged in a 15 ml tube (Greiner bio-one, UK) at 155 
RCF/ 1000 RPM for 5 minutes using a C-28 A centrifuge (Boeco, Germany). The supernatant 
was discarded and the pellet re-suspended in 1 ml of appropriate media and used to seed 
new tissue culture flasks or for experimental purposes.  
 
2.2.2 Cell counting 
For experimental purposes cells would be counted in order to seed the correct number of 
cells per well. The number of viable cells in a cell suspension was determined using the Vi-
Cell® (BeckMan Coulter, UK) automated trypan blue dye exclusion assay. 100 µl of the 1 ml 
cell suspension was diluted in 500 µl of appropriate media in a Vi-Cell® counting cup and 
analysed. The Vi-Cell® mixed the diluted cell suspension with trypan blue dye which was 
taken up by non-viable cells with permeable membranes whereas viable cells were able to 
exclude the dye. The Vi-Cell® accounted for the 6 fold dilution factor and reported the 
number of viable cells/ ml (Figure 2. 2). The correct amount of cell suspension required to 
seed the correct number of cells required was calculated as follows: 
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(
1000
𝑛𝑢𝑚𝑏𝑒𝑟 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠
) × 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 
=  µ𝑙 𝑜𝑓 𝑐𝑒𝑙𝑙 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 
 
The appropriate number of cells were seeded in 6, 12, 24 or 96-well plates (Greiner bio-
one, UK) and incubated (overnight at a minimum) until ready for experimental purposes.  
In the last few months of the project a Countess™ automated cell counter (Thermo Fisher 
Scientific) was used for cell counting using the same trypan blue assay principle described 
above. 
 
 
Figure 2. 2 Vi-Cell cell counter software 
An example of a display shown by the Vi-Cell when cells are being counted. Data given 
includes total cells/ml, viable cells / ml, % viability and average diameter of cells 276. 
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2.2.3 Cryopreservation of cell lines 
For long term storage cells were harvested, centrifuged and re-suspended in 1 ml of 
Recovery™  cell culture freezing medium (Gibco, UK), containing 10% DMSO (dimethyl 
sulfoxide) and transferred into a Cryo Tube™ Vial (Thermo Scientific, UK). DMSO reduces 
the freezing point of the cell suspension, causing a slower cooling rate and reducing the 
possibility of ice crystal formation, which can cause cell damage and death. Within 5 
minutes of re-suspending the cells in Recovery™  cell culture freezing medium, the Cryo 
Tube™ Vial was placed into a Mr. Frosty™ cryo 1°C freezing container (Nalgene™, Thermo 
Scientific, UK) (filled with 250 ml isopropyl alcohol (IPA)(Sigma Aldrich, UK)), which allows 
regulated cooling, by -1°C/ minute) and placed in a -80°C freezer overnight. The Cryo Tube™ 
Vials were then transferred to liquid nitrogen storage tank (Thermo Scientific, UK) at -
196°C. To resurrect cells from liquid nitrogen, the Cryo Tube™ Vials were thawed rapidly at 
37°C. The cell suspension was added drop-wise to a T75 flask containing 8 ml appropriate, 
warmed media. The cells would be incubated and left to adhere overnight before the media 
was changed to remove the toxic dimethyl sulfoxide (DMSO). 
 
2.2.4 Mycoplasma testing 
Mycoplasma are prokaryotes which can contaminate cell cultures, are difficult to detect 
and can affect cell growth by competing for nutrients. Cells in culture were routinely 
screened for mycoplasma contamination, by Mrs Suzanne Little, BSc, MSc, using the 
MycoAlert™ mycoplasma detection kit (Lonza, UK) at least once a month, as well as before 
and after long term liquid nitrogen storage. After the addition of MycoAlert™ substrate 
(Lonza, UK), an increase in ATP and therefore mycoplasma contamination can be detected 
via emitted light (Figure 2. 3). 
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A 1.5 ml sample of media, which had been unchanged for at least 24h, was taken from a 
T75 flask of cells. The 1.5 ml reaction tube (Greiner bio-one, UK) was centrifuged for 5 
minutes at 200 RCF/ 1500 RM in a centrifuge 5415 R (Eppendorf, UK), to ensure any cells 
were pelleted. A 100 µl sample of media was added to a well of a white, flat-bottomed 96-
well plate and 100 µl of MycoAlert™ reagent (Lonza, UK) added to each sample. The plate 
was incubated at room temperature for 5 minutes before luminescence was measured 
using a POLARstar OPTIMA (BMG Labtech, UK) plate reader in triplicate (reading A). 100 µl 
of MycoAlert™ substrate (Lonza, UK) was added to each sample and the plate incubated at 
room temperature for 10 minutes.  Luminescence was measured in triplicate again using a 
POLARstar OPTIMA (BMG Labtech, UK) plate reader (reading B). Samples were run with a 
MycoAlert™ positive control (Lonza, UK) and MycoAlert™ assay buffer (Lonza, UK) as a 
negative control. The detection of mycoplasma was determined as follows: 
𝐴𝑣𝑒𝑟𝑎𝑒 𝑜𝑓 𝑟𝑒𝑎𝑑𝑖𝑛𝑔 𝐵
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑟𝑒𝑎𝑑𝑖𝑛𝑔 𝐴
 
If the ratio was < 0.9 the cells were mycoplasma free, if the ratio was 0.9 - 1.2 the cells were 
borderline and retested after 24h, if the ratio was > 1.2 there was an increase in ATP, 
indicating a mycoplasma contamination and the cells discarded.  
 
 
Figure 2. 3 Mycoplasma detection reation 
The above reaction occurs in the wells of the 96-well plate. The concentration of ATP is 
linearly related to the intensity of the light emitted. 
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2.2.5 Cell line authentication 
STRs (Short Tandem Repeats) are DNA regions with short repeat units approximately 2-6 
base pairs (bp) long. STR repeats have a low mutation rate and are highly variable between 
individuals, giving cell lines a unique DNA profile. Cell lines were authenticated by Mrs Katie 
Loveson, BSc, MSc, to verify they are of human origin and have not been cross-
contaminated, by analysing multiple STR loci using the Agilent 2100 Bioanalyzer using the 
protocol published by An et al (2014) 277 with slight modification to the thermal cycling 
protocol.  
 
2.2.5.1 DNA extraction 
Genomic DNA was extracted from cultured cells using the QIAamp DNA Mini Kit (Qiagen, 
UK). Proteinase K, cells suspended in PBS and lysis buffer AL were incubated at 56°C for 10 
minutes to lyse the cells and ensure maximum DNA yield. 100% ethanol was added and the 
sample was transferred to a QIAamp Mini spin column in a collection tube and centrifuged, 
binding the DNA to the QIAamp membrane. The QIAamp Mini spin column was washed 
with two wash buffers (AW1 followed by AW2). The QIAamp Mini spin column was 
incubated at room temperature for 1 minute with elution buffer AE before being 
centrifuged, twice. The eluted DNA was stored at -20°C until required. 
 
2.2.5.2 PCR 
The GenePrint 10 System (Promega, UK) was used to perform STR-based multiplex PCR. The 
primers of the GenePrint 10 System Kit amplify ten human STR loci, including CSF1PO, 
D16S539, D13S317, D21S11, D5S818, D7S820, TH01, TPOX, and vWA, as well as amelogenin 
for gender identification. The probability of a random match of genetic profiles using these 
STR loci is 1 in 2.92 x 109. A mix of 2ng of template DNA, 1 x enzyme mix, and 1 x primer 
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pair mix were added together, and a negative control was also included, where template 
DNA was replaced with water. PCR was performed on the MyCycler Thermal Cycler (Bio-
Rad, UK) as follows – step 1: 96°C for 1 minute, step 2: 94°C for 10 seconds, step 3: 59°C for 
1 minute, step 4: 72°C for 30 seconds (x 30 cycles), step 5: 60°C for 10 minutes then 4°C for 
10 minutes. 
 
2.2.5.3 Agilent 2100 Bioanalyzer 
The amplified alleles in the STR-PCR products were separated using Agilent 2100 
Bioanalyzer with the Agilent DNA 1000 Kit (Agilent, UK). The DNA chip was primed with the 
gel-dye mixture, and then PCR product and the internal marker (Agilent, UK) were added. 
Agilent DNA 1000 ladder (Agilent, UK) and the internal marker were loaded into the ladder 
well. The chip was placed into the bioanalyzer and the electrophoresis assay run. The 
amplified alleles were analysed using 2100 Expert software to reveal their unique DNA 
profile (Figure 2. 4).   
A   B   
C   D  
Figure 2. 4 STR profiles of the cell lines used throughout this project illustrated as DNA 
electrophoresis traces. 
A) UW402 , B) DAOY, C) Res256, D) CC2565. Fragments of the PCR-amplified STR markers 
are seperated based on their sizes to reveal unique DNA profiles. Data provided by Mrs 
Katie Loveson, BSc, MSc. 
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2.3 Flow cytometry (FC) 
Flow cytometry is a quantitative method of analysis which can be used to measure the 
proportion of cells expressing an antigen and the abundance of expression per cell. This 
method was used to compare LDHA expression between medulloblastoma and astrocyte 
cell lines under normoxic and hypoxic conditions. As LDHA is expressed intracellularly, the 
cells were fixed and permeabilised to allow antigen detection.  This protocol was optimised 
using the A549 cell line (Table 2. 1) as a positive control for LDHA antigen expression. 
 
2.3.1 Cell harvesting, permeabilisation and fixation 
Cells were plated in 6-well plates (Greiner bio-one, UK) at an appropriate seeding density 
(Table 8. 2) to give 80-90% confluence after 72 hours of incubation in a normoxic or hypoxic 
incubator. Cells were harvested from the 6-well plates, using 25 cm cell scrapers (Sarstedt, 
UK) to gently detach the cells from the surface of the plate, and transferred into 1.5 ml 
reaction tubes (Greiner bio-one, UK). Cells were pelleted using a centrifuge 5415 R 
(Eppendorf, UK) at 300 RCF/ 1800 RPM for 5 minutes at 4°C. The supernatant was removed 
and discarded, and the pellet re-suspended in 100 µl PBS (without calcium or magnesium) 
(Gibco, UK) containing 1% goat serum (Biosera, UK). The cells were centrifuged at 300 RCF/ 
1800 RPM for 5 minutes at 4°C. The supernatant was removed and discarded, the pellet re-
suspended in 250 µl of BD cytofix/cytoperm™ fixation and permeabilisation solution (BD 
Biosciences, UK), and incubated for 20 minutes at 4°C in the dark. 
 
2.3.2 Antigen staining 
The cells were washed with 100 µl wash buffer (filtered PBS with 0.2% saponin, and 1% 
goat serum), centrifuged at 500 RCF/ 2300 RPM for 5 minutes at 4°C and supernatant 
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removed, twice. Cells were re-suspended and incubated in 100 µl of wash buffer, wash 
buffer containing primary antibody (1:175), or wash buffer containing isotype control 
(1:704) (Table 8. 3) and incubated for 30 minutes at 4°C in the dark. The cells were washed 
with 100 µl wash buffer, centrifuged at 500 RCF/ 2300 RPM for 5 minutes at 4°C and 
supernatant removed, twice. Cells were re-suspended and incubated in 100 µl of wash 
buffer containing secondary antibody (1:500) (Table 8. 4), and incubated for 15 minutes at 
4°C in the dark. The cells were washed with 100 µl wash buffer, centrifuged at 500 RCF/ 
2300 RPM for 5 minutes at 4°C and supernatant removed, twice. Cells were re-suspended 
in 300 µl of staining buffer (filtered PBS with 1% goat serum and 0.09% w/v sodium azide 
pH to 7.4-7.6) and transferred to a round-bottom tube (BD Falcon™, BD Biosciences, UK) 
ready for analysis. 
 
2.3.3 Sample analysis 
20,000 cells of each sample were analysed using a BD FACSCalibur™. As cells passed 
through the laser light, side scattered light and fluorescent signals are collected and 
delivered to detectors via a system of mirrors and optical filters. A 15mW 488nm argon gas 
laser and a 530/30nm filter were used to detect Alexaflour 488/FITC. 
Acquisition and analysis were performed using CellQuestPro software to determine cell line 
expression of antigen (Figure 2. 5). For each experiment, one negative control (without 
primary antibody) and one isotype control sample were run with three antigen stained 
samples. Using the negative control sample as a guide, the M1 gate was positioned to 
exclude all cells which were not stained with the antigen. Total protein expression and 
expression intensity were calculated as follows: 
𝑀1 % 𝑡𝑜𝑡𝑎𝑙 𝑜𝑓 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 𝑠𝑡𝑎𝑖𝑛𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒 −  𝑀1 % 𝑡𝑜𝑡𝑎𝑙 𝑜𝑓 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙  
= 𝑇𝑜𝑡𝑎𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛  
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 𝐴𝑙𝑙 𝐺𝑒𝑜 𝑀𝑒𝑎𝑛 𝑜𝑓 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 𝑠𝑡𝑎𝑖𝑛𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒 −  𝐴𝑙𝑙 𝐺𝑒𝑜 𝑀𝑒𝑎𝑛 𝑜𝑓 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
= 𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 
 
 A  
B  
Figure 2. 5 Flow cytometry raw data 
An example of the data output from the CellQuestPro software. A) Negative control sample 
with no primary antibody. B) Antigen stained sample. Left shows graphical representation 
of results, right shows a table of results for the total gated sample and sample within the 
M1 gated range displayed on the graph. 
 
2.4 Immunocytochemistry (ICC) 
Immunocytochemistry is a qualitative method which shows the location and intensity of 
expression of antigens within individual cultured, fixed cells. This method was used to 
visualise the location of LDHA in medulloblastoma and astrocyte cell lines. LDHA is 
expressed intracellularly so the cells were permeabilised to allow antigen detection. This 
protocol was optimised using the A549 cell line as a positive control for LDHA antigen 
expression. 
 Events % Gated % Total X Geo Mean Median 
All 17582 100.00 87.91 3.24 3.08 
M1 12 0.07 0.06 13.54 12.98 
 Events % Gated % Total X Geo Mean Median 
All 17885 100.00 89.42 38.30 41.42 
M1 17199 96.16 86.00 40.75  42.55 
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2.4.1 Cell preparation, fixation and permeabilisation  
Cells were plated on 22 x 22 mm sterile cover glasses (Menzel-Gläser, Thermo Scientific, 
UK), in 6-well plates (Greiner bio-one, UK) at an appropriate seeding density (Table 8. 2) to 
give 80-90% confluence after 72 hours of incubation in normoxic or hypoxic incubators. 
Media from the wells was aspirated and discarded and the cells were gently washed with 
PBS (Gibco, UK) three times. The cells were fixed with 1 ml 4% paraformaldehyde (PFA) 
(diluted in PBS) and incubated at room temperature for 5 minutes in a fume hood. The cells 
were washed three times with PBS before they were permeabilised with 1 ml of 0.1% Triton 
X-100 (Sigma Aldrich, UK) (diluted in PBS) and incubated at 4°C for 10 minutes.  
 
2.4.2 Antigen and nuclear staining 
The cells were washed with PBS three times and incubated in 1 ml 10% goat serum 
(Biosera, UK), diluted in PBS, for 1 hour at room temperature. The cells were then washed 
three times with PBS  before incubation with 500 µl of PBS with 1% goat serum, PBS with 
1% goat serum and primary antibody, or PBS with 1% goat serum and isotype control (Table 
8. 3) for 1 hour at room temperature. Cells were then washed three times with PBS and 
incubated with 500 µl of PBS with 1% goat serum and secondary antibody (Table 8. 4), for 
30 minutes at room temperature in the dark. Cells were then washed three times with PBS 
and incubated with Hoechst stain solution (Sigma Aldrich, UK) (1mg / µl, diluted 1:100 in 
dH2O) for 10 seconds. Cells were washed three times with PBS and mounted onto 
microscope slides (Menzel-Gläser, Thermo Scientific, UK) using a small drop of Vectashield® 
mounting medium for fluorescence (Vector laboratories, UK).  
 
96 
 
2.4.3 Antigen expression analysis 
Slides were viewed using a Zeiss Axio Imager ZI fluorescent microscope and Hammamatsu 
digital camera (C4742-95) with 38 FITC (Excitation: 470 nm, emission 525nm) and 49 DAPI 
(Excitation: 380 nm, emission 445nm) filters. Images were taken using Velocity acquisition 
software. Images were taken at x 20 using the following settings: 38 FITC exposure 627 ms, 
49 DAPI exposure 7 ms, gain 0, offset 0. Images were taken at 40 x magnification using the 
following settings: 38 FITC exposure 753 ms, 49 DAPI exposure 11 ms, gain 0, offset 0. 
 
2.5 Immunohistochemistry (IHC) 
Immunohistochemistry was used to verify the presence and localisation of LDHA antigen 
within patient’s tissue sections of medulloblastoma. Paraffin embedded slides of human 
tissue were obtained from Addenbrookes National Health Service human research tissue 
bank. The LDHA antibody and peptide blocking protocol was optimised using muscle tissue 
as a positive control. Negative, positive and peptide controls were run in parallel with 
antigen stained samples. All IHC staining was optimised and carried out by Miss Gemma-
Kirstie Noble BSc student and Miss Yara Alenazi Msc student. 
 
2.5.1 Deparaffinisation and rehydration 
The slides were warmed until the wax was melted and immersed in xylene (Fisher 
Chemicals, UK), followed by decreasing concentrations of ethanol (100% ethanol, (VWR 
Chemicals, UK) diluted with dH2O) and dH2O to deparaffinise and rehydrate the tissue. 
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2.5.2 LDHA antigen detection 
The slides were immersed in citrate buffer (0.01M sodium citrate trisodium salt dehydrate, 
0.05% Tween-20, pH to 6.0) to unmask the antigen and washed in TBST (0.2M Trizma base 
(Sigma Aldrich, UK), 1.4M Sodium chloride (Sigma Aldrich, UK), 0.1% Tween-20 (Sigma 
Aldrich, UK), pH 7.6). Tissue sections were outlined using a PAP pen when necessary to 
prevent mixing of staining reagents. The slides were incubated in normal horse serum to 
prevent non-specific binding. LDHA antibody (1:200), LDHA peptide (1:72) or PBS (Table 8. 
3) was added to the tissue. The slides were washed twice in TBST and incubated in 3% 
hydrogen peroxide (diluted in methanol) to block endogenous activity. The slides were 
incubated in pre-diluted biotinylated pan-specific universal secondary antibody before 
being washed twice in TBST. The slides were incubated in 4-5 drops of streptavidin 
peroxidase complex before being washed twice in TBST. The slides were incubated in 
peroxidase substrate 3, 3’-diaminobenzidine (DAB) solution (Vector laboratories, UK), 
washed in dH2O before being counterstained with Mayer’s Haematoxylin for 90 seconds 
and rinsed under running tap water.  
 
2.5.3 Dehydration and mounting 
The slides were immersed in increasing concentrations of ethanol (100% ethanol, (VWR 
Chemicals, UK) diluted with dH2O) followed by xylene to dehydrate the tissue. 22 x 50 mm 
cover glass was mounted onto the slides using Vecta Mount™ (Vector laboratories, UK).  
Slides were scanned and imaged using Ariol image analysis and scanning system (Leica 
biosystems, Germany). 
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2.5.4 Haematoxylin and eosin (H & E) staining 
H & E staining was used to visualise the tissue morphology of medulloblastoma tissue 
sections. Haematoxylin combined with a “mordant”, such as aluminium, (which helps it 
bind to the tissue) which is positively charged and stains blue when it reacts with negatively 
charged basophilic cell components including nucleic acids and the nucleus. Eosin is 
negatively charged and stains pink when it reacts with positively charged acidophilic cell 
components including amino groups in the cytoplasm.  
The slides were deparaffinised as described previously. The slides were stained with 
Mayer’s haematoxylin solution (Sigma Aldrich, UK) for 5 minutes and washed in tap water 
for a minute. The slides were differentiated in acid alcohol for 10 seconds and washed in 
tap water for a minute.  The slides were stained with 1% eosin Y disodium salt (Fisher 
Scientific, UK) for 5 minutes and washed in tap water for 30 seconds. The slides were 
dehydrated, mounted and analysed as described previously. 
 
2.6 Protein isolation, polyacrylamide gel electrophoresis (PAGE) and 
Western Blotting (WB) 
Western blotting is semi-quantitative method used to analyse protein expression in tissue 
and cell lysates. It was used to compare protein expression of LDHA in adult and foetal 
cerebellum tissue lysates,  medulloblastoma and astrocyte cell lines at 24h, 48h and 72h 
time points as well as verifying the efficacy of the LDHA specific siRNA at 24h, 48h, 72h and 
96h time points under normoxic and hypoxic conditions. This protocol was optimised using 
the A549 cell line as a positive control for LDHA, LDHB and LDHC antigen expression. 
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2.6.1 Protein isolation 
Lysates for WB analysis were prepared as follows; the media was aspirated and discarded 
from 6-well plates, 12-well plates, T25 flasks or T75 flasks (Greiner bio-one, UK) of 80-90% 
confluence and the plates or flasks washed twice with PBS (Gibco, UK). Lysis buffer which 
consisted of M-PER® (Mammalian Protein Extraction Reagent) (Thermo Scientific, UK) and 
Halt™ protease and phosphatase inhibitor cocktail (Thermo Scientific, UK, 1:100) was added 
to the plate or flask and incubated on ice, on a platform shaker (Stuart Scientific, UK) for 10 
minutes. Cells were scraped from the surface of the flask and transferred into a labelled 1.5 
ml reaction tube (Greiner bio-one, UK), vortexed using a WhirliMixer® (FSA laboratory 
supplies, UK) for 10 seconds, and centrifuged for 15 minutes at 16,000 RCF/ 13,200 RPM at 
4°C using a centrifuge 5415 R (Eppendorf, UK). The supernatant was removed, transferred 
to a labelled 1.5 ml reaction tube and stored at -20°C. 
 
2.6.2 Bicinchoninic acid (BCA) protein assay 
The concentration of protein in the lysate was determined using a bicinchoninic acid (BCA) 
assay which relies on the formation of a CU2+ protein complex under alkaline conditions, 
followed by reduction of the CU2+ to CU1+, the amount of reduction is proportional to the 
protein present.  
The lysate sample was diluted 10 fold by adding 5 µl of lysate sample and 45 µl of dH2O to a 
0.5 ml reaction tube. Protein standards containing different bovine serum albumin (BSA) 
concentrations were prepared and 400 µl of BCA solution (comprising of bicinchoninic acid 
solution and Copper (II) sulphate solution at a 50:1 ratio) was added to each sample and 
standard. 100 µl of each sample and standard were transferred to a well in a clear-flat-
bottomed 96-well plate in triplicate. The plate was incubated for 30 minutes in an oven 
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(Memmert, UK) at 37°C before the absorbance at 595 nm was recorded using a POLARstar 
OPTIMA plate reader (BMG Labtech, UK). 
The average reading of the blank control (standard I) was subtracted from all other 
standard and sample values. The values of the standards were used to plot a polynomial 
standard curve and the equation of the line generated was used to determine the protein 
concentration of the test samples. The calculated protein concentration of the samples was 
multiplied by 10, to compensate for the 1:10 dilution in dH2O, to give the protein 
concentration of the undiluted lysate. 
 
2.6.3 PAGE 
The amount of lysate required to load 50 µg of protein was added to a 1.5 ml reaction tube 
(Greiner bio-one, UK) along with 10 µl of 5 x laemmli buffer (15.6% Tris HCL pH 6.8 (Sigma 
Aldrich, UK), 25% 2-Mercaptoethanol (Sigma Aldrich, UK), 9.4% dH2O, 50% glycerol (Sigma 
Aldrich, UK), 0.34M SDS (Sigma Aldrich, UK) and a small amount of Bromophenol (Sigma 
Aldrich, UK)), the sample volume was made up to 50 µl with M-PER® (Thermo Scientific, 
UK). The samples were briefly vortexed using a WhirliMixer® (FSA laboratory supplies, UK) 
and spun down using a centrifuge (VWR mini Star, UK). The samples were placed in a water 
bath at 90 -95°C for 5 minutes. Tris-Glycine 4-20% gradient pre-made gels (Thermo 
Scientific, UK) were assembled in a Mini-PROTEAN Tetra cell (Bio-Rad, UK) filled with 1 x 
running buffer (0.19M glycine (Sigma Aldrich, UK), 0.02M Trizma base (Sigma Aldrich, UK) 
and 3.46 mM SDS (Sigma Aldrich, UK) in dH2O. The samples and 5 µl of precision plus 
protein™ dual colour standards ladder (Bio-Rad, UK) were carefully loaded into the wells of 
the gel. Proteins were separated by SDS-PAGE at 100V for 1 hour and 20 minutes using a 
PowerPac™ (Bio-Rad, UK). 
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Immun-Blot® PVDF membranes for protein blotting (Bio-Rad, UK) were activated in 
methanol (Fisher Chemicals, UK) for 5 minutes, rinsed twice in dH2O and pre-soaked in 1 x 
transfer buffer (70% dH2O, 0.19M glycine (Sigma Aldrich, UK) and 0.02M Trizma base 
(Sigma Aldrich, UK)) and 20% methanol (Sigma Aldrich, UK). The gels were assembled 
together with the Immun-Blot® PVDF membrane as part of a blotting sandwich. The gels 
were transferred in 1 x transfer buffer at 100V for 1 hour 20 minutes using a PowerPac™ 
(Bio-Rad, UK). 
 
2.6.4 Probing for proteins 
After protein transfer, Immun-Blot® PVDF membranes were incubated in blocking buffer 
(5% milk (Marvel, UK) in TBST (0.01M Trizma HCL (Sigma Aldrich, UK), 0.13M sodium 
chloride (Sigma Aldrich, UK), 0.1% Tween-20 (Sigma Aldrich, UK), in dH2O and pH to 7.6) on 
a platform shaker (Stuart Scientific, UK) for 1 hour to prevent non-specific antibody-binding 
to the membrane. Immun-Blot® PVDF membranes were incubated overnight at 4°C in 5% 
milk blocking buffer containing primary antibody (1:10000) (Table 8. 3) on a platform 
shaker. The Immun-Blot® PVDF membranes were washed in TBST for 5 x 5 minutes. The 
appropriate secondary antibody (1:10000) (Table 8. 4) was added to the Immun-Blot® PVDF 
membranes and incubated for 1 hour on a platform shaker at room temperature. The 
Immun-Blot® PVDF membranes were washed in TBST for 5 x 5 minutes.  
 
2.6.5 Antigen detection 
Secondary antibodies, conjugated to horseradish peroxidise, use hydrogen peroxide to 
oxidise chemiluminescent substrates and emit light which could be detected using a G-Box 
chemiluminescent imaging system (Syngene, UK) and GeneSnap image acquisition software 
(Syngene, UK). The Immun-Blot® PVDF membranes were incubated with 1 ml of Luminata™ 
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Forte Western HRP Substrate (Merck Millipore, UK) for 1-3 minutes before being placed on 
cling film (Sarogold® Pro, Fisher Scientific, UK) positioned in the G-Box chemiluminescent 
imaging system (Syngene, UK). First an image was taken using the “upper light” setting to 
show the position of the ladder which could be used to verify band sizes during analysis. 
Images were taken using the “no light” setting at various exposures depending on the 
intensity of the protein expression.  Semi-quantitative downstream analysis of protein 
expression was performed using Image J software. 
 
2.6.6 Stripping the blot 
After initial analysis the Immun-Blot® PVDF membranes were stripped of primary antibody 
by 1 x 5 minute wash in 0.2M NaOH (Sigma Aldrich, UK), 2 x 3 minute washes in dH2O and 3 
x 5 minute washes in TBST. The Immun-Blot® PVDF membranes were re-probed as 
described above with cyclophilin A, a loading control antibody, to ensure consistent protein 
loading.  
 
2.7 Sodium oxamate preparation 
Oxamate is an analogue of pyruvate and was used with astrocyte and medulloblastoma cell 
lines as an inhibitor of LDHA activity. For all experiments with oxamate, cells were seeded 
and left to adhere overnight before treatment with 25 mM, 50 mM or 75 mM of sodium 
oxamate (0h). Cells were harvested or used for experimental purposes at 24h, 48h or 72h 
time points. Sodium oxamate (Sigma Aldrich, UK) stock was prepared at 0.5M 
concentrations in dH2O and filtered, using a Millex®-GP 22 µm filter unit (Merck Millipore, 
UK), in a biological level II sterile laminar flow cabinet (NUAIRE, UK) using aseptic technique. 
Aliquots were stored at -20°C.  
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2.8 Small interfering RNA (siRNA) knock down 
Small interfering RNA (siRNA) is an RNA interference (RNAi) substrate designed to bind to 
and inhibit mRNA transcription of a specific target gene, enabling gene-silencing. Transient 
LDHA siRNA transfections were used to examine the functional role of LDHA in 
medulloblastoma. Successful LDHA protein knock down was verified by Western blots, the 
samples for which were prepared in parallel to every functional siRNA experiment.  
 
Table 2. 2 LDHA siRNA target sequence 
The LDHA siRNA target sequence is made up of nucleotide bases adenine (A), cytosine (C), 
guanine (G), thymine (T) and uracil (U). 
 Sense Antisense 
Sequence (5’ to 3’) CCAUGAUUAAGGGUCUUUATT UAAAGACCCUUAAUCAUGGTG 
 
Dried LDHA Silencer® select pre-designed siRNA (Ambion, UK, product number 4392420) 
(Table 2. 2) and Silencer® select Negative control #1 siRNA (Ambion, UK) were stored at -
20°C until required. All siRNA procedures were carried out in a NUAIRE biological level II 
sterile laminar flow cabinet using an aseptic technique and filter pipette tips. LDHA 
Silencer® select pre-designed siRNA and Silencer® select Negative control #1 siRNA stock 
solutions were prepared at 50 µM concentration in nuclease-free water (Ambion, UK), 
aliquoted and stored at -20°C. 
Cells were harvested as described previously and seeded at a density of 70,000 per well, in 
a 12-well plate (Greiner bio-one, UK), in 1 ml of media and left to adhere overnight. LDHA 
Silencer® select pre-designed siRNA and Silencer® select Negative control #1 siRNA stock 
solutions were diluted in Opti-MEM (Gibco, UK) to make a 2 µM concentration stock 
solution. The required amount siRNA stock solution was added to a separate tube which 
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already contained the required amount of jetPRIME® buffer (Polyplus transfection®, Source 
Bioscience Life Sciences, UK) required. The solution was mixed by pipetting. The required 
amount of jetPRIME® reagent was added to the tube. The tube was briefly vortexed for 10 
seconds, centrifuged, and incubated at room temperature for 10 minutes. The appropriate 
amount of siRNA solution to give a 15nmol concentration per well was added to the correct 
wells in a drop-wise manner (0h). MTS assays were conducted in 96-well plates with the 
same smaller volumes of reagents but the concentration of jetPRIME® reagent, jetPRIME® 
buffer and siRNA was unchanged (Table 2. 3).  
 
Table 2. 3 Contents of wells undergoing siRNA transfection 
The surface area, number of cells and volume of reagents used in each siRNA transfection 
assay. 
 
 12-well plate/ well 96-well plate/ well 
Surface area 3.9cm2 1cm2 
Cells 70,000 4602 
Media 1000 µl 65.74 µl 
siRNA 7.5 µl 0.49 µl 
jetPRIME® buffer 100 µl 6.57 µl 
jetPRIME® reagent 4 µl 0.26 µl 
 
Cells were harvested and used for experimental purposes for 24h, 48h, 72h or 96h time 
points. After 24h incubation, the media was changed in all plates not required immediately 
for experimental purposes, in order to avoid any toxicity effects which may be caused by 
jetPRIME® reagent. The volume of media in 96-well plates was increased to 100 µl after 24h 
to prevent wells drying out at the longer time points. 
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2.9 Glycolysis assays 
Glycolysis assays (pyruvate and lactate) were used to measure the total amount of a 
specific metabolite in a cell lysate, indicating the glycolytic activity of cells. The glycolysis 
assays were used to verify the inhibition of LDHA activity by sodium oxamate and LDHA 
specific siRNA. For each cell line, three independent sets of samples were run in duplicate. 
Pyruvate and lactate concentrations were measured using pyruvate and lactate assay kits 
(MAK071 and MAK064, Sigma Aldrich, UK) respectively, according to the manufacturer’s 
instructions with slight modifications (Table 2. 4) which result in a colourimetric product 
proportional to the pyruvate or lactate present. Cells were plated in 6-well plates (Greiner 
bio-one, UK) (Table 8. 2) and left to adhere overnight before treatment. In order to 
normalise the results, cells were lysed and protein concentration determined by BCA assay 
as described previously. A series of lactate or pyruvate standards were prepared in 
duplicate in wells of a black-walled, flat, clear-bottomed, 96-well plate.  
 
Table 2. 4 Pyruvate and lactate assay master reaction mix 
Volumes of reagents used to prepare the pyruvate and lactate assay master reaction mix. 
Reagent Master Reaction Mix per well 
Pyruvate or lactate assay buffer 48μl 
Pyruvate or lactate enzyme Mix 1 µl 
Pyruvate or lactate Probe 1μl 
 
For the pyruvate assays, 30 µl of each lysate was added to wells in duplicate with 20 µl of 
pyruvate assay buffer. For the lactate assay, 20 µl of each lysate was added to wells in 
duplicate with 30 µl of lactate assay buffer. The Pyruvate probe was diluted 5 fold in 
pyruvate assay buffer before use and the lactate probe was diluted 2.5 fold in lactate assay 
106 
 
buffer before use. 50 µl of the reaction assay master mix (Table 2. 4) was added to each 
standard and each sample well. 
The plate was incubated in the dark at room temperature for 30 minutes. Absorbance was 
measured at 570nm using POLARstar OPTIMA plate reader (BMG Labtech, UK). The average 
reading of the blank control was subtracted from all other standard and sample values. The 
standard values were used to plot a polynomial standard curve and the equation of the line 
generated was used to determine the nmole of lactate or pyruvate in each sample. The 
results were analysed using GraphPad Prism software. The concentration and ng/ µg of 
lactate and pyruvate were calculated as follows: 
 
𝑃𝑦𝑟𝑢𝑣𝑎𝑡𝑒/ 𝑙𝑎𝑐𝑡𝑎𝑡𝑒 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒 (𝑛𝑚𝑜𝑙𝑒)
𝑆𝑎𝑚𝑝𝑙𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 (𝜇𝑙)
 = 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑛𝑚𝑜𝑙𝑒/µ𝑙) 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑛𝑚𝑜𝑙𝑒/µ𝑙 × 88.08 𝑛𝑔/𝑛𝑚𝑜𝑙𝑒 = 𝑛𝑔/µ𝑙 𝑝𝑦𝑟𝑢𝑣𝑎𝑡𝑒 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑛𝑚𝑜𝑙𝑒/µ𝑙 × 89.07 𝑛𝑔/𝑛𝑚𝑜𝑙𝑒 = 𝑛𝑔/µ𝑙 𝑙𝑎𝑐𝑡𝑎𝑡𝑒 
𝑃𝑦𝑟𝑢𝑣𝑎𝑡𝑒 𝑜𝑟 𝑙𝑎𝑐𝑡𝑎𝑡𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑛𝑔/µ𝑙  
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (µ𝑔/µ𝑙)
 = 𝑛𝑔/µ𝑔 𝑝𝑦𝑟𝑢𝑣𝑎𝑡𝑒 𝑜𝑟 𝑙𝑎𝑐𝑡𝑎𝑡𝑒  
 
2.10 Growth curve assay 
Trypan blue exclusion assays allow a population of cells to be counted excluding the dead 
cells which are stained blue. Growth curves were used to measure effects on the 
population growth rate of each cell line with the addition of increasing concentrations of 
sodium oxamate. 
Cells were counted as described previously and seeded at a density of 100,000 per well in a 
6-well plate (Greiner bio-one, UK), in 2 ml appropriate media and left to adhere overnight 
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before treatment. Cells were harvested from the 6-well plates using 25cm cell scrapers 
(Sarstedt, UK) and transferred into 1.5 ml reaction tubes. Cells were pelleted using a 
centrifuge 5415 R (Eppendorf, UK) at 300 RCF/ 1800 RPM for 5 minutes. The supernatant 
was removed and cell pellet re-suspended in 600 µl appropriate media and transferred to a 
Vi-Cell cup.  The cells were counted using the Vi-Cell, as described previously, but with a 
dilution factor of 1 to give the total number of viable cells per sample.  
 
2.11 Viability assay 
MTS assays use the measurement of a formazan product to quantify viable, metabolically 
active cells in proliferation. The CellTiter 96® Aqueous One Solution (Promega, UK) contains 
3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt (MTS) and a cell-permeable electron coupling reagent; phenazine ethosulfate 
(PES). PES shuttles into cells where it is reduced by NADPH or NADH, it then shuttles out of 
the cell where it reduces MTS to formazan the absorbance of which is measured at 490nm 
(Figure 2. 6).  
Cells were counted and seeded (Table 8. 2) in 200 µl appropriate media, in the centre (to 
avoid edge effects) of a clear, flat-bottomed 96-well plate and left to adhere overnight 
before treatment. The media was removed and replaced with 100 µl of fresh media and 
100 µl was also added to empty wells in triplicate as a background control. 10 µl of CellTiter 
96® Aqueous One Solution (Promega, UK) was added to each well. The plate was incubated 
in the dark in an oven (Memmert, UK) at 37°C for 3 hours. The absorbance was read at 490 
nm using a POLARstar OPTIMA (BMG Labtech, UK) plate reader. The average background 
reading was then subtracted from all the sample readings and results analysed using 
GraphPad Prism software. 
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Figure 2. 6 MTS to formazan reaction 
MTS is reduced to formazan by PES that has been reduced by NADH. The absorbance of 
formazan can be measured at 490nm 278. 
 
2.12 Cell cycle analysis 
The nuclear DNA content of a cell can be used to examine the proportion of cells in each 
stage of the cell cycle using the principle that cells in G1/G0 phase will have one set of 
paired chromosomes per cell, cells in G2/M phase will have two sets of paired 
chromosomes per cell and cells in S phase will have a variable amount of DNA; between 
one and two sets of paired chromosomes per cell.  4',6-diamidino-2-phenylindole (DAPI) is a 
fluorescent stain that passes through intact cell membranes and binds strongly to A-T rich 
regions of DNA which can be detected using the NucleoCounter® NC-3000 (ChemoMetec, 
UK), an advanced cell analyser which uses fluorescence imaging.  This method was used to 
examine the effects of sodium oxamate on the cell cycle of medulloblastoma cell lines. 
 
Cells were plated in 6-well plates (Greiner bio-one, UK) at an appropriate seeding density 
(Table 8. 2) to give 80-90% confluence after 24-48 hours of incubation. Cells were 
harvested from the 6-well plates using 25cm cell scrapers (Sarstedt, UK) and transferred 
into 1.5 ml reaction tubes. Cells were pelleted using a centrifuge 5415 R (Eppendorf, UK) at 
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500 RCF/ 2300 RPM for 5 minutes at room temperature. The supernatant was aspirated 
and discarded and the cells were washed in 200 µl PBS (Gibco, UK) before being re-
suspended in 100 µl PBS.  The cells were fixed with 450 µl cold 70% ethanol which was 
added drop wise whilst vortexing to avoid cells clumping. The cells were stored at 4°C for a 
week before analysis. 
 
Figure 2. 7 NucleoCounter NC-3000 raw data 
An example of the data output from the NucleoView NC-3000 (ChemoMetec, UK) software. 
M1, M2 and M3 were used to gate the percentage of cells in G0, S and G2/M phase 
respectively. 
 
The ethanol-suspended cells were centrifuged at 800 RCF/ 2900 RPM for 10 minutes at 4°C. 
The supernatant was carefully removed and the cells re-suspended in 500 µl PBS and 
centrifuged at 800 RCF/ 2900 RPM for 10 minutes at 4°C. The supernatant was removed 
and cells were re-suspended in 100 µl of Chemometec Solution 3 (1 µg/ ml DAPI, 0.1% 
triton x-100 in PBS). DAPI preferentially binds to double stranded DNA so there is no need 
to use RNase treatment to remove RNA before analysis. 10 µl of each cell suspension was 
loaded into a chamber of a NC-Slide A8™ and run using the “Fixed Cell Cycle-DAPI assay” 
settings on the NucleoCounter® NC-3000 which analyses a minimum number of 10,000 cells 
P
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per sample. DNA content is quantified from cellular fluorescence at 365nm using the Blue 
channel LED Ex 365 and emission filter Em 470/55. Results were analysed further using 
NucleoView NC-3000 (ChemoMetec, UK) software (Figure 2. 7).  
 
2.13 Metabolism assays using the Seahorse extracellular flux 
analyser 
The Seahorse extracellular flux analyser measures mitochondrial respiration and glycolysis 
of live cells. Specialised sensitive probes measure the oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR) of assay wells simultaneously. These experiments 
were carried out on the UW402 cell line on different instruments and models; the Seahorse 
XFe96 analyser at Bergan University, Norway and the Seahorse XF96 analyser at 
Southampton University, UK. Seahorse Bioscience technical team member Mr Jacob 
Konowitch advised that their head of engineering department stated “the performance of 
the XF96 has been tested with the XFe96 and they are equivalent in use”. 
 
2.13.1 Glycolysis stress test 
Less than an hour before the assay was run, the media on the cells was changed to 
glycolysis stress test assay medium (2 mM L-glutamine (Sigma Aldrich, UK) in XF base 
medium (Seahorse bioscience) pH 7.35) which does not contain glucose. When glucose was 
injected, it was taken up by the cells and catabolised by their glycolytic pathway, producing 
protons and ATP causing a rapid increase in the ECAR. Oligomycin inhibits mitochondrial 
ATP production causing the cells to increases their rate of glycolysis, as it becomes their 
only source of ATP, and the increase in ECAR shows the maximum glycolytic capacity of the 
cells. 2-DG is an analogue of glucose and competitively binds to glucose hexokinase and 
shuts down the glycolysis pathway, inhibiting any further glycolysis (Figure 2. 8). 
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Figure 2. 8 Glycolytic stress test mechanism using the Seahorse extracellular flux analyser 
The glycolytic stress test is used to determine the glycolytic profile of cells. By injecting 
glucose, oligomycin and 2-DG at separate time points the dependence of the cells on the 
pathway can be examined 279. 
 
2.13.2 Mito stress test 
Oligomycin inhibits mitochondrial complex V (ATP synthase) and after injection, the 
following decrease in oxygen consumption correlates with mitochondrial ATP production. 
Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) is an uncoupling agent that 
transports hydrogen ions through the membrane, disrupting the mitochondrial membrane 
potential. This allows an unrestricted flow of electrons to run through the ETC and oxygen is 
maximally consumed by mitochondrial complex IV. Antimycin A is a complex III inhibitor 
and rotenone is a complex I inhibitor and when combined inhibits all mitochondrial 
respiration (Figure 2. 9). 
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Figure 2. 9 Mito stress test mechanism using the Seahorse extracellular flux analyser 
The mito stress stress test is used to determine the cells use of oxidative phosphorylation. 
By injecting oligomycin, FCCP, antimycin A and rotenone at separate time points the 
dependence of the cells on the pathway can be examined 280. 
 
2.13.3 Cell counting and seeding 
As a Vi-Cell was unavailable at the locations the Seahorse experiments took place, the cell 
counting procedure was different from that described previously. Cells were harvested as 
described previously and re-suspended in 1 ml of appropriate media, 10 µl of the cell 
suspension culture was loaded into a BC2000 Neubauer cell counting chamber (Hawksley, 
UK). Cells were manually counted in at least three of the 1mm2 squares, made up of 16 
smaller squares. Only cells within the square and touching the same two of the four sides 
were counted to avoid counting cells twice. The cell concentration was calculated as 
follows: 
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𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 1 𝑚𝑚2𝑠𝑞𝑢𝑎𝑟𝑒𝑠
 ×  10,000 = 𝑐𝑒𝑙𝑙𝑠 / 𝑚𝑙 
The amount of media required to seed the correct number cells was calculated as described 
previously. Cells were seeded at a density of 5,000 per well in 80 µl of appropriate media in 
a Seahorse 96-well XF cell culture microplate (Seahorse Bioscience, UK). Cells were left to 
adhere overnight before treatment with sodium oxamate. For each plate 19 wells were 
used for control samples and samples treated with 25 mM of sodium oxamate, whereas 18 
wells were used for samples treated with 50 mM and 75 mM of sodium oxamate and a 
vehicle control, the four corner wells were used as background control wells.  
The day before the assay, an XF96 flux sensor cartridge (Seahorse Bioscience, UK) was 
hydrated by adding 200 µl of Seahorse XF calibrant (Seahorse Bioscience, UK) to each well 
of the 96-well utility plate. The flux sensor cartridge was lowered onto the utility plate, the 
sensors submerged, and placed into a non-CO2 37°C incubator (Shel lab, UK) overnight. The 
Seahorse instrument was also turned on to warm up to 37°C and stabilise overnight. 
 
2.13.4 Medium preparation 
On the day of the assay 100 ml of sterile XF base medium (Seahorse Bioscience, UK) was 
aliquoted and prepared to create XF cell Mito stress test assay medium (2 mM L-glutamine 
(Sigma Aldrich, UK), 10 mM Glucose (Corning, UK), 1 mM sodium pyruvate (Sigma Aldrich, 
UK), in XF base medium (Seahorse bioscience) pH 7.4) or XF glycolysis stress test assay 
medium (2 mM L-glutamine (Sigma Aldrich, UK) in XF base medium (Seahorse bioscience) 
pH 7.35). The assay medium was filtered to sterilise and kept at 37°C until ready to use. 
Media was removed from the Seahorse 96-well XF cell culture microplate (Seahorse 
Bioscience, UK) and washed twice with 200 µl of appropriate assay medium. After the last 
wash, 175 µl of appropriate assay medium was added to each well. The Seahorse 96-well XF 
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cell culture microplate was placed into a non-CO2 37°C incubator for 30 minutes before the 
assay. 
 
2.13.5 Reagent preparation 
The reagents to be loaded into the ports of the sensor cartridge were prepared to make 
stock solutions as per the manufacturer’s instructions. The stock solutions were diluted 
(Table 2. 5 and Table 2.6) to concentrations which could be loaded into the sensor cartridge 
to give the desired final well concentration. Solutions were loaded into the correct chamber 
using a 50 ml reagent reservoir (Corning Incorporated, UK), multichannel pipette 
(Transferpette®-8, Brand, UK) and template lid provided. The Sensor cartridge was loaded 
into the Seahorse XF analyser and calibrated before the XF cell culture microplate was 
inserted and the assay ran according to a pre-designed assay template (Figure 2. 10).  
To normalise the results a BCA assay was performed, as described previously, to compare 
the ratio of protein in each group. After the assay had finished, the media was removed 
from the XF cell culture microplate and it was washed with 200 µl PBS. The XF cell culture 
microplate was stored at -80°C. The XF cell culture microplate was thawed and 200 µl of 
BCA solution added to each well and transferred to a compatible clear, flat-bottomed 96-
well plate. The average value of the background wells at each time point was taken off each 
well value at each time point and data analysis was conducted using Wave software. 
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Table 2. 5 Reagent dilutions for glycolysis stress test 
List of stock and assay media volumes required to prepare the glycolysis stress test assay 
reagents. 
Reagent Port Stock 
volume (µl) 
Assay media 
volume (µl) 
Add to 
port (µl) 
Final well 
conc. (mM) 
Glucose 100mM A 3000 750 25 10 
Oligomycin 0.1mM B 270 2730 25 0.001 
2-DG 500mM C 3000 0 25 50 
 
 
 
Table 2. 6 Reagent dilutions for mito stress test 
List of stock and assay media volumes required to prepare the mito stress test assay 
reagents. 
Reagent Port Stock 
volume (µl) 
Assay media 
volume (µl) 
Add to 
port (µl) 
Final well 
conc. (µM) 
Oligomycin 100 µM A 240 2760 25 1 
FCCP 100 µM B 135 2865 25 0.5 
Rotenone / 
antimycin A 50 µM 
C 300 2700 25 0.5 
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Figure 2. 10 Plan of Seahorse assay setup 
Basic experimental plan of glycolysis stress test and mito stress test. 
 
2.14 Live cell imaging  
Live cell imaging was used to examine the behaviour of cell movement when a scratch was 
made in a confluent monolayer. During the live cell imaging experiments, cells were 
maintained inside a temperature (tempcontrol 37-2 digital, Meyer instruments, UK), CO2 
and oxygen (Bold line, Okolab, Indigo Scientific, UK) controlled incubator which enclosed 
the Ziess Axiovert 200M microscope stage, objectives and filters (Figure 2. 11). The 
incubator was set to 37°C, 95% air, 5% CO2 for experiments performed under normoxic 
conditions and 37°C, 1% O2, 5% CO2 for experiments performed under hypoxic conditions. 
Cells were plated in 24-well plates (Greiner bio-one, UK); in 500 µl appropriate media at an 
appropriate seeding density (Table 8. 2) to give a confluent monolayer after overnight 
incubation. A Gilson® style 200 µl pipette tip (Greiner bio-one, UK) was used to make a 
scratch through the middle of the confluent monolayer of cells in each well. The media was 
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removed and replaced with 500 µl of appropriate media (with sodium oxamate treatments, 
if required) and secured into the Ziess Axiovert 200M microscope stage. The points at which 
the microscope focused were set using the velocity software. Images were taken once 
every 30 minutes for 72 hours using Volocity® acquisition software (PerkinElmer, UK).  
The area of the gap was measured at 6 hour time points using T Scratch software 
developed by the Koumoutsakos group (CSE Lab), at ETH Zürich 281 (Figure 2. 12). 10 cells 
from the edge of each scratch (5 each side) were tracked manually for the first 24 hours of 
each video sequence using Volocity® analysis software (PerkinElmer, UK) (Figure 2. 13).  
 
 
Figure 2. 11 Live cell imaging microscope aparatus 
Image showing the set-up of the live cell imaging microscope, incubator, gas connections 
and other apparatus. 
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Figure 2. 12 T scratch analysis software 
Image of the T scratch analysis software used to determine % of gap open for scratch 
wound assays. The software automatically detects cells and colours them in (light grey), the 
software can then calculate the percentage of the image not coloured in, where there is a 
gap (dark grey). 
 
 
Figure 2. 13 Volocity cell tracking analysis software 
Image of Volocity software used to manually track cells during the first 24h of gap closure. 
A box is drawn around a cell, as the user goes through each frame, the box can be moved to 
track the movement of the cell. 
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2.15 Statistics 
Unless stated otherwise, for all experiments three samples were completed together and 
independently in triplicate for each condition and cell line. All statistical analysis was carried 
out using GraphPad Prism 6 software. P-values less than 0.05 were considered significant. T 
tests were used to analyse the WB and FC data to compare difference in LDHA expression 
under normoxic and hypoxic conditions in each cell line. Ordinary one-way anova with 
Fisher’s LSD test was used to analyse the R2 data base genomic data to compare 
differences between LDHA expression between MB subgroups and non-neoplastic tissues 
and to analyse 24h of cell tracking data and compare the treated samples to the control 
samples.  Two-way ANOVA with Fisher’s LSD test was used for all other experiments to 
compare treated samples to the control sample at different time points. 
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Chapter 3: LDHA expression in MB and CNS tissues and cell lines  
Hypothesis 1: 
LDHA expression is elevated in MB compared to non-neoplastic cells and a higher LDHA 
expression is associated with a more aggressive and metastatic MB subgroup (Group 3 
and Group 4) 
To establish whether LDHA expression was deregulated in MB, initially the expression of 
LDHA in non-neoplastic CNS tissue and MB tissue was compared. Subsequently the 
expression of LDHA in non-neoplastic and MB cell lines was also examined. 
 
3.1 R2 database; expression of LDHA in non-neoplastic CNS tissues 
and MB subgroups 
Normal LDHA mRNA expression in various non-neoplastic CNS tissues (where 8 or more 
samples were available) were compared using the R2 database and publically available Roth 
normal tissue dataset (Figure 3. 1), as described in chapter 2. There was only one available 
sample for foetal brain (so it could not be used for statistical analysis). The age range of the 
other samples was unavailable. Out of all the CNS samples examined, the cerebellum and 
spinal cord had the lowest mean LDHA expression. Furthermore, the cerebellum expressed 
significantly less LDHA than the midbrain (P ≤ 0.01), frontal lobe and parietal lobe (P ≤ 0.05).  
Using the R2 database, LDHA mRNA expression in the Gilbertson MB dataset and Roth 
normal tissue dataset could be compared as they both used the u133p2 chiptype, and were 
both normalised by the MAS5.0 algorithm (Figure 3. 2). The mean expression of LDHA 
within the MB subgroups was as follows; Group 3 > Wnt > Group 4 > Shh. Group 3 
expressed significantly more LDHA than all the other MB subgroups (Group 4 and Shh P ≤ 
0.0001, Wnt P ≤ 0.001). The Wnt subgroup expressed significantly more LDHA than the Shh 
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subgroup (P ≤ 0.01) and Group 4 also expressed significantly more LDHA than the Shh 
subgroup (P ≤ 0.05). Moreover Group 3 and the Wnt subgroup both expressed significantly 
more LDHA than non-neoplastic cerebellum and spinal cord (P ≤ 0.0001 and P ≤ 0.05 
respectively). 
In Summary non-neoplastic cerebellum and spinal cord tissue express less LDHA than most 
other CNS tissues. Furthermore two MB subgroups (Wnt and Group 3) significantly over 
express LDHA and Group 3, the most metastatic subgroup, also expresses significantly more 
LDHA than the other MB subgroups. 
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3.1.1 Non-neoplastic CNS tissue 
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Figure 3. 1 LDHA expression in non-neoplastic CNS tissues 
LDHA expression in a range of non-neoplastic CNS tissues mined using the R2 data base and 
dataset Normal Various - Roth - 504 – MAS5.0 - u133p2 271. The number of samples per 
tissue is stated in brackets.  Mean LDHA values; cerebellum (9) 1307, spinal cord (9) 1303, 
cerebral cortex (8) 1447, hippocampus (8) 1309, midbrain (9) 2116, frontal lobe (9) 1885, 
parietal lobe (8) 1954, temporal lobe (8) 1653, occipital lobe (8) 1465 and foetal brain (1) 
1246. LDHA expression in cerebellum and CNS were compared to every other CNS tissue. 
Graphs show box plots (highest value, lowest value, upper quartile, lower quartile, 
interquartile range and median). Ordinary one-way ANOVA; not significant P > 0.05, * P ≤ 
0.05, ** P ≤ 0.01.  
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3.1.2 MB subgroups and non-neoplastic CNS tissue 
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Figure 3. 2 LDHA expression in non-neoplastic CNS tissues and MB subgroups 
LDHA expression in a range of non-neoplastic CNS tissues and MB subgroups, mined using 
the R2 data base and the following datasets: Tumor Medulloblastoma - Gilbertson - 76 - 
MAS5.0 - u133p2 and Normal Various - Roth - 504 – MAS5.0 - u133p2 271. The number of 
samples per tissue is stated in brackets. Mean LDHA values; Wnt (8) 2236, Shh (10) 1087, 
Group 3 (16) 3507, Group 4 (39) 1835, cerebellum (9) 1307, spinal cord (9) 1303 and foetal 
brain (1) 1246. LDHA expression was compared between MB subgroups and compared to 
normal cerebellum and spinal cord. Graphs show box plots (highest value, lowest value, 
upper quartile, lower quartile, interquartile range and median). Ordinary one-way ANOVA; 
not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 
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3.2 Characterisation of MB tissue histology 
The histology of a MB tissue section from a patient with a WHO 2007 Grade 4 MB, aged 4 
years and 7 months, was examined using haematoxylin and eosin A staining (Figure 3. 3). 
The nuclei were stained blue and cytoplasm pink. Large, irregular nuclei (green arrows) and 
blood vessels can be seen (blue arrows). The histology and nuclei to cytoplasm ratio varies 
throughout the tissue but characteristically fits into the classic MB histological subgroup. 
 
Figure 3. 3 Haematoxylin and eosin staining of MB tissue 
Representative haematoxylin and eosin staining of a WHO 2007 grade 4 MB tissue section. 
The nucleus is stained blue whereas the cytoplasm is stained pink. Green arrows show large 
irregular nuclei, blue arrows show blood vessels. Images were obtained using an Ariol 
microscope (Leica, Germany) at x40 magnification.  
1002
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3.3 Characterisation of LDHA expression in MB tissue sections by 
immunohistochemistry 
MB tissue sections, from the same patient as mentioned previously, were stained with 
LDHA antibody or appropriate negative controls (Figure 3. 4 and Figure 3.5). The initial 
purpose was to optimise the LDHA antibody and show LDHA expression in MB tissue before 
collaborators at the Hospital for Sick kids, Toronto, would use it on one of their rare MB 
tissue microarrays. There was strong cytoplasmic LDHA expression throughout the MB 
tissue section suggesting this tumour was highly glycolytic. There was also strong nuclear 
LDHA expression throughout indicating that LDHA may also have been playing a nuclear 
role in transcription or translation. However, notably blood vessels did not express LDHA. 
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Figure 3. 4 Immunohistochemistry with MB tissue 
Three slices of a WHO 2007 grade 4 MB tissue section were stained with LDHA antibody in 
parallel with a negative control and peptide control. Brown indicates positive staining. A) 
Negative control. B) Peptide control. C) LDHA stain. Images were obtained using an Ariol 
microscope (Leica, Germany) at x 40 magnification. 
100 
µm 
10000 
µm 
A 
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Figure 3. 5 LDHA staining of MB tissue 
Enlarged representative images of the LDHA stained WHO 2007 grade 4 MB tissue section. 
Brown indicates positive LDHA expression. Images were obtained using an Ariol microscope 
(Leica, Germany) at x 40 magnification. 
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3.4 MB and foetal astrocyte cell line morphology 
Cell morphology and confluency was monitored by phase contrast microscopy to maintain 
optimum cell growth and quickly detect any bacterial or fungal contaminations. Figure 3. 6 
shows the morphology of UW402 (A), DAOY (B), Res256 (C) and CC2565 (D), the four main 
cell lines used throughout this project.  
 
Figure 3. 6 Cell line morphology  
Cell line morphology of the four main cell lines used throughout this project. A) UW402, are 
small, elongated MB cells, B) DAOY are small, rounded MB cells, C) Res256 are small, 
rounded MB cells, D) CC2565 are elongated astrocyte cells with filamentous processes. 
Small bright round cells are detached cells. Images taken at x 4 magnification Scale bar = 
500 µm.  
 
In vivo, tumours are very heterogeneous and include cancer stem cells as well as many 
mutated daughter cells with various unique mutations. Therefore, when tumours are first 
established as primary cultures and at early passages, they maintain their heterogeneous 
A B 
C D 500µ
m 
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m 
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m 
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features, however as some cells are less suited to in vitro conditions than others, they are 
outgrown and cell lines become more homogenous and more removed from the true in 
vivo environment with every passage. Unfortunately, MB cell lines have proved difficult to 
establish in the past 282, and combined with few biopsies being available for processing to 
attempt to create new cell lines, few cell lines are available for research purposes and often 
the cell lines that are available have been passaged so many times they are very 
homogenous and don’t truly represent the molecular subgroups seen in patients.  
The MB cell lines available for this project were at high passages and as a result are very 
homogenous. UW402 cells are small but more elongated than Res256 and DAOY; they have 
not been molecularly subgrouped but are known to have isochromosome 17q 283 which is 
typical of Group 3 and Group 4 MBs. Res256 cells are the smallest and have the most 
rounded phenotype of the three MB cell lines and they have not been molecularly 
subgrouped. DAOY cells also have a rounded phenotype but are larger than Res256 cells 
and have been molecularly subgrouped as SHH MB 284.  
The foetal non-neoplastic astrocyte cell line CC2565, has a short life-span in vitro and was 
used for experiments between passages 5 and 9; the cells were typically elongated with 
long filamentous processes. CC2565 cells were used as a control cell line as they are best 
available paediatric, non-neoplastic cell line however, as discussed in section 4 in more 
detail; they are not ideal control cell lines to compare to MB. The main purpose of including 
them in this study was to foresee if targeting LDHA would have any significant detrimental 
effects on non-neoplastic astrocyte cells. 
 
130 
 
3.5 Characterisation of LDHA protein expression in CNS tissue and 
cell lines by Western blotting 
LDHA protein expression was compared between MB cell lines, adult and foetal cerebellar 
tissue lysates and non-neoplastic astrocyte cell lines using Western blotting. Cyclophilin A 
protein expression was also examined, as it is a constitutively expressed housekeeping 
gene, to verify equal amounts of total protein of each sample were loaded and differences 
in LDHA expression were not due to unequal sample sizes. The blots were analysed using 
image J software to evaluate the intensity of LDHA expression in each sample compared to 
normal foetal cerebellar tissue. The LDHA expression of each sample was normalised to the 
Cyclophilin A expression to remove any small differences in protein concentrations. 
LDHA was expressed in all screened in MB cell lines, adult and foetal astrocyte cell lines and 
adult and foetal cerebellar tissue lysates (Figure 3. 7). LDHA expression was highest in the 
astrocyte cell lines SC1800 and CC2565 (ratios 2.50 and 2.39 respectively) and lowest in the 
adult and foetal cerebellar tissue lysates (ratios 0.96 and 1 respectively). The ratio of LDHA 
expression in all MB cell lines was elevated compared to normal foetal cerebellar tissue but 
not as much as the astrocyte cell lines; UW402 (1.43), Res256 (1.20) and DAOY (1.37). 
In summary LDHA protein expression is more abundant in astrocyte cell lines than adult and 
foetal cerebellar tissue and MB cell lines. However MB cell lines over express LDHA 
compared to normal foetal and adult cerebellar tissue. 
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Figure 3. 7 LDHA expression in a range of cell lines and tissue lysates as shown by WB 
Representative Western blot of lysates from adult astrocyte cell line SC1800, foetal 
astrocyte cell line CC2565, adult and foetal cerebellar tissue* (Novus Biologicals, UK) and 
MB cell lines UW402, Res256 and DAOY grown under normoxic conditions for 72h. 50 µg of 
protein was loaded into each well and the blot was probed for LDHA (37 kDa) and 
cyclophillin A (18 kDa) as a loading control. Results are representative of two independent 
experiments. A) Western blot bands. B) Semi-quantitative analysis of LDHA expression in 
cell lines and tissue lysates using image J software. Results were normalised to Cyclophilin 
expression and represented as a ratio to foetal cerebellum. * Tissue lysates, not cell line 
lysates. Graph shows mean with SEM, mean values: adult cerebellum 0.96, SC1800 2.50, 
foetal cerebellum 1.00, CC2565 2.39, UW402 1.43, Res256 1.20 and DAOY 1.37.  
*
  
*
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Chapter 4: Regulation of LDHA expression under hypoxia 
Hypothesis 3: 
Under hypoxic conditions MB cell metabolism will depend on upregulated LDHA 
expression therefore the inhibition of LDHA will have a greater effect on MB metabolism, 
motility and proliferation compared to normoxic conditions. 
After establishing that LDHA was over expressed in MB tissue and cell lines, I investigated 
the regulation of LDHA expression by hypoxia in MB cell lines. As described in chapter one, 
LDHA is upregulated under hypoxic conditions by the HIF1 transcription factor. 
Furthermore MB is not often studied under hypoxic conditions and the hypoxic 
environment of 1% O2 is likely to be closer to the in vivo conditions of MB than normoxic 
conditions. 
 
4.1 Characterisation of LDHA expression and localisation in foetal 
astrocyte and MB cell lines under normoxic and hypoxic conditions 
by immunocytochemistry 
As described in section 1.1, LDHA is expressed in the cytoplasm where it is functionally 
active in converting pyruvate and NADH to lactate and NAD+, but it can also be expressed in 
the nucleus where it may have an unknown transcriptional role. Immunocytochemistry was 
used to visualise the intracellular location of LDHA expression within the MB cell lines 
UW402 (Figure 4. 1), DAOY (Figure 4. 2) and Res256 (Figure 4. 3), and non-neoplastic 
astrocyte cell line CC2565 (Figure 4. 4) under normoxic and hypoxic conditions. 
All cell lines displayed cytoplasmic LDHA expression (green) under normoxic and hypoxic 
conditions. All cell lines also showed nuclear LDHA expression (bright blue/green) at a range 
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of intensities within the population, under normoxic and hypoxic conditions. A few cells 
showed more intense LDHA expression under hypoxic conditions, however there was no 
clear difference in intensity of LDHA expression between normoxic and hypoxic conditions 
within each cell line or between cell lines. ICC is very subjective and antibody expression 
can appear differently depending on how the image is viewed, also ICC can only represent a 
few cells of a population, WB and FC are more appropriate methods for examining 
differences in the quantity of LDHA expression under normoxic and hypoxic conditions in a 
larger population of the cell lines. 
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4.1.1 UW402 
 
 
 
 
Figure 4. 1 Localisation of LDHA expression in UW402 cells as shown by ICC under 
normoxic and hypoxic conditions 
Immunocytochemistry staining of LDHA in UW402 MB cells under normoxic (A and B) and 
hypoxic (C and D) conditions. LDHA is stained green and nuclei stained blue. A and C: 
images taken at x 40 magnification, scale bar 16 µm. B and D: images taken at x 20, scale 
bar 32 µm. Results are representative of three independent experiments. LDHA is 
expressed in the nucleus and cytoplasm and expression varies between cells under 
normoxic and hypoxic conditions. A few cells grown under hypoxic conditions show more 
abundant LDHA expression than cells grown under normoxic conditions. 
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4.1.2 DAOY 
 
 
  
 
Figure 4. 2 Localisation of LDHA expression in DAOY cells as shown by ICC under normoxic 
and hypoxic conditions 
Immunocytochemistry staining of LDHA in DAOY MB cells under normoxic (A and B) and 
hypoxic (C and D) conditions. LDHA is stained green and nuclei stained blue. A and C: 
images taken at x 40 magnification, scale bar 16 µm. B and D: images taken at x 20, scale 
bar 32 µm. Results are representative of three independent experiments. LDHA is 
expressed in the nucleus and cytoplasm and expression varies between cells under 
normoxic and hypoxic conditions. At x 40 LDHA expression appears more intense but there 
is no distinct difference between LDHA expression under normoxic or hypoxic conditions at 
x 40 or x 20. 
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4.1.3 Res256 
 
 
 
 
Figure 4. 3 Localisation of LDHA expression in Res256 cells as shown by ICC under 
normoxic and hypoxic conditions 
Immunocytochemistry staining of LDHA in Res256 MB cells under normoxic (A and B) and 
hypoxic (C and D) conditions. LDHA is stained green and nuclei stained blue. A and C: 
images taken at x 40 magnification, scale bar 16 µm. B and D: images taken at x 20, scale 
bar 32 µm. Results are representative of three independent experiments. LDHA is 
expressed in the nucleus and cytoplasm and expression varies between cells under 
normoxic and hypoxic conditions. A few cells grown under hypoxic conditions show more 
abundant LDHA expression than cells grown under normoxic conditions but overall there is 
not a pronounced difference between LDHA expression under normoxic or hypoxic 
conditions. 
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4.1.4 CC2565 
 
 
 
 
Figure 4. 4 Localisation of LDHA expression in CC2565 cells as shown by ICC under 
normoxic and hypoxic conditions 
Immunocytochemistry staining of LDHA in CC2565 foetal astrocyte cells under normoxic (A 
and B) and hypoxic (C and D) conditions. LDHA is stained green and nuclei stained blue. A 
and C: images taken at x 40 magnification, scale bar 16 µm. B and D: images taken at x 20, 
scale bar 32 µm. Results are representative of three independent experiments. LDHA is 
expressed in nucleus and cytoplasm and expression varies between cells under normoxic 
and hypoxic conditions. A few cells grown under hypoxic conditions show more abundant 
LDHA expression than cells grown under normoxic conditions but it is not clear whether this 
observation is representative of the whole population.  
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4.2 Characterisation of LDHA protein expression in non-neoplastic 
foetal astrocyte and MB cell lines under normoxic and hypoxic 
conditions by Western blotting 
LDHA protein expression was detected in MB and non-neoplastic astrocyte cell lines using 
Western blotting. Cyclophilin A protein expression was also examined, as it is a 
constitutively expressed housekeeping gene, to verify equal amounts of total protein of 
each sample were loaded and differences in LDHA expression were not due to unequal 
sample sizes. The blots were analysed using image J software to evaluate the intensity of 
LDHA expression in each sample compared to LDHA expression under normoxic conditions 
at each time point. The LDHA expression of each sample was normalised to the Cyclophilin 
A expression to remove any small differences in protein concentrations. 
At 24h, 48h and 72h time points, changes in LDHA expression under hypoxic conditions 
within MB cell lines UW402 (Figure 4. 5), DAOY (Figure 4. 6) , Res256 (Figure 4. 7), and non-
neoplastic astrocyte cell line CC2565 (Figure 4. 8) were investigated. Hypoxia was generally 
associated with a small increase in LDHA expression at every time point in every cell line 
however the results were only significant in the UW402 cell line at 72h and DAOY cell line at 
48h. Western blot analysis using image J is only semi-quantitative and a more accurate 
method for examining statistical differences in LDHA expression under hypoxic conditions in 
a large population of cells is flow cytometry. 
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4.2.1 UW402  
 
A  
 
B 
2 4 h 4 8 h 7 2 h
0
1
2
3
T im e
*
F
o
ld
 L
D
H
A
 e
x
p
r
e
s
s
io
n N o rm o x ic
H y p o x ic
 
 
Figure 4. 5 LDHA expression in UW402 under normoxic and hypoxic conditions as shown 
by WB 
Western blot of lysates prepared from UW402 cells grown for 24-72h under normoxic and 
hypoxic conditions. 50 µg of protein was loaded into each well and the blot was probed for 
LDHA (37 kDa) and cyclophillin A (18 kDa) as a loading control. A) Representative Western 
blot bands. - lysates grown under normoxic conditions, + lysates grown under hypoxic 
conditions. B) Semi-quantitative analysis of three independent experiments using image J 
software. LDHA expression was normalised to Cyclophilin expression. LDHA expression is 
represented as a fold change from expression under normoxic conditions at each time 
point.  Graph shows mean with SEM, mean values: 24h normoxic 1.00, 24h hypoxic 1.16, 
48h normoxic 1.00, 48h hypoxic 1.33, 72h normoxic 1.00, 72h hypoxic 1.33. Multiple T 
tests, not significant P > 0.05, * P ≤ 0.05. 
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4.2.2 DAOY  
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Figure 4. 6 LDHA expression in DAOY under normoxic and hypoxic conditions as shown by 
WB 
Western blot of lysates prepared from DAOY cells grown for 24-72h under normoxic and 
hypoxic conditions. 50 µg of protein was loaded into each well and the blot was probed for 
LDHA (37 kDa) and cyclophillin A (18 kDa) as a loading control. A) Representative Western 
blot bands. - lysates grown under normoxic conditions, + lysates grown under hypoxic 
conditions. B) Semi-quantitative analysis of three independent experiments using image J 
software. LDHA expression was normalised to Cyclophilin expression. LDHA expression is 
represented as a fold change from expression under normoxic conditions at each time 
point.  Graph shows mean with SEM, mean values: 24h normoxic 1.00, 24h hypoxic 1.48, 
48h normoxic 1.00, 48h hypoxic 1.73, 72h normoxic 1.00, 72h hypoxic 2.18. Multiple T 
tests, not significant P > 0.05, * P ≤ 0.05. 
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4.2.3 Res256  
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Figure 4. 7 LDHA expression in Res256 under normoxic and hypoxic conditions as shown 
by WB 
Western blot of lysates prepared from Res256 cells grown for 24-72h under normoxic and 
hypoxic conditions. 50 µg of protein was loaded into each well and the blot was probed for 
LDHA (37 kDa) and cyclophillin A (18 kDa) as a loading control. A) Representative Western 
blot bands. - lysates grown under normoxic conditions, + lysates grown under hypoxic 
conditions. B) Semi-quantitative analysis of three independent experiments using image J 
software. LDHA expression was normalised to Cyclophilin expression. LDHA expression is 
represented as a fold change from expression under normoxic conditions at each time 
point. Graph shows mean with SEM, mean values: 24h normoxic 1.00, 24h hypoxic 1.50, 
48h normoxic 1.00, 48h hypoxic 1.48, 72h normoxic 1.00, 72h hypoxic 1.21. Multiple T 
tests, not significant P > 0.05.  
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4.2.4 CC2565 
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Figure 4. 8 LDHA expression in CC2565 under normoxic and hypoxic conditions as shown 
by WB 
Western blot of lysates prepared from CC2565 cells grown for 24-72h under normoxic and 
hypoxic conditions. 50 µg of protein was loaded into each well and the blot was probed for 
LDHA (37 kDa) and cyclophillin A (18 kDa) as a loading control. A) Representative Western 
blot bands. - lysates grown under normoxic conditions, + lysates grown under hypoxic 
conditions. B) Semi-quantitative analysis of three independent experiments. using image J 
software. LDHA expression was normalised to Cyclophilin expression. LDHA expression is 
represented as a fold change from expression under normoxic conditions at each time 
point. Graph shows mean with SEM, mean values: 24h normoxic 1.00, 24h hypoxic 1.30, 
48h normoxic 1.00, 48h hypoxic 0.99, 72h normoxic 1.00, 72h hypoxic 1.48. Multiple T 
tests, not significant P > 0.05.  
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4.3 Characterisation of LDHA protein expression in foetal astrocyte 
and MB cell lines under normoxic and hypoxic conditions by flow 
cytometry  
The intracellular expression of LDHA within each cell line population was analysed by flow 
cytometry. Flow cytometry analysis determines the percentage of the population analysed 
expressing LDHA and the mean amount of LDHA expressed per cell (fold increase in 
fluorescence). 
Changes in LDHA expression after 72h incubation under hypoxic conditions were analysed 
within MB cell lines UW402 (Figure 4. 9), DAOY (Figure 4. 10) and Res256 (Figure 4. 11) and 
non-neoplastic astrocyte cell line CC2565 (Figure 4. 12). Only UW402 cells showed a 
significant increase in the percentage of cells expressing LDHA under hypoxic conditions (P 
= 0.0076). There was no significant increase in the mean amount of LDHA expressed per cell 
under hypoxic conditions in the astrocyte cell line CC2565. However, all MB cell lines 
showed a significant increase in the mean amount of LDHA expressed per cell under 
hypoxic conditions (* P ≤ 0.05). 
LDHA expression between each cell line was also compared (Figure 4. 13). All cell lines had 
LDHA expression in over 80% of their population and mean fluorescence intensity over 35 
under normoxic and hypoxic conditions. The astrocyte cell line CC2565 had the highest 
mean percentage LDHA expression under normoxic and hypoxic conditions, 95.25% and 
96.16% respectively. CC2565 cells also had the highest mean amount of LDHA expressed 
per cell under normoxic and hypoxic conditions, 78.18 and 78.38 mean fluorescence 
intensity respectively. Under normoxic conditions the UW402 cell line had a significantly 
lower percentage of LDHA expression than Res256 (P = 0.0065), DAOY (P = 0.0002) and 
CC2565 (P <0.0001), and the astrocyte cell line CC2565 also had a significantly higher 
percentage of LDHA expression than Res256 (P = 0.0042). Under hypoxic conditions the 
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Res256 cell line had a significantly lower percentage of LDHA expression than CC2565 (P = 
0.0005) and DAOY (p = 0.0254), and CC2565 also had a significantly higher percentage of 
LDHA expression than UW402 (P = 0.0024). 
Under normoxic conditions the astrocyte cell line CC2565 had a significantly higher mean 
amount of LDHA expressed per cell than all the MB cell lines (P = <0.0001). Under hypoxic 
conditions the CC2565 cell line still had a significantly higher mean amount of LDHA 
expressed per cell than the MB cell lines Res256 and DAOY (P = <0.0001) but not UW402. 
Under hypoxic conditions, UW402 also had a significantly higher mean amount of LDHA 
expressed per cell than the MB cell lines Res256 (P = <0.0001) and DAOY (P = 0.01). 
In summary, FC shows that CC2565 expressed more LDHA than all MB cell lines. Although 
MB cell line UW402 had the lowest percentage of population expressing LDHA under 
normoxic conditions, it had the highest mean amount of LDHA expressed per cell amongst 
MB cell lines under normoxic and hypoxic conditions. The expression of LDHA under 
hypoxic conditions also increased the most in UW402 cells. 
From ICC, WB and FC experiments it is clear that CC2565 cells expresses the most amount 
of LDHA followed by UW402 and DAOY cells which express similar amounts, followed by 
Res256 cells which express the least. UW402 was chosen for additional downstream 
experiments as it was a MB cell line which expressed one of the highest amounts of LDHA 
and is most likely to belong to the most metastatic subgroup of MB, with the worst 
prognosis, Group 3. 
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4.3.1 UW402 
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Figure 4. 9 LDHA expression in UW402 cells under normoxic and hypoxic conditions as 
shown by FC 
Flow cytometry analysis of LDHA expression in MB cell line UW402 under normoxic and 
hypoxic conditions after 72h. A) Percentage of UW402 cell population expressing LDHA: 
normoxic 83.03%, hypoxic 89.49%. B) Mean LDHA expression (fluorescence intensity) per 
UW402 cell: normoxic 47.96, hypoxic 69.05. C) Graphic representation of results, 
representative of three independent experiments. Solid purple – negative control, pink line 
– LDHA expression under normoxic conditions, green line – LDHA expression under hypoxic 
conditions. Graphs show mean with SEM. LDHA expression under normoxic conditions was 
compared to LDHA expression under hypoxic conditions. Unpaired T test; not significant P > 
0.05, * P ≤ 0.05, ** P ≤ 0.01. 
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4.3.2 DAOY 
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Figure 4. 10 LDHA expression in DAOY cells under normoxic and hypoxic conditions as 
shown by FC 
Flow cytometry analysis of LDHA expression in MB cell line DAOY under normoxic and 
hypoxic conditions after 72h. A) Percentage of DAOY cell population expressing LDHA: 
normoxic 91.46%, hypoxic 93.22%. B) Mean LDHA expression (fluorescence intensity) per 
DAOY cell normoxic 41.51, hypoxic 51.09. C) Graphic representation of results, 
representative of three independent experiments. Solid purple – negative control, pink line 
– LDHA expression under normoxic conditions, green line – LDHA expression under hypoxic 
conditions. Graphs show mean with SEM. LDHA expression under normoxic conditions was 
compared to LDHA expression under hypoxic conditions. Unpaired T test; not significant P > 
0.05, * P ≤ 0.05. 
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4.3.3 Res256 
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Figure 4. 11 LDHA expression in Res256 cells under normoxic and hypoxic conditions as 
shown by FC 
Flow cytometry analysis of LDHA expression in MB cell line Res256 under normoxic and 
hypoxic conditions after 72h. A) Percentage of Res256 cell population expressing LDHA: 
normoxic 88.98%, hypoxic 88.39%. B) Mean LDHA expression (fluorescence intensity) per 
Res256 cell: normoxic 39.58, hypoxic 44.65. C) Graphic representation of results, 
representative of three independent experiments. Solid purple – negative control, pink line 
– LDHA expression under normoxic conditions, green line – LDHA expression under hypoxic 
conditions. Graphs show mean with SEM. LDHA expression under normoxic conditions was 
compared to LDHA expression under hypoxic conditions. Unpaired T test; not significant P > 
0.05, * P ≤ 0.05. 
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4.3.4 CC2565 
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Figure 4. 12 LDHA expression in CC2565 cells under normoxic and hypoxic conditions as 
shown by FC 
Flow cytometry analysis of LDHA expression in foetal astrocyte cell line CC2565 under 
normoxic and hypoxic conditions after 72h. A) Percentage of CC2565 cell population 
expressing LDHA: normoxic 95.25%, hypoxic 96.16%. B) Mean LDHA expression 
(fluorescence intensity) per CC2565 cell: normoxic 78.18, hypoxic 78.38. C) Graphic 
representation of results, representative of three independent experiments. Solid purple – 
negative control, pink line – LDHA expression under normoxic conditions, green line – LDHA 
expression under hypoxic conditions. Graphs show mean with SEM. LDHA expression under 
normoxic conditions was compared to LDHA expression under hypoxic conditions. Unpaired 
T test; not significant P > 0.05. 
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4.3.5 Comparison of all cell lines 
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Figure 4. 13 LDHA expression in all cell lines under normoxic and hypoxic conditions as 
shown by FC 
Flow cytometry analysis of LDHA expression in MB cell lines Res256, UW402 and DAOY and 
astrocyte cell line CC2565 under normoxic and hypoxic conditions after 72h. A) Percentage 
of cell populations expressing LDHA: Res256 normoxic 88.98%, UW402 normoxic 83.03%, 
DAOY normoxic 91.46%, CC2565 normoxic 95.25%, Res256 hypoxic 88.39%, UW402 hypoxic 
89.49%, DAOY hypoxic 93.22%, CC2565 hypoxic 96.16%. B) Mean LDHA expression 
(fluorescence intensity) per cell: Res256 normoxic 39.58, UW402 normoxic 47.96, DAOY 
normoxic 41.51, CC2565 normoxic 78.18, Res256 hypoxic 44.65, UW402 hypoxic 69.05, 
DAOY hypoxic 51.09, CC2565 hypoxic 78.38. Graphs show mean with SEM. LDHA expression 
under normoxic conditions was compared between cell lines and LDHA expression under 
hypoxic conditions was compared between cell lines. 2way ANOVA; not significant P > 0.05, 
* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 
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Chapter 5: Functional effects of LDHA activity inhibition by 
oxamate in foetal astrocyte and MB cell lines under normoxic 
and hypoxic conditions 
Hypothesis 2: 
Inhibition of LDHA will decrease MB lactate production, cell proliferation, and motility. 
Hypothesis 3: 
Under hypoxic conditions MB cell metabolism will depend on upregulated LDHA 
expression therefore the inhibition of LDHA will have a greater effect on MB metabolism, 
motility and proliferation compared to normoxic conditions 
In order to reveal the potential therapeutic benefits of targeting LDHA in MB patients, the 
next objective was to inhibit LDHA activity using oxamate (a structural analogue of 
pyruvate) and examine the downstream effects on MB viability, proliferation, metabolism 
and motility. 
 
5.1 Verification of sodium oxamate inhibition of LDHA activity 
LDHA converts pyruvate and NADH to lactate and NAD+ so if LDHA is successfully inhibited, 
LDHA and NAD+ concentrations will decrease whereas pyruvate and NADH concentrations 
may increase or may be diverted into another pathway. Pyruvate can enter the OXPHOS 
pathway or be used to synthesise alanine and as NAD+ can also be regenerated from NADH 
by complex I in the electron transport chain, lactate concentrations are the most reliable 
way to detect the inhibition of LDHA activity. 
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5.1.1 Lactate assays 
Lactate concentrations were measured in MB cell lines UW402, DAOY and Res256, and non-
neoplastic astrocyte cell line CC2565 treated with 0 mM, 25 mM, 50 mM and 75mM 
oxamate for 24h, 48h and 72h time points under normoxic and hypoxic conditions.  
The mean lactate concentrations of the untreated UW402 cells ranged from 2.2-2.7 ng/ µg 
under normoxic conditions and increased to 2.9-4.7 ng/ µg under hypoxic conditions, the 
increase was significant at 48h and 72h (P ≤ 0.01 and P ≤ 0.05 respectively) (Figure 5. 1). 
The mean lactate concentrations of the untreated DAOY cells ranged from 2.4-3.0 ng/ µg 
under normoxic conditions and increased to 3.8-4.4 ng/ µg under hypoxic conditions, 
however the increase was not significant at any time point (Figure 5. 1). The mean lactate 
concentrations of the untreated Res256 cells ranged from 2.5-2.8 ng/ µg under normoxic 
conditions and increased to 2.9-3.6 ng/ µg under hypoxic conditions, however the increase 
was not significant at any time point (Figure 5. 1). The mean lactate concentrations of the 
untreated CC2565 cells ranged from 0.8-1.1 ng/ µg under normoxic conditions and 1.1-1.5 
ng/ µg under hypoxic conditions, however the increase was not significant at any time point 
(Figure 5. 1). 
Under normoxic conditions untreated CC2565 cells had a significantly lower mean lactate 
concentration than all untreated MB cell lines at every time point, apart from UW402 at 
48h (24h P ≤ 0.05, 48h DAOY P ≤ 0.01, Res256 P ≤ 0.05, 72h P ≤ 0.05) (Figure 5. 2). Under 
hypoxic conditions untreated CC2565 cells had a significantly lower mean lactate 
concentration than all untreated MB cell lines at every time point (24h UW402 P ≤ 0.01, 
DAOY P ≤ 0.0001, Res256 P ≤ 0.001, 48h UW402 and DAOY P ≤ 0.0001, Res256 P ≤ 0.01, 72h 
UW402 and DAOY P ≤ 0.0001, Res256 P ≤ 0.01) (Figure 5. 2). There were no significant 
differences between untreated MB cell line mean lactate concentrations under normoxic 
conditions or untreated DAOY and Res256 under hypoxic conditions. However under 
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hypoxic conditions the untreated UW402 cells had a significantly lower mean lactate 
concentration than untreated DAOY cells at 24h (P ≤ 0.05), but a significantly higher mean 
lactate concentration than untreated Res256 cells at 48h (P ≤ 0.05) (Figure 5. 2). 
In the UW402 cell line, at each time point, under normoxic conditions there was a 
significant decrease in lactate concentrations with the addition of 25 mM, 50 mM, and 75 
mM oxamate (p ≤ 0.05, p ≤ 0.05 and p ≤ 0.01 respectively) (Figure 5. 3). In the UW402 cell 
line, under hypoxic conditions at 24h there was a significant decrease in lactate 
concentrations with the addition of 25 mM, 50 mM, and 75 mM oxamate (p ≤ 0.01), at 48h 
and 72h the significance of the decrease in lactate concentrations with the addition of all 
oxamate treatments increased (P ≤ 0.0001). 
In the DAOY cell line, under normoxic conditions, at every time point there was a significant 
decrease in lactate concentrations with the addition of 75 mM oxamate (p ≤ 0.05); at 48h 
and 72h time points there was also a significant decrease in lactate concentrations with the 
addition of 25 mM and 50 mM oxamate (p ≤ 0.05) (Figure 5. 4). In the DAOY cell line under 
hypoxic conditions there was an increase in significance of the decrease in lactate 
concentrations with the addition of 25 mM, 50 mM, and 75 mM oxamate at 24h (P ≤ 0.01, 
*** P ≤ 0.001 and p ≤ 0.0001 respectively), 48h and 72h (p ≤ 0.0001). 
In the Res256 cell line, at each time point, under normoxic conditions there was a 
significant decrease in lactate concentrations with the addition of 25 mM, 50 mM, and 75 
mM oxamate (p ≤ 0.001, p ≤ 0.001 and p ≤ 0.0001 respectively) (Figure 5. 5). In the Res256 
cell line, at each time point, under hypoxic conditions the decrease in lactate 
concentrations with the addition of 25 mM, 50 mM, and 75 mM oxamate was even more 
significant (p ≤ 0.0001). 
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In the CC2565 cell line, under normoxic conditions, compared to untreated cells, there was 
a significant decrease in lactate concentrations with the addition of 50 mM, and 75 mM 
oxamate at 24h (P ≤ 0.05, and P ≤ 0.01 respectively), and with the addition of 25 mM, 50 
mM and 75 mM oxamate at 48h (P ≤ 0.05, P ≤ 0.05, and P ≤ 0.01 respectively) and 72h (P ≤ 
0.05, P ≤ 0.05, and P ≤ 0.01 respectively) (Figure 5. 6). In the CC2565 cell line, at each time 
point, under hypoxic conditions there was an increased significant decrease in lactate 
concentrations with the addition of 25 mM, 50 mM, and 75 mM oxamate (P ≤ 0.001, P ≤ 
0.001 and P ≤ 0.0001 respectively). 
In summary, lactate concentrations were lower in non-neoplastic astrocyte cell lines than 
MB cell lines under normoxic and hypoxic conditions. MB cell lines had similar lactate 
concentrations under normoxic conditions which increased under hypoxic conditions more 
in the UW402 and DAOY cell lines than the Res256 cell line. Lactate concentrations were 
significantly decreased by oxamate under normoxic and hypoxic conditions in all MB cell 
lines and non-neoplastic astrocyte cell line CC2565, indicating successful LDHA inhibition. 
The effects were more significant under hypoxic conditions in all cell lines. The Res256 cell 
line was the most sensitive MB cell line to oxamate whereas the DAOY cell line was the 
least sensitive. 
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5.1.1.1 Comparison of cell lines 
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Figure 5. 1 Lactate concentrations in cell lines under normoxic and hypoxic conditions 
Lactate concentrations of lysates prepared from UW402 (A), DAOY (B), Res256 (C) and 
CC2565 (D) cells grown for 24-72h under normoxic and hypoxic conditions. Lactate 
concentrations were normalised to the protein concentrations of each sample. Graphs 
show mean with SEM. (A) Mean UW402 lactate concentrations (ng/ µg) under normoxic 
conditions: 24h; 2.71, 48h; 2.21, 72h; 2.44. Mean UW402 lactate concentrations (ng/ µg) 
under hypoxic conditions: 24h; 2.90, 48h; 4.79, 72h; 3.82 B) Mean DAOY lactate 
concentrations (ng/ µg) under normoxic conditions: 24h; 2.69, 48h; 3.02, 72h; 2.43. Mean 
DAOY lactate concentrations (ng/ µg) under hypoxic conditions: 24h; 4.26, 48h; 4.48, 72h; 
3.85. C) Mean Res256 lactate concentrations (ng/ µg) under normoxic conditions: 24h; 2.86, 
48h; 2.54, 72h; 2.51. Mean Res256 lactate concentrations (ng/ µg) under hypoxic 
conditions: 24h; 3.69, 48h; 3.43, 72h; 2.98. D) Mean CC2565 lactate concentrations (ng/ µg) 
under normoxic conditions: 24h; 1.13, 48h; 1.13, 72h; 0.85. Mean CC2565 lactate 
concentrations (ng/ µg) under hypoxic conditions: 24h; 1.35, 48h; 1.51, 72h; 1.17. Normoxic 
conditions were compared to hypoxic conditions and at each time point within each cell 
line, 2way ANOVA; not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01.  
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Figure 5. 2 Comparison of lactate concentrations between cell lines 
Lactate concentrations of lysates prepared from UW402, DAOY, Res256 and CC2565 cells 
grown for 24-72h under normoxic (A) and hypoxic (B) conditions. Lactate concentrations 
were normalised to the protein concentrations of each sample. Graphs show mean with 
SEM. A) Mean lactate concentrations (ng/ µg) under normoxic conditions: 24h; UW402 
2.71, DAOY 2.69, Res256 2.86, CC2565 1.13, 48h; UW402 2.21, DAOY 3.02, Res256 2.54, 
CC2565 1.13, 72h; UW402 2.44, DAOY 2.43, Res256 2.51, CC2565 0.85. B) Mean lactate 
concentrations (ng/ µg) under hypoxic conditions: 24h; UW402 2.90, DAOY 4.26, Res256 
3.69, CC2565 1.35, 48h; UW402 4.79, DAOY 4.48, Res256 3.43, CC2565 1.51, 72h; UW402 
3.82, DAOY 3.85, Res256 2.98, CC2565 1.17. Cell lines were compared to each other under 
normoxic and hypoxic conditions at each time point, 2way ANOVA; not significant P > 0.05, 
* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 
A 
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5.1.1.2 UW402 
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Figure 5. 3 UW402 lactate concentrations with oxamate treatments under normoxic and 
hypoxic conditions 
Lactate concentrations of lysates prepared from UW402 cells grown in the presence of 0 
mM, 25 mM, 50 mM or 75 mM oxamate for 24-72h under normoxic (A) and hypoxic (B) 
conditions. Lactate concentrations were normalised to the protein concentrations of each 
sample. Graphs show mean with SEM. A) Mean lactate concentrations (ng/ µg) under 
normoxic conditions: 24h; 0 mM 2.71, 25 mM 1.49, 50 mM 1.42, 75 mM 1.25, 48h; 0 mM 
2.21, 25 mM 1.17, 50 mM 1.10, 75 mM 0.78, 72h; 0 mM 2.44, 25 mM 1.14, 50 mM 1.28, 75 
mM 0.94. B) Mean lactate concentrations (ng/ µg) under hypoxic conditions: 24h; 0 mM 
2.90, 25 mM 1.56, 50 mM 1.40, 75 mM 1.38, 48h; 0 mM 4.79, 25 mM 1.59, 50 mM 1.41, 75 
mM 1.41, 72h; 0 mM 3.82, 25 mM 1.56, 50 mM 1.58, 75 mM 1.36. Oxamate treated 
samples were compared to the untreated control at each time point, 2way ANOVA; * P ≤ 
0.05, ** P ≤ 0.01, **** P ≤ 0.0001. 
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5.1.1.3 DAOY 
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Figure 5. 4 DAOY lactate concentrations with oxamate treatments under normoxic and 
hypoxic conditions 
Lactate concentrations of lysates prepared from DAOY cells grown in the presence of 0 mM, 
25 mM, 50 mM or 75 mM oxamate for 24-72h under normoxic (A) and hypoxic (B) 
conditions. Lactate concentrations were normalised to the protein concentrations of each 
sample. Graphs show mean with SEM. A) Mean lactate concentrations (ng/ µg) under 
normoxic conditions: 24h; 0 mM 2.69, 25 mM 1.75, 50 mM 1.85, 75 mM 1.22, 48h; 0 mM 
3.02, 25 mM 1.76, 50 mM 1.69, 75 mM 1.54, 72h; 0 mM 2.43, 25 mM 1.25, 50 mM 1.18, 75 
mM 1.00. B) Mean lactate concentrations (ng/ µg) under hypoxic conditions: 24h; 0 mM 
4.26, 25 mM 2.64, 50 mM 2.27, 75 mM 1.58, 48h; 0 mM 4.48, 25 mM 1.63, 50 mM 1.57, 75 
mM 0.97, 72h; 0 mM 3.85, 25 mM 1.49, 50 mM 1.69, 75 mM 1.51. Oxamate treated 
samples were compared to the untreated control at each time point, 2way ANOVA; not 
significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 
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5.1.1.4 Res256 
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Figure 5. 5 Res256 lactate concentrations with oxamate treatments under normoxic and 
hypoxic conditions 
Lactate concentrations of lysates prepared from Res256 cells grown in the presence of 0 
mM, 25 mM, 50 mM or 75 mM oxamate for 24-72h under normoxic (A) and hypoxic (B) 
conditions. Lactate concentrations were normalised to the protein concentrations of each 
sample. Graphs show mean with SEM. A) Mean lactate concentrations (ng/ µg) under 
normoxic conditions: 24h; 0 mM 2.86, 25 mM 1.35, 50 mM 1.23, 75 mM 1.12, 48h; 0 mM 
2.54, 25 mM 0.99, 50 mM 1.00, 75 mM 0.90, 72h; 0 mM 2.51, 25 mM 0.98, 50 mM 0.94, 75 
mM 0.85. B) Mean lactate concentrations (ng/ µg) under hypoxic conditions: 24h; 0 mM 
3.69, 25 mM 1.73, 50 mM 1.42, 75 mM 1.40, 48h; 0 mM 3.43, 25 mM 1.50, 50 mM 1.42, 75 
mM 1.40, 72h; 0 mM 2.98, 25 mM 1.10, 50 mM 1.31, 75 mM 0.99. Oxamate treated 
samples were compared to the untreated control at each time point, 2way ANOVA; *** P ≤ 
0.001, **** P ≤ 0.0001. 
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5.1.1.5 CC2565 
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Figure 5. 6 CC2565 lactate concentrations with oxamate treatments under normoxic and 
hypoxic conditions  
Lactate concentrations of lysates prepared from CC2565 cells grown in the presence of 0 
mM, 25 mM, 50 mM or 75 mM oxamate for 24-72h under normoxic (A) and hypoxic (B) 
conditions. Lactate concentrations were normalised to the protein concentrations of each 
sample. Graphs show mean with SEM. A) Mean lactate concentrations (ng/ µg) under 
normoxic conditions: 24h; 0 mM 1.13, 25 mM 0.85, 50 mM 0.59, 75 mM 0.43, 48h; 0 mM 
1.13, 25 mM 0.59, 50 mM 0.65, 75 mM 0.43, 72h; 0 mM 0.85, 25 mM 0.433, 50 mM 0.38, 
75 mM 0.30. B) Mean lactate concentrations (ng/ µg) under hypoxic conditions: 24h; 0 mM 
1.35, 25 mM 0.68, 50 mM 0.65, 75 mM 0.53, 48h; 0 mM 1.51, 25 mM 0.82, 50 mM 0.78, 75 
mM 0.60, 72h; 0 mM 1.17, 25 mM 0.52, 50 mM 0.50, 75 mM 0.33. Oxamate treated 
samples were compared to the untreated control at each time point, 2way ANOVA; *** P ≤ 
0.001, **** P ≤ 0.0001.  
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5.2 Effects of oxamate on foetal astrocyte and MB cell line 
proliferation  
In order to test the hypothesis that LDHA inhibition will inhibit MB proliferation trypan blue 
growth curves, cell cycle analysis and MTS assays were conducted. 
5.2.1 Viability assay 
MTS assays were used to quantify the amount of viable, metabolically active cells, via 
absorbance at 490nm, within a population of UW402, DAOY and Res256 MB cells and non-
neoplastic astrocyte cells CC2565 treated with 0 mM, 25 mM, 50 mM or 75 mM oxamate at 
24h, 48h and 72h time points under normoxic and hypoxic conditions. 
In untreated UW402 cells, the mean absorbance at 490nm increased under hypoxic 
conditions at each time point, however the increase was only significant at 48h (P ≤ 0.05) 
(Figure 5. 7). In untreated DAOY cells, the mean absorbance at 490nm decreased 
significantly under hypoxic conditions at each time point, furthermore the significance 
increased at each time point (24h P ≤ 0.01, 48h P ≤ 0.001, and 72h P ≤ 0.0001) (Figure 5. 7). 
In untreated Res256 cells the mean absorbance at 490nm decreased under hypoxic 
conditions at each time point, however the decrease was only significant at 48h and 72h (P 
≤ 0.01 and P ≤ 0.05 respectively) (Figure 5. 7). In untreated CC2565 cells the mean 
absorbance at 490nm decreased under hypoxic conditions at each time point however the 
decrease was not significant at any time point (Figure 5. 7). 
Untreated CC2565 cells had a significantly lower mean absorbance at 490nm than all 
untreated MB cell lines under normoxic and hypoxic conditions at each time point (P ≤ 
0.0001) (Figure 5. 8). Under normoxic conditions there was no significant difference 
between untreated DAOY and Res256 cells mean absorbance at 490nm, however untreated 
UW402 cells had a significantly lower mean absorbance at 490nm than DAOY cells at every 
time point (24h P ≤ 0.01, 48h P ≤ 0.001 and 72h P ≤ 0.001) and Res256 at 48h and 72h (P ≤ 
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0.0001 and P ≤ 0.001 respectively) (Figure 5. 8). Under hypoxic conditions there was no 
significant difference in the mean absorbance at 490nm of untreated MB cell lines (Figure 
5. 8). 
Under normoxic conditions there was only a significant decrease in absorbance at 490 nm 
of UW402 cells treated 75 mM oxamate at 24h (P ≤ 0.05), 48h (P ≤ 0.01) and 72h time 
points (P ≤ 0.01) (Figure 5. 9). Under hypoxic conditions there was a significant decrease in 
absorbance at 490nm of UW402 cells treated with 25 mM, 50 mM and 75 mM oxamate at 
48h (P ≤ 0.01, P ≤ 0.0001 and P ≤ 0.0001 respectively), and 72h time points (P ≤ 0.01, P ≤ 
0.0001 and P ≤ 0.0001 respectively).  
Under normoxic conditions there was only a significant decrease in absorbance at 490 nm 
of DAOY cells treated 75 mM oxamate at 24h (P ≤ 0.05), 48h (P ≤ 0.05) and 72h time points 
(P ≤ 0.01) (Figure 5. 10). Under hypoxic conditions there was a significant decrease in 
absorbance at 490nm of DAOY cells treated with 50 mM and 75 mM oxamate at 24h (P ≤ 
0.05 and P ≤ 0.01 respectively), 48h (P ≤ 0.001 and P ≤ 0.0001 respectively) and 25 mM, 50 
mM and 75 mM at 72h time points (P ≤ 0.01, P ≤ 0.0001 and P ≤ 0.0001 respectively).  
Under normoxic conditions there was a significant decrease in absorbance at 490 nm of 
Res256 cells treated with 50 mM and 75 mM oxamate at 48h (P ≤ 0.01 and P ≤ 0.0001 
respectively) and 72h time points (P ≤ 0.0001) (Figure 5. 11). Under hypoxic conditions 
there was a significant decrease in absorbance at 490nm of Res256 cells treated with 50 
mM and 75 mM oxamate at 24h (P ≤ 0.05 and P ≤ 0.001 respectively), and 25 mM, 50 mM 
and 75 mM oxamate at 48h (P ≤ 0.01, P ≤ 0.001 and P ≤ 0.0001 respectively) and at 72h 
time points (P ≤ 0.0001).  
Under normoxic conditions there was a significant decrease in absorbance at 490 nm of 
CC2565 cells treated with 75 mM oxamate at 48h (P ≤ 0.05) and at 72h with CC2565 cells 
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treated with 50 mM and 75 mM oxamate (P ≤ 0.05 and P ≤ 0.001 respectively) (Figure 5. 
12). Under hypoxic conditions there was a significant decrease in absorbance at 490nm of 
CC2565 cells treated with 75 mM oxamate at 48h (P ≤ P ≤ 0.001), and at 72h with CC2565 
cells treated with 50 mM and 75 mM oxamate (P ≤ 0.0001). 
Statistical analysis of cell viability and metabolic activity after 72h of 0 mM, 25 mM, 50 mM 
or 75 mM oxamate treatments under normoxic and hypoxic conditions showed that 
hypoxia alone significantly reduced Res256 viability and metabolic activity, but not the 
viability and metabolic activity of other cell lines tested (Figure 5. 13). Treatment of 25 mM, 
50 mM and 75 mM oxamate for 72h decreased cell viability and metabolic activity in all MB 
cell lines and this effect was more significant under hypoxic conditions than normoxic 
conditions. Oxamate treatments also decreased cell viability and metabolic activity in 
CC2565 cells however there was no significant difference between hypoxic conditions and 
normoxic conditions.  
In summary, oxamate significantly decreased MB cell line viability and metabolic activity in 
a time and concentration dependent manner. In all MB cell lines this effect was more 
significant under hypoxic conditions and the Res256 MB cell line was the most sensitive to 
oxamate treatments under normoxic and hypoxic conditions.  
Furthermore 25 mM oxamate had no significant effect on CC2565 cell line viability and 
metabolic activity under normoxic or hypoxic conditions. 50 mM oxamate only had a 
significant effect on CC2565 viability and metabolic activity after 72h, whereas 75 mM 
oxamate had a significant effect on CC2565 viability and metabolic activity after 48h and 
72h under normoxic and hypoxic conditions and the effects were also more significant 
under hypoxic conditions. 
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5.2.1.1 Comparison of cell lines 
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Figure 5. 7 Viability in cell lines under normoxic and hypoxic conditions 
Absorbance at 490nm of UW402 (A), DAOY (B), Res256 (C) and CC2565 (D) cells grown 
under normoxic and hypoxic conditions and incubated with MTS for 3 hours. Graphs show 
mean with SEM. A) Mean absorbance (490nm) of UW402 cells under normoxic conditions: 
24h; 0.75, 48h; 0.84, 72h; 0.93. Mean absorbance (490nm) of UW402 cells under hypoxic 
conditions: 24h; 0.84, 48h; 0.96, 72h 0.99. B) Mean absorbance (490nm) of DAOY cells 
under normoxic conditions: 24h; 0.92, 48h; 1.07, 72h; 1.10. Mean absorbance (490nm) of 
DAOY cells under hypoxic conditions: 24h; 0.83, 48h; 0.96, 72h; 0.96. C) Mean absorbance 
(490nm) of Res256 cells under normoxic conditions: 24h; 0.82, 48h; 1.13, 72h; 1.18. Mean 
absorbance (490nm) of Res256 cells under hypoxic conditions: 24h; 0.91, 48h; 0.87, 72h 
1.01. D) Mean absorbance (490nm) of CC2565 cells under normoxic conditions: 24h; 0.42, 
48h; 0.50 72h; 0.63. Mean absorbance (490nm) of CC2565 cells under hypoxic conditions: 
24h; 0.38, 48h; 0.47, 72h 0.61. Normoxic conditions were compared to hypoxic conditions 
and at each time point within each cell line, 2way ANOVA; not significant P > 0.05, * P ≤ 
0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 
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Figure 5. 8 Comparison of viability between cell lines 
Absorbance at 490nm of untreated cell lines 24-72h under normoxic (A) and hypoxic (B) 
conditions and incubated with MTS for 3 hours. Graphs show mean with SEM. Mean 
absorbance (490nm) under normoxic conditions: 24h; UW402 0.75, DAOY 0.92, Res256 
0.82, CC2565 0.42, 48h; UW402 0.84, DAOY 1.07, Res256 1.13, and CC2565 0.50, 72h; 
UW402 0.93, DAOY 1.10, Res256 1.18, and CC2565 0.63. Mean absorbance (490nm) under 
hypoxic conditions: 24h; UW402 0.84, DAOY 0.83, Res256 0.91, CC2565 0.38, 48h; UW402 
0.96, DAOY 0.96, Res256 0.87, CC2565 0.47, 72h; UW402 0.99, DAOY 0.96, Res256 1.01, 
CC2565 0.61. Cell lines were compared to each other under normoxic and hypoxic 
conditions at each time point, 2way ANOVA; not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, 
*** P ≤ 0.001, **** P ≤ 0.0001 
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5.2.1.2 UW402 
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Figure 5. 9 UW402 MTS assays with oxamate treatments under normoxic and hypoxic 
conditions 
Absorbance at 490nm of UW402 cells grown in the presence of 0 mM, 25 mM, 50 mM or 75 
mM oxamate for 24-72h under normoxic (A) and hypoxic (B) conditions and incubated with 
MTS for 3 hours. Graphs show mean with SEM. A) Mean absorbance (490nm) under 
normoxic conditions: 24h; 0 mM 0.74, 25 mM 0.72, 50 mM 0.69, 75 mM 0.63, 48h; 0 mM 
0.84, 25 mM 0.78, 50 mM 0.74, 75 mM 0.69, 72h; 0 mM 0.93, 25 mM 0.94, 50 mM 0.91, 75 
mM 0.79. B) Mean absorbance (490nm) under hypoxic conditions: 24h; 0 mM 0.84, 25 mM 
0.85, 50 mM 0.86, 75 mM 0.83, 48h; 0 mM 0.96, 25 mM 0.82, 50 mM 0.72, 75 mM 0.62, 
72h; 0 mM 0.99, 25 mM 0.82, 50 mM 0.67, 75 mM 0.57. Oxamate treated samples were 
compared to the untreated control at each time point, 2way ANOVA; not significant P > 
0.05, * P ≤ 0.05, ** P ≤ 0.01, **** P ≤ 0.0001.  
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5.2.1.3 DAOY 
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Figure 5. 10 DAOY MTS assays with oxamate treatments under normoxic and hypoxic 
conditions 
Absorbance at 490nm of DAOY cells grown in the presence of 0 mM, 25 mM, 50 mM or 75 
mM oxamate for 24-72h under normoxic (A) and hypoxic (B) conditions and incubated with 
MTS for 3 hours. Graphs show mean with SEM. A) Mean absorbance (490nm) under 
normoxic conditions: 24h; 0 mM 0.92, 25 mM 0.92, 50 mM 0.86, 75 mM 0.79, 48h; 0 mM 
1.07, 25 mM 1.04, 50 mM 0.98, 75 mM 0.97, 72h; 0 mM 1.10, 25 mM 1.04, 50 mM 1.02, 75 
mM 0.95. B) Mean absorbance (490nm) under hypoxic conditions: 24h; 0 mM 0.83, 25 mM 
0.75, 50 mM 0.64, 75 mM 0.55, 48h; 0 mM 0.96, 25 mM 0.87, 50 mM 0.65, 75 mM 0.47, 
72h; 0 mM 0.96, 25 mM 0.69, 50 mM 0.54, 75 mM 0.46. Oxamate treated samples were 
compared to the untreated control at each time point, 2way ANOVA; not significant P > 
0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001.  
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5.2.1.4 Res256 
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Figure 5. 11 Res256 MTS assays with oxamate treatments under normoxic and hypoxic 
conditions  
Absorbance at 490nm of Res256 cells grown in the presence of 0 mM, 25 mM, 50 mM or 75 
mM oxamate for 24-72h under normoxic (A) and hypoxic (B) conditions and incubated with 
MTS for 3 hours. Graphs show mean with SEM. A) Mean absorbance (490nm) under 
normoxic conditions: 24h; 0 mM 0.82, 25 mM 0.81, 50 mM 0.79, 75 mM 0.88, 48h; 0 mM 
1.13, 25 mM 1.01, 50 mM 0.92, 75 mM 0.74, 72h; 0 mM 1.18, 25 mM 1.06, 50 mM 0.84, 75 
mM 0.60. B) Mean absorbance (490nm) under hypoxic conditions: 24h; 0 mM 0.91, 25 mM 
0.82, 50 mM 0.76, 75 mM 0.66, 48h; 0 mM 0.87, 25 mM 0.67, 50 mM 0.61, 75 mM 0.49, 
72h; 0 mM 1.01, 25 mM 0.68, 50 mM 0.59, 75 mM 0.34. Oxamate treated samples were 
compared to the untreated control at each time point, 2way ANOVA; not significant P > 
0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001.  
A 
B 
N
o
rm
o
xi
c 
H
yp
o
xi
c 
168 
 
5.2.1.5 CC2565 
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Figure 5. 12 CC2565 MTS assays with oxamate treatments under normoxic and hypoxic 
conditions 
Absorbance at 490nm of CC2565 cells grown in the presence of 0 mM, 25 mM, 50 mM or 
75 mM oxamate for 24-72h under normoxic (A) and hypoxic (B) conditions and incubated 
with MTS for 3 hours. Graphs show mean with SEM. A) Mean absorbance (490nm) under 
normoxic conditions: 24h; 0 mM 0.42, 25 mM 0.39, 50 mM 0.33, 75 mM 0.33, 48h; 0 mM 
0.50, 25 mM 0.47, 50 mM 0.42, 75 mM 0.38, 72h; 0 mM 0.63, 25 mM 0.58, 50 mM 0.49, 75 
mM 0.40. B) Mean absorbance (490nm) under hypoxic conditions: 24h; 0 mM 0.38, 25 mM 
0.37, 50 mM 0.32, 75 mM 0.32, 48h; 0 mM 0.47, 25 mM 0.41, 50 mM 0.36, 75 mM 0.30, 
72h; 0 mM 0.61, 25 mM 0.53, 50 mM 0.38, 75 mM 0.29. Oxamate treated samples were 
compared to the untreated control at each time point, 2way ANOVA; not significant P > 
0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 
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5.2.1.6 Comparison of 72h oxamate treatments under normoxic and hypoxic 
conditions 
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Figure 5. 13 Viability of cell lines under normoxic and hypoxic conditions with 72h 
oxamate treatments 
Absorbance at 490nm of UW402 (A), DAOY (B), Res256 (C) and CC2565 (D) cells grown in 
the presence of 0 mM, 25 mM, 50 mM or 75 mM oxamate for 72h under normoxic and 
hypoxic conditions and incubated with MTS for 3 hours. Graphs show mean with SEM. A) 
Mean absorbance (490nm) of UW402 cells under normoxic conditions: 0 mM 0.93, 25 mM 
0.94, 50 mM 0.91, 75 mM 0.79. Mean absorbance (490nm) of UW402 cells under hypoxic 
conditions: 0 mM 0.99, 25 mM 0.82, 50 mM 0.67, 75 mM 0.57. B) Mean absorbance 
(490nm) of DAOY cells under normoxic conditions: 0 mM 1.10, 25 mM 1.04, 50 mM 1.02, 75 
mM 0.95. Mean absorbance (490nm) of DAOY cells under hypoxic conditions: 0 mM 0.96, 
25 mM 0.69, 50 mM 0.54, 75 mM 0.46. C) Mean absorbance (490nm) of Res256 cells under 
normoxic conditions: 0 mM 1.18, 25 mM 1.06, 50 mM 0.84, 75 mM 0.60. Mean absorbance 
(490nm) of Res256 cells under hypoxic conditions: 0 mM 1.01, 25 mM 0.68, 50 mM 0.59, 75 
mM 0.34. D) Mean absorbance (490nm) of CC2565 cells under normoxic conditions: 0 mM 
0.63, 25 mM 0.58, 50 mM 0.49, 75 mM 0.40. Mean absorbance (490nm) of CC2565 cells 
under hypoxic conditions: 0 mM 0.61, 25 mM 0.53, 50 mM 0.38, 75 mM 0.29. Normoxic 
conditions were compared to hypoxic conditions for each oxamate treatment 
concentration, 2way ANOVA; not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, 
**** P ≤ 0.0001. 
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5.2.2 Growth curve assay 
Automated trypan blue assays were used to count the number of viable cells and exclude 
dead, non-viable cells within the population of UW402, DAOY and Res256 MB cell lines 
treated with 0 mM, 25 mM, 50 mM or 75 mM oxamate at 24h, 48h and 72h time points 
under normoxic and hypoxic conditions. 
The UW402 and DAOY cell lines had a population doubling time of 50.62h and 40.8h 
respectively under normoxic conditions and 37.72h and 59.89h respectively under hypoxic 
conditions (Figure 5. 14). The Res256 cell line was the fastest growing MB cell line with a 
population doubling time of 37.93h under normoxic conditions and 30.37h under hypoxic 
conditions (Figure 5. 14). 
Under normoxic conditions there was a significant decrease in viable UW402 cells at 24h 
with the addition of 75 mM oxamate (P ≤ 0.05), at 48h with the addition of 50 mM and 75 
mM oxamate (P ≤ 0.05 and P ≤ 0.01 respectively) and at 72h with the addition of 25 mM, 50 
mM and 75 mM oxamate (P ≤ 0.01, P ≤ 0.01, and P ≤ 0.001 respectively) (Figure 5. 15). 
Under hypoxic conditions there was a significant decrease in the number of viable UW402 
cells with the addition of 25 mM, 50 mM and 75 mM oxamate at 24h (P ≤ 0.05, P ≤ 0.01 and 
P ≤ 0.0001 respectively), at 48h (P ≤ 0.01, P ≤ 0.0001 and P ≤ 0.0001 respectively) and at 
72h (P ≤ 0.0001). 
Under normoxic conditions there was a significant decrease in viable DAOY cells with the 
addition of 50 mM and 75 mM oxamate at 48h (P ≤ 0.05 and P ≤ 0.01 respectively), and at 
72h (P ≤ 0.05 and P ≤ 0.01 respectively) (Figure 5. 16).  Under hypoxic conditions there was 
a significant decrease in the number of viable DAOY cells with the addition of 50 mM and 
75 mM oxamate at 24h ( P ≤ 0.01), at 48h (P ≤ 0.01 and P ≤ 0.001 respectively) and 25 mM, 
50 mM and 75 mM oxamate at 72h (P ≤ 0.05 , P ≤ 0.0001 and P ≤ 0.0001 respectively). 
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There was a significant decrease in viable Res256 cells at 24h with the addition of 75 mM 
oxamate under normoxic and hypoxic conditions (P ≤ 0.05) (Figure 5. 17). At 48h and 72h 
there was a significant decrease in viable Res256 cells with the addition of 25 mM, 50 mM 
and 75 mM oxamate (P ≤ 0.0001). 
Statistical analysis of the number of viable cells after 72h of 0 mM, 25 mM, 50 mM or 75 
mM oxamate treatments under normoxic and hypoxic conditions showed that hypoxia 
alone significantly reduced the number of viable DAOY cells, but not the number of viable 
UW402 or Res256 cells (Figure 5. 18). Oxamate treatments decreased the number of viable 
UW402 and Res256 cells however there was no significant difference in this effect under 
hypoxic conditions compared to normoxic conditions. In the DAOY cell line oxamate 
treatments decreased the number of viable cells and this effect was more significant under 
hypoxic conditions than normoxic conditions. 
In summary, UW402 and Res256 MB cell lines had an increased growth rate under hypoxic 
conditions whereas the DAOY MB cell line had a decreased growth rate under hypoxic 
conditions. Oxamate significantly decreased MB cell line growth in a time and 
concentration dependent manner, the Res256 MB cell line was the most sensitive to 
oxamate treatments and was affected equally under normoxic and hypoxic conditions. In 
UW402 and DAOY MB cell lines this effect was more significant under hypoxic conditions 
when compared to untreated cells under the same oxygen conditions. 
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5.2.2.1 Comparison of cell lines 
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Figure 5. 14 Population doubling times of cell lines under normoxic and hypoxic 
conditions  
Population doubling times of the MB cell lines UW402, DAOY and Res256 under normoxic 
and hypoxic conditions. Population doubling times under normoxic conditions: UW402 
50.62h, DAOY 40.8h, Res256 37.93h. Population doubling times under hypoxic conditions: 
UW402 37.72h, DAOY 59.89h, Res256 30.37h. 
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5.2.2.2 UW402 
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Figure 5. 15 UW402 growth curves with oxamate treatments under normoxic and hypoxic 
conditions 
Number of viable UW402 cells grown in the presence of 0 mM, 25 mM, 50 mM or 75 mM 
oxamate for 0-72h under normoxic (A) and hypoxic (B) conditions counted by Vi-Cell 
automated cell counter. Graphs show mean with SEM. A) Mean number of viable cells 
under normoxic conditions: 0h; 104,889,  24h; 0 mM 200,667, 25 mM 143,111, 50 mM 
138,889, 75 mM 79,333, 48h; 0 mM 229,667, 25 mM 136,667, 50 mM 97,000, 75 mM 
69,000, 72h; 0 mM 281,111, 25 mM 142.111, 50 mM 124,222, 75 mM 83,222. B) Mean 
number of viable cells under hypoxic conditions: 0h; 94,111, 24h; 0 mM 143,333, 25 mM 
97,000, 50 mM 82,777, 75 mM 65,777, 48h; 0 mM 194,444, 25 mM 134,444, 50 mM 
100,667, 75 mM 92,222, 72h; 0 mM 353,333, 25 mM 171,333, 50 mM 134,111, 75 mM 
99,777. Oxamate treated samples were compared to the untreated control at each time 
point, 2way ANOVA; not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 
0.0001.  
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5.2.2.3 DAOY 
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Figure 5. 16 DAOY growth curves with oxamate treatments under normoxic and hypoxic 
conditions 
Number of viable DAOY cells grown in the presence of 0 mM, 25 mM, 50 mM or 75 mM 
oxamate for 0-72h under normoxic (A) and hypoxic (B) conditions counted by Vi-Cell 
automated cell counter. Graphs show mean with SEM. A) Mean number of viable cells 
under normoxic conditions: 0h; 68,666, 24h; 0 mM 117,000, 25 mM 94,111, 50 mM 71,555, 
75 mM 53,000, 48h; 0 mM 194,889, 25 mM 140,778, 50 mM 116,778, 75 mM 85,222, 72h; 
0 mM 233.333, 25 mM 166,333, 50 mM 148,222, 75 mM 124,111. B) Mean number of 
viable cells under hypoxic conditions: 0h; 49,111, 24h; 0 mM 73,888, 25 mM 55,444, 50 mM 
44,777, 75 mM 39,555, 48h; 0 mM 75,555, 25 mM 56,666, 50 mM 46,000, 75 mM 39,666, 
72h; 0 mM 113,000, 25 mM 85,555, 50 mM 56,888, 75 mM 43,333. Oxamate treated 
samples were compared to the untreated control at each time point, 2way ANOVA; not 
significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001.  
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5.2.2.4 Res256 
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Figure 5. 17 Res256 growth curves with oxamate treatments under normoxic and hypoxic 
conditions 
Number of viable Res256 cells grown in the presence of 0 mM, 25 mM, 50 mM or 75 mM 
oxamate for 0-72h under normoxic (A) and hypoxic (B) conditions counted by Vi-Cell 
automated cell counter. Graphs show mean with SEM. A) Mean number of viable cells 
under normoxic conditions: 0h; 154,889, 24h; 0 mM 214,222, 25 mM 129,667, 50 mM 
111,111, 75 mM 77,777, 48h; 0 mM 447,778, 25 mM 121,556, 50 mM 89,000, 75 mM 
77,777, 72h; 0 mM 577,444, 25 mM 131,444, 50 mM 81,111, 75 mM 54,000. B) Mean 
number of viable cells under hypoxic conditions: 0h; 86,555, 24h; 0 mM 128,556, 25 mM 
81,111, 50 mM 72,555, 75 mM 66,444, 48h; 0 mM 254,333, 25 mM 108,556, 50 mM 
72,000, 75 mM 82,555, 72h; 0 mM 447,778, 25 mM 82,666, 50 mM 91,000, 75 mM 95,444. 
Oxamate treated samples were compared to the untreated control at each time point, 
2way ANOVA; not significant P > 0.05, * P ≤ 0.05, **** P ≤ 0.0001. 
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5.2.2.6 Comparison of 72h oxamate treatments under normoxic and hypoxic 
conditions 
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Figure 5. 18 Number of viable MB cells under normoxic and hypoxic conditions with 72h 
oxamate treatments 
Number of viable UW402 (A), DAOY (B), and Res256 (C) cells grown in the presence of 0 
mM, 25 mM, 50 mM or 75 mM oxamate for 72h under normoxic and hypoxic conditions 
counted by Vi-Cell automated cell counter. Graphs show mean with SEM. A) Mean number 
of viable UW402 cells under normoxic conditions:  0 mM 281,111, 25 mM 142.111, 50 mM 
124,222, 75 mM 83,222. Mean number of viable of UW402 cells under hypoxic conditions: 
0 mM 353,333, 25 mM 171,333, 50 mM 134,111, 75 mM 99,777. B) Mean number of viable 
DAOY cells under normoxic conditions: 0 mM 233.333, 25 mM 166,333, 50 mM 148,222, 75 
mM 124,111. Mean number of viable DAOY cells under hypoxic conditions: 0 mM 113,000, 
25 mM 85,555, 50 mM 56,888, 75 mM 43,333. C) Mean number of viable Res256 cells 
under normoxic conditions: 0 mM 577,444, 25 mM 131,444, 50 mM 81,111, 75 mM 54,000. 
Mean number of viable Res256 cells under hypoxic conditions: 0 mM 447,778, 25 mM 
82,666, 50 mM 91,000, 75 mM 95,444. Normoxic conditions were compared to hypoxic 
conditions for each oxamate treatment concentration, 2way ANOVA; not significant P > 
0.05, * P ≤ 0.05, ** P ≤ 0.01. 
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5.2.3 Cell cycle analysis  
The Growth curve assays demonstrated a decrease in cell growth in MB cell lines with the 
addition of oxamate so cell cycle analysis were conducted to investigate a potential 
mechanism which may have caused this. 
Changes in the percentage of UW402, DAOY and Res256, MB cell line populations in each 
phase of the cell cycle, after treatment with 0 mM, 25 mM, 50 mM and 75 mM oxamate, 
for 24h and 48h under normoxic and hypoxic conditions, were examined using a DAPI stain 
and the NucleoCounter® NC-3000 to analyse DNA content per cell.  The majority of cells in a 
population are usually at rest and not dividing (G0), a small percentage are undergoing cell 
division which consists of a short period of DNA synthesis (S phase) before a final growth 
period and preparation for mitosis (G2/M). 
In untreated UW402 cells the % of cells in G0 phase increased significantly under hypoxic 
conditions after 24h and 48h (P ≤ 0.01 and P ≤ 0.0001 respectively) (Figure 5. 19). The 
percentage of untreated UW402 cells in G2/M phase also decreased under hypoxic 
conditions however this was only significant after 48h (P ≤ 0.05). In untreated DAOY cells 
the % of cells in each cell cycle does not significantly change after 24h under hypoxic 
conditions (Figure 5. 19). However after 48h there is a significant increase in the % of 
untreated DAOY cells in G0 phase (P ≤ 0.01) and a significant decrease in the % of untreated 
DAOY cells in G2/M phase (P ≤ 0.05). In untreated Res256 cells the % of cells in G0 phase 
increased significantly under hypoxic conditions after 24h and 48h (P ≤ 0.0001 and P ≤ 0.01 
respectively) (Figure 5. 19). The percentage of untreated Res256 cells in G2/M phase also 
decreased under hypoxic conditions however this was only significant at 24h (P ≤ 0.001). 
Under normoxic and hypoxic conditions there were significantly more untreated DAOY cells 
in G0 phase and significantly fewer untreated DAOY cells in the G2/M phase than the other 
untreated MB cells at 24h and 48h, apart from untreated UW402 cells in G2/M at 48h 
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under normoxic conditions (24h normoxic G0 and G2/M P ≤ 0.0001, 24h hypoxic G0 UW402 
P ≤ 0.01, Res256 P ≤ 0.001, 24h hypoxic G2/M P ≤ 0.01, 48h normoxic G0 ≤ 0.01, 48h 
normoxic G2/M Res256 ≤ 0.05, 48h hypoxic G0 and G2/M P ≤ 0.0001) (Figure 5. 20). The 
only significant difference in cell cycle phases between untreated Res256 cells and 
untreated UW402 cells were at 24h under normoxic conditions; there were significantly 
more UW402 cells than Res256 cells in G0 (P ≤ 0.05) (Figure 5. 20). The only significant 
difference between the S phase of untreated MB cell lines was at 48h under hypoxic 
conditions; there were significantly more UW402 cells than Res256 in S phase P ≤ 0.01) 
(Figure 5. 20). 
Under normoxic conditions, in UW402 cells treated with 25 mM, 50 mM and 75 mM 
oxamate, there was a significant decrease in the percentage of cells in G0 at 24h (P ≤ 0.001, 
P ≤ 0.0001 and P ≤ 0.0001 respectively) and 48h (P ≤ 0.01, P ≤ 0.0001 and P ≤ 0.0001 
respectively), and a significant increase in the percentage of cells in G2/M at 24h (P ≤ 0.001, 
P ≤ 0.0001 and P ≤ 0.0001 respectively) and 48h (P ≤ 0.001, P ≤ 0.0001 and P ≤ 0.0001 
respectively) (Figure 5. 21 and Figure 5. 22). Under hypoxic conditions, in UW402 cells 
treated with 25 mM, 50 mM and 75 mM oxamate, there was a significant decrease in the 
percentage of cells in G0 at 24h (P ≤ 0.0001) and 48h (P ≤ 0.0001), and a significant increase 
in the percentage of cells in G2/M at 24h (P ≤ 0.0001) and 48h (P ≤ 0.0001). 
Under normoxic conditions, in DAOY cells treated with 25 mM, 50 mM and 75 mM 
oxamate, there were no significant changes in the cell cycle phases apart from an increase 
in the percentage of cells in G2/M treated with 75 mM oxamate for 48h (P ≤ 0.05) (Figure 5. 
23 and Figure 5. 24). Under hypoxic conditions, there was a significant decrease in the 
percentage of DAOY cells in G0 at 24h when treated with 75 mM oxamate (P ≤ 0.05) and at 
48h when treated with 50 mM and 75 mM (P ≤ 0.0001). There was a significant increase in 
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the percentage of DAOY cells in G2/M when treated with 50 mM and 75 mM under hypoxic 
conditions at 24h (P ≤ 0.05 and P ≤ 0.01 respectively) and 48h (P ≤ 0.0001). 
Under normoxic conditions, in Res256 cells treated with 25 mM, 50 mM and 75 mM 
oxamate, there was a significant decrease in the percentage of cells in G0 at 24h (P ≤ 0.05, P 
≤ 0.0001 and P ≤ 0.0001 respectively) and 48h (P ≤ 0.0001), and a significant increase in the 
percentage of cells in G2/M at 24h (P ≤ 0.01, P ≤ 0.0001 and P ≤ 0.0001 respectively) and 
48h (P ≤ 0.01, P ≤ 0.0001 and P ≤ 0.0001 respectively) (Figure 5. 25 and Figure 5. 26). Under 
hypoxic conditions, in Res256 cells treated with 25 mM, 50 mM and 75 mM oxamate, there 
was a significant decrease in the percentage of cells in G0 at 24h (P ≤ 0.0001) and 48h (P ≤ 
0.0001), and a significant increase in the percentage of cells in G2/M at 24h (P ≤ 0.0001) 
and 48h (P ≤ 0.0001). 
In summary, in all MB cell lines hypoxia caused an increase in the percentage of cells in G0 
phase and a decrease in the percentage of cells in G2/M phase. Oxamate significantly 
decreased the percentage of MB cells in G0 and significantly increased the percentage of 
MB cells in G2/M in a concentration dependent manner, suggesting LDHA inhibition by 
oxamate has a cytostatic effect, causing G2/M cell cycle arrest and a decrease in 
proliferation. In all MB cell lines this effect was more significant under hypoxic conditions. 
The Res256 and UW402 MB cell lines were similarly sensitive whereas the DAOY cell line 
was much less sensitive to the oxamate treatments under normoxic and hypoxic conditions. 
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5.2.3.1 Comparison of cell lines 
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Figure 5. 19 Cell cycle analysis in cell lines under normoxic and hypoxic conditions 
(A) Mean percentage of UW402 cells in each phase at 24h under normoxic conditions:  G0 
64.78%, S 8.44%, G2/M 27.21%, under hypoxic conditions: G0 69.54%, S 7.37%, G2/M 
24.31%. (B) Mean percentage of DAOY cells in each phase at 24h under normoxic 
conditions:  G0 76.00%, S 8.53%, G2/M 17.82%, under hypoxic conditions: G0 74.00%, S 
5.68%, G2/M 19.94%. (C) Mean percentage of Res256 cells in each phase at 24h under 
normoxic conditions:  G0 61.51%, S 9.33%, G2/M 28.39%, under hypoxic conditions: G0 
68.78%, S 6.97%, G2/M 23.93%. (D) Mean percentage of UW402 cells in each phase at 48h 
under normoxic conditions:  G0 67.23%, S 8.09%, G2/M 23.42%, under hypoxic conditions: 
G0 74.18%, S 8.74%, G2/M 19.87%. (E) Mean percentage of DAOY cells in each phase at 48h 
under normoxic conditions:  G0 75.72%, S 7.66%, G2/M 18.51%, under hypoxic conditions: 
G0 81.56%, S 4.37%, G2/M 13.50%.(F) Mean percentage of Res256 cells in each phase at 
48h under normoxic conditions:  G0 67.50%, S 7.78%, G2/M 23.66%, under hypoxic 
conditions: G0 74.13%, S 6.67%, G2/M 20.68%. Normoxic conditions were compared to 
hypoxic conditions and at each time point within each cell line, 2way ANOVA; not 
significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 
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Figure 5. 20 Comparison of cell cycle analysis between cell lines  
(A) Mean percentage of untreated cell lines in G0, S and G2/M phases of the cell cycle 
grown under normoxic conditions at 24h: UW402;  G0 64.78%, S 8.44%, G2/M 27.21%, 
DAOY; G0 76.00%, S 8.53%, G2/M 17.82%, Res256; :  G0 61.51%, S 9.33%, G2/M 28.39%. (B) 
Mean percentage of untreated cell lines in G0, S and G2/M phases of the cell cycle grown 
under hypoxic conditions at 24h: UW402; G0 69.54%, S 7.37%, G2/M 24.31%, DAOY; G0 
74.00%, S 5.68%, G2/M 19.94%, Res256; G0 68.78%, S 6.97%, G2/M 23.93%. (C) Mean 
percentage of untreated cell lines in G0, S and G2/M phases of the cell cycle grown under 
normoxic conditions at 48h: UW402; G0 67.23%, S 8.09%, G2/M 23.42%, DAOY; G0 75.72%, 
S 7.66%, G2/M 18.51%, Res256; G0 67.50%, S 7.78%, G2/M 23.66%. (D) Mean percentage 
of untreated cell lines in G0, S and G2/M phases of the cell cycle grown under hypoxic 
conditions at 48h: UW402; G0 74.18%, S 8.74%, G2/M 19.87%, DAOY; G0 81.56%, S 4.37%, 
Res256; G2/M 13.50%, G0 74.13%, S 6.67%, G2/M 20.68%. Cell lines were compared to 
each other in each phase under normoxic and hypoxic conditions at each time point, 2way 
ANOVA; not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001 
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5.2.3.2 UW402 
 
 
    
    
    
    
Figure 5. 21 UW402 Cell cycle histograms with oxamate treatments under normoxic and 
hypoxic conditions 
Representative histograms of UW402 cells used for cell cycle analysis. Cells were grown in 
the presence of 0 mM, 25 mM, 50 mM or 75 mM oxamate for 24h and 48h under normoxic 
and hypoxic conditions. 
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Figure 5. 22 UW402 Cell cycle analysis with oxamate treatments under normoxic and 
hypoxic conditions 
Percentage of UW402 cells in G0, S and G2/M phases of the cell cycle analysed using 
nucleocounter NC-3000. Cells were grown in the presence of 0 mM, 25 mM, 50 mM or 75 
mM oxamate for 24h (A and B) or 48h (C and D) under normoxic (A and C) and hypoxic (B 
and D) conditions. Graphs show mean with SEM. A) Mean percentage of cells in each phase 
under normoxic conditions at 24h: G0; 0 mM 64.78%, 25 mM 58.57%, 50 mM 52.41%, 75 
mM 56.51%, S; 0 mM 8.44%, 25 mM 8.36%, 50 mM 9.38%, 75 mM 8.43%, G2/M; 0 mM 
27.21%, 25 mM 32.82%, 50 mM 37.71%, and 75 mM 35.13%. B) Mean percentage of cells in 
each phase under hypoxic conditions at 24h: G0; 0 mM 69.54%, 25 mM 48.15%, 50 mM 
44.39%, 75 mM 49.10%, S; 0 mM 7.37%, 25 mM 8.86%, 50 mM 10.85%, 75 mM 9.87%, 
G2/M; 0 mM 24.31%, 25 mM 43.46%, 50 mM 44.76%, and 75 mM 42.17%. C) Mean 
percentage of cells in each phase under normoxic conditions at 48h: G0; 0 mM 67.23%, 25 
mM 61.90%, 50 mM 57.12%, 75 mM 55.53%, S; 0 mM 8.09%, 25 mM 8.06%, 50 mM 9.88%, 
75 mM 9.27%, G2/M; 0 mM 23.42%, 25 mM 29.60%, 50 mM 31.94%, 75 mM 33.71%. D) 
Mean percentage of cells in each phase under hypoxic conditions at 48h: G0; 0 mM 74.18%, 
25 mM 59.27%, 50 mM 45.85%, 75 mM 46.15%, S; 0 mM 8.74%, 25 mM 7.68%, 50 mM 
9.02%, 75 mM 9.41%, G2/M; 0 mM 19.87%, 25 mM 33.74%, 50 mM 44.85%, and 75 mM 
46.02%. Oxamate treated samples were compared to the untreated control, 2way ANOVA; 
not significant P > 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001.  
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5.2.3.3 DAOY 
 
 
    
    
    
    
Figure 5. 23 DAOY Cell cycle histograms with oxamate treatments under normoxic and 
hypoxic conditions 
Representative histograms of DAOY cells used for cell cycle analysis. Cells were grown in the 
presence of 0 mM, 25 mM, 50 mM or 75 mM oxamate for 24h and 48h under normoxic and 
hypoxic conditions. 
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Figure 5. 24 DAOY Cell cycle analysis with oxamate treatments under normoxic and 
hypoxic conditions 
Percentage of DAOY cells in G0, S and G2/M phases of the cell cycle analysed using 
nucleocounter NC-3000. Cells were grown in the presence of 0 mM, 25 mM, 50 mM or 75 
mM oxamate for 24h (A and B) or 48h (C and D) under normoxic (A and C) and hypoxic (B 
and D) conditions. Graphs show mean with SEM. A) Mean percentage of cells in each phase 
under normoxic conditions at 24h: G0; 0 mM 76.39%, 25 mM 77.11%, 50 mM 76.97%, 75 
mM 74.04%, S; 0 mM 8.53%, 25 mM 7.58%, 50 mM 6.55%, 75 mM 8.17%, G2/M; 0 mM 
17.82%, 25 mM 17.5%, 50 mM 18.49%, and 75 mM 20.38%. B) Mean percentage of cells in 
each phase under hypoxic conditions at 24h: G0; 0 mM 74.00%, 25 mM 76.77%, 50 mM 
72.07%, 75 mM 71.36%, S; 0 mM 5.68%, 25 mM 5.16%, 50 mM 4.30%, 75 mM 3.73%, 
G2/M; 0 mM 19.94%, 25 mM 17.69%, 50 mM 22.63%, and 75 mM 23.50%. C) Mean 
percentage of cells in each phase under normoxic conditions at 48h: G0; 0 mM 75.72%, 25 
mM 76.30%, 50 mM 73.77%, 75 mM 71.89%, S; 0 mM 7.66%, 25 mM 7.34%, 50 mM 6.84%, 
75 mM 6.61%, G2/M; 0 mM 18.51%, 25 mM 18.30%, 50 mM 20.88%, 75 mM 23.25%. D) 
Mean percentage of cells in each phase under hypoxic conditions at 48h: G0; 0 mM 81.56%, 
25 mM 80.53%, 50 mM 70.56%, 75 mM 70.63%, S; 0 mM 4.37%, 25 mM 4.22%, 50 mM 
5.39%, 75 mM 5.78%, G2/M; 0 mM 13.5%, 25 mM 14.46%, 50 mM 22.60%, and 75 mM 
22.37%. Oxamate treated samples were compared to the untreated control, 2way ANOVA; 
not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, **** P ≤ 0.0001.  
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5.2.3.4 Res256 
 
 
   
    
    
    
Figure 5. 25 Res256 Cell cycle histograms with oxamate treatments under normoxic and 
hypoxic conditions 
Representative histograms of Res256 cells used for cell cycle analysis. Cells were grown in 
the presence of 0 mM, 25 mM, 50 mM or 75 mM oxamate for 24h and 48h under normoxic 
and hypoxic conditions. 
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Figure 5. 26 Res256 cell cycle analysis with oxamate treatments under normoxic and 
hypoxic conditions 
Percentage of Res256 cells in G0, S and G2/M phases of the cell cycle analysed using 
nucleocounter NC-3000. Cells were grown in the presence of 0 mM, 25 mM, 50 mM or 75 
mM oxamate for 24h (A and B) or 48h (C and D) under normoxic (A and C) and hypoxic (B 
and D) conditions. Graphs show mean with SEM. A) Mean percentage of cells in each phase 
under normoxic conditions at 24h: G0; 0 mM 61.51%, 25 mM 57.02%, 50 mM 49.02%., 75 
mM 45.62%, S; 0 mM 9.33%, 25 mM 8.69%, 50 mM 9.70%, 75 mM 10.29%, G2/M; 0 mM 
28.39%, 25 mM 33.39%, 50 mM 40.49%, 75 mM 43.43%. B) Mean percentage of cells in 
each phase under hypoxic conditions at 24h: G0; 0 mM 68.78%, 25 mM 40.81%, 50 mM 
40.78%, 75 mM 43.12%, S; 0 mM 6.97%, 25 mM 9.72%, 50 mM 9.69%, 75 mM 9.94%, 
G2/M; 0 mM 23.93%, 25 mM 47.26%, 50 mM 48.09%, and 75 mM 46.10%. C) Mean 
percentage of cells in each phase under normoxic conditions at 48h: G0; 0 mM 67.50%, 25 
mM 51.89%, 50 mM 52.80%, 75 mM 49.10, S; 0 mM 7.78%, 25 mM 11.58%, 50 mM 8.37%, 
75 mM 8.18%, G2/M; 0 mM 23.66%, 25 mM 33.79%, 50 mM 36.55%, 75 mM 38.24%. D) 
Mean percentage of cells in each phase under hypoxic conditions at 48h: G0; 0 mM 74.13%, 
25 mM 56.83%, 50 mM 45.45%, 75 mM 43.58%, S; 0 mM 6.67%, 25 mM 7.65%, 50 mM 
8.27%, 75 mM 9.22%, G2/M; 0 mM 20.68%, 25 mM 36.57%, 50 mM 46.63%, and 75 mM 
48.64%. Oxamate treated samples were compared to the untreated control, 2way ANOVA; 
not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, **** P ≤ 0.0001.  
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5.3 Effects of oxamate on foetal astrocyte and MB cell line 
metabolism 
In order to further examine the effects of sodium oxamate on MB cell line metabolism, 
pyruvate assays, glycolysis stress tests and mito stress tests were conducted. 
5.3.1 Pyruvate assays 
Pyruvate concentrations were measured in MB cell lines UW402, DAOY and Res256 and 
non-neoplastic astrocyte cell line CC2565 treated with 0 mM, 25 mM, 50 mM and 75 mM 
oxamate for 24h, 48h and 72h time points under normoxic and hypoxic conditions.  
The mean pyruvate concentrations of the untreated UW402 cells ranged from 0.2 -0.5 ng/ 
µg under normoxic conditions and 0.3-0.5 ng/ µg under hypoxic conditions (Figure 5. 27). 
The mean pyruvate concentrations of the untreated DAOY cells ranged from 0.3-0.6 ng/ µg 
under normoxic conditions and 0.2-0.5 ng/ µg under hypoxic conditions (Figure 5. 27). The 
mean pyruvate concentrations of the untreated Res256 cells ranged from 0.7-1.2 ng/ µg 
under normoxic conditions and 0.6-1.2 ng/ µg under hypoxic conditions (Figure 5. 27). The 
mean pyruvate concentrations of the untreated CC2565 cells ranged from 0.4-0.7 ng/ µg 
under normoxic conditions and 0.2-0.4 ng/ µg under hypoxic conditions (Figure 5. 27). 
There was no significant difference between the concentration of pyruvate under normoxic 
and hypoxic conditions in any of the tested cell lines (Figure 5. 27). 
Under normoxic conditions untreated Res256 cells had a higher mean pyruvate 
concentration than untreated UW402 cells at every time point (24h, P ≤ 0.001, 48h P ≤ 0.01, 
and 72h P ≤ 0.05) and untreated DAOY and CC2565 cells at 24h (P ≤ 0.01) (Figure 5. 28). 
Under hypoxic conditions untreated Res256 cells also had a higher mean pyruvate 
concentration than every other untreated cell line at every time point (24h P ≤ 0.0001, 48h 
UW402 P ≤ 0.01, DAOY and CC2565 P ≤ 0.001, 72h UW402 and CC2565 P ≤ 0.05, DAOY P ≤ 
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0.01) (Figure 5. 28). There were no other significant differences between cell lines at any 
time point under normoxic or hypoxic conditions. 
In the UW402 (Figure 5. 29), DAOY (Figure 5. 30), Res256 (Figure 5. 31) and CC2565 (Figure 
5. 32) cell lines under normoxic and hypoxic conditions there was a significant decrease in 
pyruvate concentrations with the addition of 25 mM, 50 mM, and 75 mM oxamate at 24h. 
In UW402 and DAOY cells under normoxic and hypoxic conditions there was also a 
significant decrease in pyruvate concentrations with the addition of all oxamate treatments 
at 48h. In Res256 cells there was only a significant decrease in pyruvate concentrations at 
48h with the addition of 75 mM under normoxic and hypoxic conditions (P ≤ 0.05). There 
was also a significant decrease in pyruvate concentrations in CC2565 cells at 48h under 
normoxic conditions with all oxamate treatments (P ≤ 0.01) and under hypoxic conditions 
with 75 mM (P ≤ 0.05). At 72h only CC2565 cells had any significant decrease in pyruvate 
concentrations (75 mM oxamate under hypoxic conditions (P ≤ 0.05)). 
In summary, Res256 MB cells had higher mean pyruvate concentrations than the other MB 
cell lines and non-neoplastic astrocyte cell line under normoxic and hypoxic conditions. In 
all MB cell lines and the non-neoplastic astrocyte cell line CC2565, pyruvate concentrations 
were significantly decreased with the addition of sodium oxamate, however this 
significance decreased over time. The successful inhibition of LDHA by oxamate may have 
reduced the production rate of pyruvate, due to a reduction in NAD+ regeneration, and 
some pyruvate may have also been diverted into the OXPHOS pathway to maintain ATP 
production. In all cell lines the concentrations of pyruvate in the untreated cells decreased 
over time, this was likely due to an increase in cell population causing a decrease in 
available nutrients per cell, which also caused a decrease in the significant difference 
between treated and untreated cells.  
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Figure 5. 27 Pyruvate concentrations in cell lines under normoxic and hypoxic conditions 
Pyruvate concentrations of lysates prepared from UW402 (A), DAOY (B), Res256 (C) and 
CC2565 (D) cells grown for 24-72h under normoxic and hypoxic conditions. Pyruvate 
concentrations were normalised to the protein concentrations of each sample. Graphs 
show mean with SEM. (A) Mean UW402 pyruvate concentrations (ng/ µg) under normoxic 
conditions: 24h; 0.55, 48h; 0.37, 72h; 0.28. Mean UW402 pyruvate concentrations (ng/ µg) 
under hypoxic conditions: 24h; 0.54, 48h; 0.45, 72h; 0.36 B) Mean DAOY pyruvate 
concentrations (ng/ µg) under normoxic conditions: 24h; 0.68, 48h; 0.56, 72h; 0.38. Mean 
DAOY pyruvate concentrations (ng/ µg) under hypoxic conditions: 24h; 0.51, 48h; 0.39, 72h; 
0.24. C) Mean Res256 pyruvate concentrations (ng/ µg) under normoxic conditions: 24h; 
1.23, 48h; 0.88, 72h; 0.70. Mean Res256 pyruvate concentrations (ng/ µg) under hypoxic 
conditions: 24h; 1.29, 48h; 0.94, 72h; 0.67. D) Mean CC2565 pyruvate concentrations (ng/ 
µg) under normoxic conditions: 24h; 0.70, 48h; 0.59, 72h; 0.43. Mean CC2565 pyruvate 
concentrations (ng/ µg) under hypoxic conditions: 24h; 0.42, 48h; 0.38, 72h; 0.28. Normoxic 
conditions were compared to hypoxic conditions and at each time point within each cell 
line, 2way ANOVA; not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01. 
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Figure 5. 28 Comparison of pyruvate concentrations between cell lines 
Pyruvate concentrations of lysates prepared from UW402, DAOY, Res256 and CC2565 cells 
grown for 24-72h under normoxic (A) and hypoxic (B) conditions. Pyruvate concentrations 
were normalised to the protein concentrations of each sample. Graphs show mean with 
SEM. A) Mean pyruvate concentrations (ng/ µg) under normoxic conditions: 24h; UW402 
0.55, DAOY 0.68, Res256 1.23, CC2565 0.70, 48h; UW402 0.37, DAOY 0.56, Res256 0.88, 
CC2565 0.59, 72h; UW402 0.28, DAOY 0.38, Res256 0.70, CC2565 0.43. B) Mean pyruvate 
concentrations (ng/ µg) under hypoxic conditions: 24h; UW402 0.54, DAOY 0.51, Res256 
1.29, CC2565 0.42, 48h; UW402 0.45, DAOY 0.39, Res256 0.94, CC2565 0.38, 72h; UW402 
0.36, DAOY 0.24, Res256 0.67, CC2565 0.28. Cell lines were compared to each other under 
normoxic and hypoxic conditions at each time point, 2way ANOVA; not significant P > 0.05, 
* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 
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5.3.1.2 UW402 
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Figure 5. 29 UW402 pyruvate concentrations with oxamate treatments under normoxic 
and hypoxic conditions 
Pyruvate concentrations of lysates prepared from UW402 cells grown in the presence of 0 
mM, 25 mM, 50 mM or 75 mM oxamate for 24-72h under normoxic (A) and hypoxic (B) 
conditions. Pyruvate concentrations were normalised to the protein concentrations of each 
sample. Graphs show mean with SEM. A) Mean pyruvate concentrations (ng/ µg) under 
normoxic conditions: 24h; 0 mM 0.55, 25 mM 0.24, 50 mM 0.22, 75 mM 0.17, 48h; 0 mM 
0.37, 25 mM 0.22, 50 mM 0.23,  75 mM 0.22, 72h; 0 mM 0.28, 25 mM 0.17, 50 mM 0.23, 75 
mM 0.23. B) Mean pyruvate concentrations (ng/ µg) under hypoxic conditions: 24h; 0 mM 
0.58, 25 mM 0.23, 50 mM 0.21, 75 mM 0.18, 48h; 0 mM 0.62, 25 mM 0.23, 50 mM 0.25, 75 
mM0.25 , 72h; 0 mM 0.50, 25 mM 0.27, 50 mM 0.34, 75 mM 0.27. Oxamate treated 
samples were compared to the untreated control at each time point, 2way ANOVA; not 
significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, **** P ≤ 0.0001. 
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5.3.1.3 DAOY 
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Figure 5. 30 DAOY pyruvate concentrations with oxamate treatments under normoxic and 
hypoxic conditions 
Pyruvate concentrations of lysates prepared from DAOY cells grown in the presence of 0 
mM, 25 mM, 50 mM or 75 mM oxamate for 24-72h under normoxic (A) and hypoxic (B) 
conditions. Pyruvate concentrations were normalised to the protein concentrations of each 
sample. Graphs show mean with SEM. A) Mean pyruvate concentrations (ng/ µg) under 
normoxic conditions: 24h; 0 mM 0.68, 25 mM 0.35, 50 mM 0.24, 75 mM 0.25, 48h; 0 mM 
0.56, 25 mM 0.25, 50 mM 0.26, 75 mM 0.27, 72h; 0 mM 0.38, 25 mM 0.24, 50 mM 0.29, 75 
mM 0.30. B) Mean pyruvate concentrations (ng/ µg) under hypoxic conditions: 24h; 0 mM 
0.51, 25 mM 0.24, 50 mM 0.24, 75 mM 0.22, 48h; 0 mM 0.39, 25 mM 0.24, 50 mM 0.23, 75 
mM 0.18, 72h; 0 mM 0.24, 25 mM 0.19, 50 mM 0.22, 75 mM 0.27. Oxamate treated 
samples were compared to the untreated control at each time point, 2way ANOVA; not 
significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, **** P ≤ 0.0001.  
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5.3.1.4 Res256 
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Figure 5. 31 Res256 pyruvate concentrations with oxamate treatments under normoxic 
and hypoxic conditions  
Pyruvate concentrations of lysates prepared from Res256 cells grown in the presence of 0 
mM, 25 mM, 50 mM or 75 mM oxamate for 24-72h under normoxic (A) and hypoxic (B) 
conditions. Pyruvate concentrations were normalised to the protein concentrations of each 
sample. Graphs show mean with SEM. A) Mean pyruvate concentrations (ng/ µg) under 
normoxic conditions: 24h; 0 mM 1.23, 25 mM 0.75, 50 mM 0.64, 75 mM 0.51, 48h; 0 mM 
0.88, 25 mM 0.67, 50 mM 0.52, 75 mM 0.46, 72h; 0 mM 0.70, 25 mM 0.46, 50 mM 0.56, 75 
mM 0.53. B) Mean pyruvate concentrations (ng/ µg) under hypoxic conditions: 24h; 0 mM 
1.29, 25 mM 0.76, 50 mM 0.71, 75 mM 0.58, 48h; 0 mM 0.94, 25 mM 0.59, 50 mM 0.72, 75 
mM 0.55, 72h; 0 mM 0.67, 25 mM 0.47, 50 mM 0.59, 75 mM 0.51. Oxamate treated 
samples were compared to the untreated control at each time point, 2way ANOVA; not 
significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001. 
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5.3.1.5 CC2565 
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Figure 5. 32 CC2565 pyruvate concentrations with oxamate treatments under normoxic 
and hypoxic conditions 
Pyruvate concentrations of lysates prepared from CC2565 cells grown in the presence of 0 
mM, 25 mM, 50 mM or 75 mM oxamate for 24-72h under normoxic (A) and hypoxic (B) 
conditions. Pyruvate concentrations were normalised to the protein concentrations of each 
sample. Graphs show mean with SEM. A) Mean pyruvate concentrations (ng/ µg) under 
normoxic conditions: 24h; 0 mM 0.70, 25 mM 0.25, 50 mM 0.29, 75 mM 0.23, 48h; 0 mM 
0.59, 25 mM 0.21, 50 mM 0.21, 75 mM 0.19, 72h; 0 mM 0.43, 25 mM 0.19, 50 mM 0.23, 75 
mM 0.16. B) Mean pyruvate concentrations (ng/ µg) under hypoxic conditions: 24h; 0 mM 
0.42, 25 mM 0.25, 50 mM 0.23, 75 mM 0.17, 48h; 0 mM 0.38, 25 mM 0.25, 50 mM 0.27, 75 
mM 0.19, 72h; 0 mM 0.28, 25 mM 0.16, 50 mM 0.19, 75 mM 0.17. Oxamate treated 
samples were compared to the untreated control at each time point, 2way ANOVA; * P ≤ 
0.05, ** P ≤ 0.01.  
A 
B 
N
o
rm
o
xi
c 
H
yp
o
xi
c 
196 
 
5.3.2 Effects of oxamate on UW402 glycolysis and OXPHOS 
The metabolism of UW402 cells treated with 0 mM, 25 mM, 50 mM and 75 mM oxamate 
for 24h under normoxic conditions was examined more closely with glycolysis stress tests 
and mito stress tests using the Seahorse bioanalyser. Unfortunately it was not within the 
scope of this project to analyse more than one time point or more than one cell line with 
glycolysis stress tests and mito stress tests. The 24h time point was chosen to verify 
successful and significant inhibition of LDHA activity with oxamate at the earliest time point 
used for subsequent functional analysis. The UW402 MB cell line was chosen to examine in 
more detail as it had shown high LDHA protein expression and is the MB cell line most likely 
to represent Group 3 or Group 4 MBs which are the most metastatic and carry the poorest 
prognosis. 
 
5.3.2.1 Glycolysis stress test with Seahorse bioanalyser 
By analysing the changes in ECAR after the injection of glucose, oligomycin and 2-DG, as 
described in chapter 2, the inhibition of glycolysis in UW402 MB cells treated with 25 mM, 
50 mM and 75 mM oxamate for 24h under normoxic conditions could be further verified 
(Figure 5. 33).  
There was a significant decrease in non-glycolytic acidification with the addition of 50 mM 
and 75 mM oxamate (P ≤ 0.05), and a significant decrease in glycolysis, glycolytic capacity 
and the glycolytic reserve with the addition of 25 mM, 50 mM and 75 mM oxamate (P ≤ 
0.0001). This data further validates the inhibition of LDHA activity and glycolysis by 
oxamate. 
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Figure 5. 33 Changes in UW402 glycolysis metabolism with oxamate determined using 
Seahorse bioanalyser 
Extracellular acidification rate (mpH/min) of UW402 cells grown in the presence of 0 mM, 
25 mM, 50 mM or 75 mM oxamate under normoxic conditions. A) Changes in ECAR as 
glucose, oligomycin and 2-DG are added and manipulate the glycolysis pathway. Mean 
ECAR values for each time point are listed in Table 8. 5. B) Non glycolytic acidification, 
glycolysis, glycolytic capacity and glycolytic reserve calculated from changes in ECAR with 
the addition of glucose, oligomycin and 2-DG. Mean ECAR (mpH/min): non glycolytic 
acidification; 0 mM 7.34, 25 mM 6.07, 50 mM 5.06, 75 mM 4.48, glycolysis; 0 mM 15.11, 25 
mM 10.14, 50 mM 8.04, 75 mM 6.81, glycolytic capacity; 0 mM 29.51, 25 mM 19.04, 50 mM 
16.43, 75 mM 14.01, glycolytic reserve 0 mM 14.40, 25 mM 8.90, 50 mM 8.38, and 75 mM 
7.19. Graphs show mean with SEM. Oxamate treated samples were compared to the 
untreated control. 2way ANOVA; not significant P > 0.05, * P ≤ 0.05, **** P ≤ 0.0001.  
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5.3.2.2 Mito stress test with Seahorse bioanalyser 
The effect of the inhibition of glycolysis on oxidative phosphorylation, in UW402 cells 
treated with 0 mM, 25 mM, 50 mM and 75 mM oxamate for 24h under normoxic 
conditions, could be observed by analysing the changes in OCR after the injection of 
oligomycin, FCCP, rotenone and antimycin (Figure 5. 34), as described in section 2.  
There was a significant increase in basal respiration, ATP production and maximal 
respiration with the addition of 25 mM 50 mM and 75 mM oxamate (P ≤ 0.0001), but no 
significant change in spare respiratory capacity or proton leak. This data indicates that 
oxidative phosphorylation was upregulated in response oxamate inhibition of LDHA activity 
and glycolytic metabolism.  
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Figure 5. 34 Changes in UW402 mitochondrial respiration with oxamate determined using 
Seahorse bioanalyser 
Oxygen consumption rate (pmoles/min) of UW402 cells grown in the presence of 0 mM, 25 
mM, 50 mM or 75 mM oxamate under normoxic conditions. A) Changes in OCR as 
oligomycin, FCCP, rotenone and antimycin A are added and manipulate the electron 
transport chain. Mean OCR values for each time point are listed in Table 8. 6. B) Basal 
respiration, ATP production, maximal respiration, spare respiratory capacity and proton 
leak calculated from changes in OCR with the addition of oligomycin, FCCP, rotenone and 
antimycin A. Mean OCR (pmoles/min): basal respiration; 0 mM 24.00, 25 mM 35.98, 50 mM 
35.20, 75 mM 34.48, ATP production; 0 mM 17.02, 25 mM 25.86, 50 mM 25.54, 75 mM 
25.82, maximal respiration; 0 mM 25.72, 25 mM 36.23, 50 mM 36.99, 75 mM 38.12, spare 
respiratory capacity; 0 mM 1.72, 25 mM 0.25, 50 mM 1.78, 75 mM 3.64, proton leak; 0 mM 
6.97, 25 mM 10.11, 50 mM 9.65, 75 mM 8.66. Graphs show mean with SEM. Oxamate 
treated samples were compared to the untreated control. 2way ANOVA; not significant P > 
0.05, **** P ≤ 0.0001. 
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5.4 Effects of sodium oxamate on foetal astrocyte and MB cell line 
motility 
In order to test the hypothesis that LDHA inhibition will inhibit MB motility, live cell imaging 
of scratch wound assays were conducted, speed of gap closure analysed and cell movement 
was tracked. Representative scratch wound assay videos of each cell line with and without 
oxamate treatments under normoxic and hypoxic conditions are included in the PowerPoint 
file on the supplementary CD. 
 
5.4.1 Scratch wound assays  
To analyse the migration of UW402, DAOY and Res256 MB cell lines treated with 0 mM, 25 
mM, 50 mM and 75 mM oxamate, the size of a scratch in a confluent monolayer of cells 
was analysed every 12 hours over 72h under normoxic and hypoxic conditions. As CC2565 
cells are significantly more mobile than MB cells, even with oxamate treatment, the size of 
the scratch wounds decreased more rapidly so they were analysed more frequently and 
over a shorter time period than the MB cell lines. To analyse the migration of CC2565 cells 
treated with 0 mM, 25 mM, 50 mM and 75 mM oxamate, the size of a scratch in a confluent 
monolayer of cells was analysed every 6 hours over 48h under normoxic and hypoxic 
conditions. 
There was no significant difference in the rate of gap closure in untreated UW402 cells 
grown under normoxic conditions compared to hypoxic conditions (Figure 5. 35). Untreated 
DAOY cells only had a significantly larger gap at 12h when grown under hypoxic conditions, 
compared to normoxic conditions (P ≤ 0.0001) (Figure 5. 35). There was no significant 
difference in the rate of gap closure in untreated Res256 cells grown under normoxic 
conditions compared to hypoxic conditions (Figure 5. 35). Untreated CC2565 cells only had 
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a significantly larger gap at 12h when grown under hypoxic conditions, compared to 
normoxic conditions (P ≤ 0.05) (Figure 5. 35).  
Under normoxic conditions untreated UW402 cells had a significantly larger gap than the 
other untreated cell lines between 12h and 48h, apart from Res256 at 36h (Figure 5. 36). 
Untreated CC2565 cells had a significantly smaller gap than the other untreated MB cell 
lines at 12h and the Res256 cell line at 24h (Figure 5. 36). Under hypoxic conditions 
untreatedUW402 also cells had a significantly larger gap than the other cell lines between 
12h and 48h (Figure 5. 36). The only other significant difference between cell lines under 
hypoxic conditions was the untreated DAOY cell line had a significantly smaller gap than the 
Res256 cell line at 24h (Figure 5. 36). 
Scratches in UW402 monolayers, treated with 0 mM oxamate, did not all completely close 
after 72h under normoxic or hypoxic conditions (Figure 5. 37, Figure 5. 38 and Figure 5. 39). 
Under normoxic conditions, there was a significant decrease in gap closure of UW402 cells 
treated with 25 mM oxamate at 12h, 24h, 36h, and 48h time points, and UW402 cells 
treated with 50 mM and 75 mM oxamate at 12h, 24h, 48h, 36h, 48h, 60h and 72h time 
points. Under hypoxic conditions, there was a significant decrease in gap closure of UW402 
cells treated with 25 mM and 50 mM oxamate between 12h and 60h, and UW402 cells 
treated with 75 mM oxamate between 12h and 72h. There was a concentration dependent 
response to oxamate under normoxic and hypoxic conditions. 
All scratches in DAOY monolayers, treated with 0 mM oxamate, completely closed after 24h 
under normoxic and hypoxic conditions (Figure 5. 40, Figure 5. 41 and Figure 5. 42). Under 
normoxic conditions, there was a significant decrease in gap closure of DAOY cells treated 
with 25 mM oxamate at 12h, 24h, 36h, and 48h time points, and DAOY cells treated with 50 
mM and 75 mM oxamate at 12h, 24h, 48h, 36h, 60h and 72h time points. Under hypoxic 
conditions, there was a significant decrease in gap closure of DAOY cells treated with 25 
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mM oxamate between 12h and 24h, DAOY cells treated with 50 mM oxamate between 12h 
and 36h and DAOY cells treated with 75 mM oxamate between 12h and 60h. There was a 
concentration dependent response to oxamate under normoxic and hypoxic conditions. 
All scratches in Res256 monolayers, treated with 0 mM oxamate, closed after 48h under 
normoxic conditions but after only 36h under hypoxic conditions (Figure 5. 43, Figure 5. 44 
and Figure 5. 45). Under normoxic conditions, there was a significant decrease in gap 
closure of Res256 cells treated with 25 mM, 50 mM and 75 mM oxamate at 12h, 24h, 36h, 
48h, 60h and 72h time points. Under hypoxic conditions, there was a significant decrease in 
gap closure of Res256 cells treated with 25 mM oxamate between 12h and 36h, Res256 
cells treated with 50 mM oxamate between 12h and 60h, and Res256 cells and treated with 
75 mM oxamate between 12h and 72h. There was a concentration dependent response to 
oxamate under normoxic and hypoxic conditions. 
All scratches in CC2565 monolayers, treated with 0 mM oxamate, closed after 48h under 
normoxic conditions but after only 36h under hypoxic conditions (Figure 5. 46, Figure 5. 47 
and Figure 5. 48). Under normoxic conditions, there was no significant decrease in gap 
closure of CC2565 cells treated with 25 mM oxamate, only a significant decrease in gap 
closure of CC2565 cells treated with 50 mM oxamate at 12h (P ≤ 0.05) and a significant 
decrease in gap closure of CC2565 cells treated with 75 mM oxamate at 6h, 12h, 18h, and 
24h time points (P ≤ 0.05, P ≤ 0.0001, P ≤ 0.001 and P ≤ 0.05 respectively). Under hypoxic 
conditions, there was only a significant decrease in gap closure of CC2565 cells treated with 
50 mM and 75 mM oxamate at 18h (P ≤ 0.05 and P ≤ 0.01 respectively). 
In summary, the UW402 cell line was significantly slower at closing the scratch wound than 
the other cell lines under normoxic and hypoxic conditions. 25 mM oxamate had no 
significant effect on CC2565 gap closure under normoxic or hypoxic conditions. 50 mM 
oxamate had a small significant effect on CC2565 gap closure at 12h and 18h under 
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normoxic and hypoxic conditions respectively. 75 mM had a significant effect on CC2565 
gap closure at several time points under normoxic conditions but only at 18h under hypoxic 
conditions. Furthermore oxamate significantly decreased the rate of closure of a scratch in 
a monolayer of each MB cell line in a concentration dependent manner, under normoxic 
and hypoxic conditions. Under hypoxic conditions this effect was more significant at earlier 
time points and less significant at later time points. However it is not clear from this data 
alone whether the reduction in gap closure, with the addition of oxamate, is caused by a 
reduction in cell motility or just a reduction in cell proliferation. 
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5.4.1.1 Comparison of cell lines 
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Figure 5. 35 Gap closure in cell lines under normoxic and hypoxic conditions 
Percentage of scratch in a monolayer remaining open in cell lines over 48h-72h. Cells were 
grown under normoxic and hypoxic conditions. (A) Mean percentage of UW402 gap 
remaining open under normoxic conditions: 0h 100%, 12h 72.95%, 24h 42.38%, 36h 
22.13%, 48h 17.90%, 60h 12.85%, 72h 7.10%. Mean percentage of UW402 gap remaining 
open under hypoxic conditions: 0h 100%, 12h 72.69%, 24h 43.94%, 36h 22.15%, 48h 
10.25%, 60h 4.27%, and 72h 2.37%. (B) Mean percentage of DAOY gap remaining open 
under normoxic conditions: 0h 100%, 12h 56.70%, 24h 8.48%, 36h 0%, 48h 0%, 60h 0%, 72h 
0%. Mean percentage of DAOY gap remaining open under hypoxic conditions: 0h 100%, 12h 
45.63%, 24h 4.41%, 36h 0%, 48h 0%, 60h 0%, 72h 0%. (C) Mean percentage of Res256 gap 
remaining open under normoxic conditions: 0h 100%, 12h 55.00%, 24h 21.55%, 36h 
11.39%, 48h 2.89%, 60h 0%, 72h 0%. Mean percentage of Res256 gap remaining open 
under hypoxic conditions: 0h 100%, 12h 52.44%, 24h 14.27%, 36h 1.54%, 48h 0.07%, 60h 
0%, 72h 0%. (D) Mean percentage of CC2565 gap remaining open under normoxic 
conditions: 0h 100%, 6h 69.19%, 12h 33.79%, 18h 12.20%, 24h 5.45%, 30h 4.10%, 36h 
2.57%, 42h 2.49%, 48h 0.69%. Mean percentage of DAOY gap remaining open under 
hypoxic conditions: 0h 100%, 6h 70.62%, 12h 48.77%, 18h 15.77%, 24h 8.26%, 30h 3.26%, 
36h 2.71%, 42h 0%, 48h 0%.   
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Figure 5. 36 Comparison of gap closure between cell lines  
Percentage of scratch in a monolayer remaining open in cell lines over 72h. Cells were 
grown in the under normoxic (A) and hypoxic (B) conditions. (A) Mean percentage of 
UW402 gap remaining open under normoxic conditions: 0h 100%, 12h 72.95%, 24h 42.38%, 
36h 22.13%, 48h 17.90%, 60h 12.85%, 72h 7.10%. Mean percentage of UW402 gap 
remaining open under hypoxic conditions: 0h 100%, 12h 72.69%, 24h 43.94%, 36h 22.15%, 
48h 10.25%, 60h 4.27%, and 72h 2.37%. (B) Mean percentage of DAOY gap remaining open 
under normoxic conditions: 0h 100%, 12h 56.70%, 24h 8.48%, 36h 0%, 48h 0%, 60h 0%, 72h 
0%. Mean percentage of DAOY gap remaining open under hypoxic conditions: 0h 100%, 12h 
45.63%, 24h 4.41%, 36h 0%, 48h 0%, 60h 0%, 72h 0%. (C) Mean percentage of Res256 gap 
remaining open under normoxic conditions: 0h 100%, 12h 55.00%, 24h 21.55%, 36h 
11.39%, 48h 2.89%, 60h 0%, 72h 0%. Mean percentage of Res256 gap remaining open 
under hypoxic conditions: 0h 100%, 12h 52.44%, 24h 14.27%, 36h 1.54%, 48h 0.07%, 60h 
0%, 72h 0%. (D) Mean percentage of CC2565 gap remaining open under normoxic 
conditions: 0h 100%, 6h 69.19%, 12h 33.79%, 18h 12.20%, 24h 5.45%, 30h 4.10%, 36h 
2.57%, 42h 2.49%, 48h 0.69%. Mean percentage of DAOY gap remaining open under 
hypoxic conditions: 0h 100%, 6h 70.62%, 12h 48.77%, 18h 15.77%, 24h 8.26%, 30h 3.26%, 
36h 2.71%, 42h 0%, 48h 0%. Cell lines were compared to each other under normoxic and 
hypoxic conditions at each time point, 2way ANOVA; not significant P > 0.05, * P ≤ 0.05, ** 
P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001.  
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5.4.1.2 UW402 
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Figure 5. 37 UW402 gap closure with oxamate treatments under normoxic and hypoxic 
conditions  
Percentage of scratch in a monolayer of UW402 cells remaining open over 72h. Cells were 
grown in the presence of 0 mM, 25 mM, 50 mM or 75 mM oxamate under normoxic (A) and 
hypoxic (B) conditions. Images were analysed every 12 hours using live cell imaging and 
Tscratch software. Graphs show mean with SEM. A) The mean percentage of gap remaining 
open under normoxic conditions at each time point is listed in Table 8. 7. B) The mean 
percentage of gap remaining open under hypoxic conditions at each time point is listed in 
Table 8. 8. Oxamate treated samples were compared to the untreated control at each time 
point, 2way ANOVA; not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 
0.0001. 
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Figure 5. 38 UW402 gap closure images with oxamate treatments under normoxic 
conditions 
A series of still images taken at 0, 24, 48 and 72h time points from a representative UW402 
live cell imaging scratch wound assay. Cells were grown in the presence of 0 mM, 25 mM, 
50 mM or 75 mM oxamate under normoxic conditions. Images taken at x 5, scale bar = 
250.00 µm   
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Figure 5. 39 UW402 gap closure images with oxamate treatments under hypoxic 
conditions 
 
A series of still images taken at 0, 24, 48 and 72h time points from a representative UW402 
live cell imaging scratch wound assay. Cells were grown in the presence of 0 mM, 25 mM, 
50 mM or 75 mM oxamate under hypoxic conditions. Images taken at x 5, scale bar = 
250.00 µm 
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5.4.1.3 DAOY 
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Figure 5. 40 DAOY gap closure with oxamate treatments under normoxic and hypoxic 
conditions 
Percentage of scratch in a monolayer of DAOY cells remaining open over 72h. Cells were 
grown in the presence of 0 mM, 25 mM, 50 mM or 75 mM oxamate under normoxic (A) 
and hypoxic (B) conditions. Images were analysed every 12 hours using live cell imaging and 
Tscratch software. Graphs show mean with SEM. A) The mean percentage of gap remaining 
open under normoxic conditions at each time point is listed in Table 8. 9. B) The mean 
percentage of gap remaining open under hypoxic conditions at each time point is listed in 
Table 8. 10. Oxamate treated samples were compared to the untreated control at each 
time point, 2way ANOVA; not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, 
**** P ≤ 0.0001.  
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Figure 5. 41 DAOY gap closure images with oxamate treatments under normoxic 
conditions 
A series of still images taken at 0, 24, 48 and 72h time points from a representative DAOY 
live cell imaging scratch wound assay. Cells were grown in the presence of 0 mM, 25 mM, 
50 mM or 75 mM oxamate under normoxic conditions. Images taken at x 5, scale bar = 
250.00 µm 
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Figure 5. 42 DAOY gap closure images with oxamate treatments under hypoxic conditions 
A series of still images taken at 0, 24, 48 and 72h time points from a representative DAOY 
live cell imaging scratch wound assay. Cells were grown in the presence of 0 mM, 25 mM, 
50 mM or 75 mM oxamate under hypoxic conditions. Images taken at x 5, scale bar = 
250.00 µm 
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5.4.1.4 Res256 
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Figure 5. 43 Res256 gap closure with oxamate treatments under normoxic and hypoxic 
conditions 
Percentage of scratch in a monolayer of Res256 cells remaining open over 72h. Cells were 
grown in the presence of 0 mM, 25 mM, 50 mM or 75 mM oxamate under normoxic (A) and 
hypoxic (B) conditions. Images were analysed every 12 hours using live cell imaging and 
Tscratch software. Graphs show mean with SEM. A) The mean percentage of gap remaining 
open under normoxic conditions at each time point is listed in Table 8. 11. B) The mean 
percentage of gap remaining open under hypoxic conditions at each time point is listed in 
Table 8. 12. Oxamate treated samples were compared to the untreated control at each 
time point, 2way ANOVA; not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, 
**** P ≤ 0.0001.  
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Figure 5. 44 Res256 gap closure images with oxamate treatments under normoxic 
conditions 
A series of still images taken at 0, 24, 48 and 72h time points from a representative Res256 
live cell imaging scratch wound assay. Cells were grown in the presence of 0 mM, 25 mM, 
50 mM or 75 mM oxamate under normoxic conditions. Images taken at x 5, scale bar = 
250.00 µm 
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Figure 5. 45 Res256 gap closure images with oxamate treatments under hypoxic 
conditions 
A series of still images taken at 0, 24, 48 and 72h time points from a representative Res256 
live cell imaging scratch wound assay. Cells were grown in the presence of 0 mM, 25 mM, 
50 mM or 75 mM oxamate under hypoxic conditions. Images taken at x 5, scale bar = 
250.00 µm 
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5.4.1.5 CC2565 
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Figure 5. 46 CC2565 gap closure with oxamate treatments under normoxic and hypoxic 
conditions 
Percentage of scratch in a monolayer of CC2565 cells remaining open over 72h. Cells were 
grown in the presence of 0 mM, 25 mM, 50 mM or 75 mM oxamate under normoxic (A) and 
hypoxic (B) conditions. Images were analysed every 12 hours using live cell imaging and 
Tscratch software. Graphs show mean with SEM. A) The mean percentage of gap remaining 
open under normoxic conditions at each time point is listed in Table 8. 13. B) The mean 
percentage of gap remaining open under hypoxic conditions at each time point is listed in 
Table 8. 14. Oxamate treated samples were compared to the untreated control at each 
time point, 2way ANOVA; not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, 
**** P ≤ 0.0001. 
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Figure 5. 47 CC2565 gap closure images with oxamate treatments under normoxic 
conditions 
A series of still images taken at 0, 24, 48 and 72h time points from representative CC2565 
live cell imaging scratch wound assays. Cells were grown in the presence of 0 mM, 25 mM, 
50 mM or 75 mM oxamate under normoxic conditions. Images taken at x 5, scale bar = 
250.00 µm   
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Figure 5. 48 CC2565 gap closure images with oxamate treatments under hypoxic 
conditions 
A series of still images taken at 0, 24, 48 and 72h time points from representative CC2565 
live cell imaging scratch wound assays. Cells were grown in the presence of 0 mM, 25 mM, 
50 mM or 75 mM oxamate under hypoxic conditions. Images taken at x 5, scale bar = 
250.00 µm 
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5.4.2 Cell tracking  
In order to establish whether oxamate inhibited MB and non-neoplastic astrocyte cell 
motility, individual cells were tracked to determine the average distance travelled by and 
velocity of UW402, DAOY and Res256, MB cells and non-neoplastic astrocyte CC2565 cells 
treated with 0 mM, 25 mM, 50 mM and 75 mM oxamate under normoxic and hypoxic 
conditions over 24h. 
The mean distance travelled by untreated UW402 cells in 24h under normoxic conditions is 
214.36 µm and 237.90  µm under hypoxic conditions (P ≤ 0.05) (Figure 5. 50). The mean 
distance travelled by untreated DAOY cells in 24h under normoxic conditions is 291.95 µm 
and 352.95 µm under hypoxic conditions (P ≤ 0.01) (Figure 5. 49). The mean distance 
travelled by untreated Res256 cells in 24h under normoxic conditions is 241.91 µm and 
306.43 µm under hypoxic conditions (P ≤ 0.0001) (Figure 5. 49). The mean distance 
travelled by untreated CC2565 cells under normoxic conditions was 633.87 µm and 497.29 
µm under hypoxic conditions (P ≤ 0.001) (Figure 5. 49). The mean velocity of untreated 
UW402 cells under normoxic conditions is 3.57 µm/minute and 3.93 µm/minute under 
hypoxic conditions (Figure 5. 49). The mean velocity of untreated DAOY cells under 
normoxic conditions is 4.86 µm/minute and 5.88 µm/minute under hypoxic conditions (P ≤ 
0.01) (Figure 5. 49). The mean velocity of untreated Res256 cells under normoxic conditions 
is 4.03 µm/minute and 5.10 µm/minute under hypoxic conditions (P ≤ 0.0001) (Figure 5. 
49). The mean velocity of untreated CC2565 cells under normoxic conditions was 10.56 µm/ 
minute and 8.28 µm/ minute under hypoxic conditions (P ≤ 0.001) (Figure 5. 49).  
The untreated CC2565 cells were significantly more motile than the untreated MB cells 
under normoxic and hypoxic conditions (P ≤ 0.0001) (Figure 5. 50). However, unlike all the 
MB cell lines which were significantly more motile under hypoxic conditions, they were 
significantly less motile under hypoxic conditions (Figure 5. 50). Untreated DAOY cells were 
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also significantly more motile than the other untreated MB cell lines under normoxic 
(UW402 P ≤ 0.01, Res256 P ≤ 0.05) and hypoxic conditions (UW402 P ≤ 0.0001, Res256 P ≤ 
0.05) (Figure 5. 50). Under hypoxic conditions untreated Res256 cells are also significantly 
more motile than UW402 cells (P ≤ 0.001) (Figure 5. 50). 
With the addition of 25 mM, 50 mM and 75 mM there was a significant decrease in the 
velocity and distance travelled by UW402 (Figure 5. 51) and Res256 (Figure 5. 53)MB cell 
lines under normoxic and hypoxic conditions and DAOY cells (Figure 5. 52) under normoxic 
conditions (P ≤ 0.0001). Under hypoxic conditions DAOY cells were less sensitive to 25 mM 
oxamate (P ≤ 0.001) than 50 mM and 75 mM (P ≤ 0.0001). 
Under normoxic conditions, there was no significant decrease in velocity or distance 
travelled by CC2565 cells treated with 25 mM or 50 mM oxamate, there was only a 
significant decrease in velocity and distance travelled by CC2565 cells treated with 75 mM 
(P ≤ 0.05) (Figure 5. 54). Under hypoxic conditions, there was no significant decrease in 
velocity or distance travelled by CC2565 cells treated with 25 mM, however there was a 
significant decrease in velocity and distance travelled by CC2565 cells treated with 50 mM 
and 75 mM (P ≤ 0.01 and P ≤ 0.001 respectively). 
Statistical analysis of distance travelled by cells after 24h of 0 mM, 25 mM, 50 mM or 75 
mM oxamate treatments under normoxic and hypoxic conditions showed that hypoxia 
alone significantly increased the distance travelled by all MB cell lines and significantly 
decreased the distance travelled by CC2565 cells (Figure 5. 55). Oxamate treatments 
decreased the distance travelled by MB cells and this effect was significantly greater under 
normoxic conditions than hypoxic conditions. Oxamate treatments decreased the distance 
travelled by CC2565 cells (with the exception of 25 mM oxamate under normoxic 
conditions) and the significance of this effect was greater under hypoxic conditions than 
normoxic conditions. 
220 
 
In summary oxamate significantly decreased MB cell motility under normoxic and hypoxic 
conditions. The most motile MB cell line was DAOY and the least motile MB cell line was 
UW402 under normoxic conditions and hypoxic conditions. All MB cell lines were more 
motile under hypoxic conditions than normoxic conditions, with and without oxamate 
treatment. CC2565 cells were significantly more motile than all the MB cell lines but less 
motile under hypoxic conditions than normoxic conditions, suggesting their motility is 
partly oxygen dependent. 25 mM oxamate did not significantly decrease CC2565 cell 
motility under normoxic or hypoxic conditions. 50 mM oxamate only significantly decreased 
CC2565 motility under hypoxic conditions. 75 mM oxamate significantly decreased CC2565 
motility under normoxic and hypoxic conditions, and this effect was more significant under 
hypoxic conditions. 
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5.4.2.1 Comparison of cell lines 
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Figure 5. 49 Cell motility in cell lines under normoxic and hypoxic conditions 
Average distance (µm) travelled by untreated cell lines grown under normoxic and hypoxic 
conditions over 24h (A, B, C and D) and average velocity (µm/ second) (E, F, G, H). Graphs 
show mean with SEM. A) Mean distance travelled (µm) in 24h by UW402 under normoxic 
conditions: 214.36, and under hypoxic conditions: 237.90. B) Mean distance travelled (µm) 
in 24h by DAOY under normoxic conditions: 291.95, and under hypoxic conditions: 352.95. 
C) Mean distance travelled (µm) in 24h by Res256 under normoxic conditions: 241.91, and 
under hypoxic conditions: 306.43. D) Mean distance travelled (µm) in 24h by CC2565 under 
normoxic conditions: 633.87, and under hypoxic conditions: 497.29. E) Mean velocity (µm/ 
minute) of UW402 cells under normoxic conditions: 3.57, and under hypoxic conditions: 
3.93. F) Mean velocity (µm/ minute) of DAOY cells under normoxic conditions: 4.86, and 
under hypoxic conditions: 5.88. G) Mean velocity (µm/ minute) of Res256 cells under 
normoxic conditions: 4.03, and under hypoxic conditions: 5.10. H) Mean velocity (µm/ 
minute) of CC2565 cells under normoxic conditions: 10.56, and under hypoxic conditions: 
8.28. Cells were imaged every 30 minutes and tracked manually using Volocity software. 
Normoxic conditions were compared to hypoxic conditions within each cell line, unpaired T 
test; not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 
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Figure 5. 50 Comparison of cell motility between cell lines 
Average distance (µm) travelled by untreated cell lines over 24h (A and C) and average 
velocity (µm/ second) (B and D). Cells were grown under normoxic and hypoxic conditions. 
Graphs show mean with SEM. A) Mean distance travelled (µm) in 24h under normoxic 
conditions: UW402 214.36, DAOY 291.95, Res256 241.91, and CC2565 633.87. B) Mean 
velocity (µm/ minute) under normoxic conditions: UW402 3.57, DAOY 4.86, Res256 4.03, 
and CC2565 10.56. C) Mean distance travelled (µm) in 24h under hypoxic conditions: 
UW402 237.90, DAOY 352.95, Res256 306.43, and CC2565 497.29. D) Mean velocity (µm/ 
minute) under hypoxic conditions: UW402 3.93, DAOY 5.88, Res256 5.10, and CC2565 8.28. 
Cells were imaged every 30 minutes and tracked manually using Volocity software. Cell 
lines were compared to each other under normoxic and hypoxic conditions at each time 
point, ordinary one-way ANOVA; not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 
0.001, **** P ≤ 0.0001. 
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5.4.2.2 UW402 
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Figure 5. 51 UW402 cell motility with oxamate treatments under normoxic and hypoxic 
conditions 
Average distance (µm) travelled by individual UW402 cells over 24h (A and C) and average 
velocity (µm/ second) (B and D). Cells were grown in the presence of 0 mM, 25 mM, 50 mM 
or 75 mM oxamate under normoxic (A and B) and hypoxic (C and D) conditions. Graphs 
show mean with SEM. A) Mean distance travelled (µm) in 24h under normoxic conditions: 0 
mM 214.36, 25 mM 118.44, 50 mM 105.50, 75 mM 84.82. B) Mean velocity (µm/ minute) 
under normoxic conditions: 0 mM 3.57, 25 mM 1.97, 50 mM 1.75, and 75 mM 1.41. C) 
Mean distance travelled (µm) in 24h under hypoxic conditions: 0 mM 237.9, 25 mM 168.37, 
50 mM 131.77, 75 mM 129.78. D) Mean velocity (µm/ minute) under hypoxic conditions: 0 
mM 3.93, 25 mM 2.81, 50 mM 2.21, and 75 mM 2.13. Cells were imaged every 30 minutes 
and tracked manually using Volocity software. Oxamate treated samples were compared to 
the untreated control, ordinary one-way ANOVA; **** P ≤ 0.0001.  
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5.4.2.3 DAOY 
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Figure 5. 52 DAOY cell motility with oxamate treatments under normoxic and hypoxic 
conditions 
Average distance (µm) travelled by individual DAOY cells over 24h (A and C) and average 
velocity (µm/ second) (B and D). Cells were grown in the presence of 0 mM, 25 mM, 50 mM 
or 75 mM oxamate under normoxic (A and B) and hypoxic (C and D) conditions. Graphs 
show mean with SEM. A) Mean distance travelled (µm) in 24h under normoxic conditions: 0 
mM 291.95, 25 mM 200.37, 50 mM 162.27, 75 mM 127.06. B) Mean velocity (µm/ minute) 
under normoxic conditions: 0 mM 4.86, 25 mM 3.34, 50 mM 2.70, 75 mM 2.11 C) Mean 
distance travelled (µm) in 24h under hypoxic conditions: 0 mM 352.95, 25 mM 292.72, 50 
mM 260.16, 75 mM 209.37. D) Mean velocity (µm/ minute) under hypoxic conditions: 0 
mM 5.88, 25 mM 4.87, 50 mM 4.33, and 75 mM 3.49. Cells were imaged every 30 minutes 
and tracked manually using Volocity software. Oxamate treated samples were compared to 
the untreated control, ordinary one-way ANOVA; *** P ≤ 0.001, **** P ≤ 0.0001.  
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5.4.2.4 Res256 
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Figure 5. 53 Res256 cell motility with oxamate treatments under normoxic and hypoxic 
conditions 
Average distance (µm) travelled by individual Res256 cells over 24h (A and C) and average 
velocity (µm/ second) (B and D). Cells were grown in the presence of 0 mM, 25 mM, 50 mM 
or 75 mM oxamate under normoxic (A and B) and hypoxic (C and D) conditions. Graphs 
show mean with SEM. A) Mean distance travelled (µm) in 24h under normoxic conditions: 0 
mM 241.91, 25 mM 112.75, 50 mM 96.04, 75 mM 74.00. B) Mean velocity (µm/ minute) 
under normoxic conditions: 0 mM 4.03, 25 mM 1.87, 50 mM 1.60, and 75 mM 1.23. C) 
Mean distance travelled (µm) in 24h under hypoxic conditions: 0 mM 306.43, 25 mM 
171.07, 50 mM 119.76, and 75 mM 92.87. D) Mean velocity (µm/ minute) under hypoxic 
conditions: 0 mM 5.10, 25 mM 2.85, 50 mM 1.99, and 75 mM 1.54. Cells were imaged every 
30 minutes and tracked manually using Volocity software. Oxamate treated samples were 
compared to the untreated control, ordinary one-way ANOVA; **** P ≤ 0.0001. 
A 
C 
B 
D 
N
o
rm
o
xi
c 
H
yp
o
xi
c 
226 
 
5.4.2.5 CC2565 
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Figure 5. 54 CC2565 cell motility with oxamate treatments under normoxic and hypoxic 
conditions 
Average distance (µm) travelled by individual CC2565 cells over 24h (A and C) and average 
velocity (µm/ second) (B and D). Cells were grown in the presence of 0 mM, 25 mM, 50 mM 
or 75 mM oxamate under normoxic (A and B) and hypoxic (C and D) conditions. Graphs 
show mean with SEM. A) Mean distance travelled (µm) in 24h under normoxic conditions: 0 
mM 633.87, 25 mM 714.09, 50 mM 588.47, 75 mM 527.77. B) Mean velocity (µm/ minute) 
under normoxic conditions: 0 mM 10.56, 25 mM 11.90, 50 mM 9.80, 75 mM 8.79. C) Mean 
distance travelled (µm) in 24h under hypoxic conditions: 0 mM 497.29, 25 mM 438.35, 50 
mM 410.76, and 75 mM 379.59. D) Mean velocity (µm/ minute) under hypoxic conditions: 0 
mM 8.28, 25 mM 7.30, 50 mM 6.84, 75 mM 6.32. Cells were imaged every 30 minutes and 
tracked manually using Volocity software. Oxamate treated samples were compared to the 
untreated control, ordinary one-way ANOVA; not significant P > 0.05, ** P ≤ 0.01, *** P ≤ 
0.001. 
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5.4.2.6 Comparison of 24h oxamate treatments under normoxic and hypoxic 
conditions 
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Figure 5. 55 Cell motility of cell lines under normoxic and hypoxic conditions with 24h 
oxamate treatment 
Average distance (µm) travelled by UW402 (A), DAOY (B), Res256 (C) and CC2565 (D) cells 
grown in the presence of 0 mM, 25 mM, 50 mM or 75 mM oxamate for 24h under normoxic 
and hypoxic conditions. Graphs show mean with SEM. A) Mean distance travelled (µm) in 
24h by UW402 under normoxic conditions: 0 mM 214.36, 25 mM 118.44, 50 mM 105.50, 75 
mM 84.82, and under hypoxic conditions: 0 mM 237.9, 25 mM 168.37, 50 mM 131.77, 75 
mM 129.78. B) Mean distance travelled (µm) in 24h by DAOY under normoxic conditions: 0 
mM 291.95, 25 mM 200.37, 50 mM 162.27, 75 mM 127.06 and under hypoxic conditions: 0 
mM 352.95, 25 mM 292.72, 50 mM 260.16, 75 mM 209.37. C) Mean distance travelled (µm) 
in 24h by Res256 under normoxic conditions: 0 mM 241.91, 25 mM 112.75, 50 mM 96.04, 
75 mM 74.00, and under hypoxic conditions: 0 mM 306.43, 25 mM 171.07, 50 mM 119.76, 
and 75 mM 92.87. D) Mean distance travelled (µm) in 24h by CC2565 under normoxic 
conditions: 0 mM 633.87, 25 mM 714.09, 50 mM 588.47, 75 mM 527.77, and under hypoxic 
conditions: 0 mM 497.29, 25 mM 438.35, 50 mM 410.76, and 75 mM 379.59. Cells were 
imaged every 30 minutes and tracked manually using Volocity software. Normoxic 
conditions were compared to hypoxic conditions for each oxamate treatment 
concentration, 2way ANOVA; not significant P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, 
**** P ≤ 0.0001. 
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Chapter 6: Functional effects of LDHA knock down by LDHA 
siRNA in MB cell line UW402 under normoxic and hypoxic 
conditions 
Hypothesis 2: 
Inhibition of LDHA will decrease MB lactate production, cell proliferation, and motility. 
Hypothesis 3: 
Under hypoxic conditions MB cell metabolism will depend on upregulated LDHA 
expression therefore the inhibition of LDHA will have a greater effect on MB metabolism, 
motility and proliferation compared to normoxic conditions 
In order to confirm that the functional effects caused by oxamate were due to inactivation 
of LDHA activity, LDHA expression was transiently knocked down using LDHA siRNA. I chose 
transient LDHA knock down over creating stable clone cell lines with LDHA knocked down 
to avoid the risk of LDHA re-expression or mutations accumulating which would overcome 
any functional deficits caused by LDHA knock down. The downstream effects of LDHA knock 
down by LDHA siRNA on MB viability, metabolism and motility were examined. 
 
6.1 Verification of LDHA knock down under normoxic and hypoxic 
conditions by Western blotting 
To verify that inhibition of LDHA was the direct cause of the functional effects seen by 
oxamate treatments, LDHA synthesis was targeted with LDHA siRNA. Unfortunately, due to 
time constraints, only one cell line could be examined with LDHA siRNA within the scope of 
this project.  The UW402 cell line was chosen for the same reasons as mentioned 
previously. Western blotting was used to verify LDHA siRNA treatment knocked down LDHA 
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protein expression in the UW402 MB cell line under normoxic and hypoxic conditions 
(Figure 6. 1). 
Under normoxic conditions LDHA siRNA caused a 70% knockdown of LDHA expression at 
72h, and a 81% knockdown at 96h (P ≤ 0.0001). Under hypoxic conditions LDHA siRNA 
caused a 73% knockdown of LDHA expression at 72h (P ≤ 0.01), and a 87% knockdown at 
96h (P ≤ 0.001).  
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Figure 6. 1 Verification of LDHA knock down by LDHA siRNA in UW402 cells under 
normoxic and hypoxic conditions 
Western blot of lysates prepared from UW402 cells treated with vehicle control (jet prime 
transfection reagent), UW402 cells treated with LDHA siRNA and jet prime transfection 
reagent and UW402 cells treated with control siRNA and jet prime transfection reagent 
72h-96h after transfection under normoxic (A and B) and hypoxic (C and D) conditions. 
25µg of protein was loaded into each well and the blot was probed for LDHA (37 kDa) and 
cyclophillin A (18 kDa) as a loading control. A) Normoxic Western blot bands. B) Normoxic 
semi-quantitative analysis of LDHA expression using image J software. Mean values: 72h 
control siRNA 1.00, 72h, LDHA siRNA 0.30, and 96h control siRNA 1.00, 96h LDHA siRNA 
0.19. C) Hypoxic Western blot bands. D) Hypoxic semi-quantitative analysis of LDHA 
expression using image J software. Mean values: 72h control siRNA 1.00, 72h, LDHA siRNA 
0.27, and 96h control siRNA 1.00, 96h LDHA siRNA 0.13. LDHA expression was normalised 
to Cyclophilin expression. LDHA expression is represented as a fold change from control 
siRNA LDHA expression at each time point. Graph shows mean with SEM. Results are 
representative of three independent experiments. 2way ANOVA; ** P ≤ 0.01, *** P ≤ 0.001, 
**** P ≤ 0.0001. 
 
  
A 
C 
B 
D 
N
o
rm
o
xi
c 
H
yp
o
xi
c 
231 
 
6.2 Effects of LDHA knock down on MB cell line UW402 viability 
MTS assays were used to quantify the amount of viable, metabolically active UW402 cells 
treated with LDHA siRNA, control siRNA ad vehicle control and untreated UW402 cells 96h 
after transfection, under normoxic and hypoxic conditions (Figure 6. 2). 
Under normoxic and hypoxic conditions 96h after transfection, there was no significant 
difference between the absorbance at 490 nm of UW402 cells treated with LDHA siRNA and 
untreated UW402 cells or any other treatments. These results indicate that the LDHA siRNA 
was not affecting UW402 cell viability and metabolic activity under normoxic or hypoxic 
conditions. 
 
 
232 
 
N e g
a tiv
e  c
o n t
ro l
V e h
ic le
 c o
n tro
l
C o n
tro l
 s iR
N A
L D H
A  s
iR N
a
0 .0
0 .5
1 .0
1 .5
A
b
s
o
r
b
a
n
c
e
 4
9
0
 n
m
N e g
a tiv
e  c
o n t
ro l
V e h
ic le
 c o
n tro
l
C o n
tro l
 s iR
N A
L D H
A  s
iR N
a
0 .0
0 .5
1 .0
1 .5
A
b
s
o
r
b
a
n
c
e
 4
9
0
 n
m
 
Figure 6. 2 UW402 MTS assays with LDHA siRNA under normoxic and hypoxic conditions 
Absorbance at 490nm of untreated UW402 cells, UW402 cells treated with LDHA siRNA and 
jet prime transfection reagent, UW402 cells treated with control siRNA and jet prime 
transfection reagent, and UW402 cells treated with only jet prime transfection reagent 
(vehicle control) 96h after transfection under normoxic (A) and hypoxic (B) conditions and 
incubated with MTS for 3 hours. Graphs show mean with SEM. A) Mean absorbance (490 
nm) under normoxic conditions: negative control 0.78, vehicle control 0.80, control siRNA 
0.77, LDHA siRNA 0.78. B) Mean absorbance (490 nm) under hypoxic conditions: negative 
control 0.83, vehicle control 0.87, control siRNA 0.84, LDHA siRNA 0.84. All samples were 
compared to each other, 2way ANOVA; not significant P > 0.05.  
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6.3 Effects of LDHA knock down on MB cell line UW402 metabolism 
6.3.1 Lactate assay 
Lactate concentrations were measured in UW402 cells treated with LDHA siRNA, control 
siRNA and vehicle control and untreated UW402 cells, 72h and 96h after transfection, 
under normoxic and hypoxic conditions (Figure 6. 3). The mean lactate concentrations of 
the untreated UW402 cells ranged from 0.8-0.9 ng/ µg under normoxic conditions and 0.6-
0.85 ng/ µg under hypoxic conditions, which was less than seen in the untreated UW402 
cells used in the oxamate studies. This may be due to differences in the seeded population, 
size of final cell populations, time in culture and differences between the 
microenvironment of a 12-well plate compared to a 6-well plate. 
Under normoxic and hypoxic conditions, 72h and 96h after transfection, there was no 
significant difference between the concentration of lactate in UW402 cells treated with 
LDHA siRNA and untreated UW402 cells or any other treatments. These results indicate 
that the LDHA siRNA was not inhibiting lactate production and glycolytic metabolism. 
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Figure 6. 3 UW402 lactate concentrations with LDHA siRNA under normoxic and hypoxic 
conditions 
Lactate concentrations of lysates prepared from untreated UW402 cells, UW402 cells 
treated with LDHA siRNA and jet prime transfection reagent, UW402 cells treated with 
control siRNA and jet prime transfection reagent, and UW402 cells treated with only jet 
prime transfection reagent (vehicle control) 72h-96h after transfection under normoxic (A) 
and hypoxic (B) conditions. Lactate concentrations were normalised to the protein 
concentrations of each sample. Graphs show mean with SEM. A) Mean lactate 
concentrations (ng/µg) under normoxic conditions: 72h negative control 0.95, 72h vehicle 
control 0.97, 72h control siRNA 1.01, 72h LDHA siRNA 0.94, 96h negative control 0.82, 96h 
vehicle control 0.89, 96h control siRNA 0.77, 96h LDHA siRNA 0.79. B) Mean lactate 
concentrations (ng/µg) under hypoxic conditions: 72h negative control 0.61, 72h vehicle 
control 0.69, 72h control siRNA 0.71, 72h LDHA siRNA 0.62, 96h negative control 0.81, 96h 
vehicle control 0.71, 96h control siRNA 0.71, 96h LDHA siRNA 0.72. All samples were 
compared to each other at each time point, 2way ANOVA; not significant P > 0.05.  
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6.3.2 Pyruvate assay 
Pyruvate concentrations were measured in UW402 cells treated with LDHA siRNA, control 
siRNA and vehicle control and untreated UW402 cells, 72h and 96h after transfection, 
under normoxic and hypoxic conditions (Figure 6. 4). The mean pyruvate concentrations of 
the untreated UW402 cells ranged from 0.2-0.5ng/ µg under normoxic conditions and 0.12-
0.14ng/ µg under hypoxic conditions, which was less than seen in the untreated UW402 
cells used in the oxamate studies. As mentioned previously, this may be due to differences 
in the seeded population, size of final cell populations, time in culture and differences 
between the microenvironment of a 12-well plate compared to a 6-well plate. 
Under normoxic and hypoxic conditions, 72h and 96h after transfection, there was no 
significant difference between the concentration of pyruvate in UW402 cells treated with 
LDHA siRNA and untreated UW402 cells or any other treatments. These results indicate 
that the LDHA siRNA was not affecting UW402 utilisation of pyruvate in the metabolic 
pathways. 
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Figure 6. 4 UW402 pyruvate concentrations with LDHA siRNA under normoxic and hypoxic 
conditions 
Pyruvate concentrations of lysates prepared from untreated UW402 cells, UW402 cells 
treated with LDHA siRNA and jet prime transfection reagent, UW402 cells treated with 
control siRNA and jet prime transfection reagent, and UW402 cells treated with only jet 
prime transfection reagent (vehicle control) 72h-96h after transfection under normoxic (A) 
and hypoxic (B) conditions. Pyruvate concentrations were normalised to the protein 
concentrations of each sample. Graphs show mean with SEM. A) Mean pyruvate 
concentrations (ng/µg) under normoxic conditions: 72h negative control 0.46, 72h vehicle 
control 0.45, 72h control siRNA 0.36, 72h LDHA siRNA 0.37, 96h negative control 0.46, 96h 
vehicle control 0.44, 96h control siRNA 0.50, 96h LDHA siRNA 0.41. B) Mean pyruvate 
concentrations (ng/µg) under hypoxic conditions: 72h negative control 0.14, 72h vehicle 
control 0.12, 72h control siRNA 0.14, 72h LDHA siRNA 0.12, 96h negative control 0.12, 96h 
vehicle control 0.14, 96h control siRNA 0.11, 96h LDHA siRNA 0.11. All samples were 
compared to each other at each time point, 2way ANOVA; not significant P > 0.05.  
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6.4 Effects of LDHA knock down on MB cell line UW402 motility 
To analyse the migration of UW402 cells treated with LDHA siRNA, control siRNA and 
vehicle control and untreated UW402 cells 72h after transfection, the size of a scratch in a 
confluent monolayer of cells was analysed every 6 hours over 48h under normoxic and 
hypoxic conditions (Figure 6. 5, Figure 6. 6 and Figure 6. 7). As untreated UW402 cells and 
UW402 treated with LDHA siRNA, control siRNA and vehicle control were significantly more 
motile than MB cells treated with oxamate, the size of the scratch wounds decreased more 
rapidly so they were analysed more frequently and over a shorter time period. 
Under normoxic and hypoxic conditions there was no significant difference between the 
rate of gap closure of UW402 cells treated with LDHA siRNA and untreated UW402 cells or 
any other treatments. These results indicate that the LDHA siRNA was not affecting UW402 
cell gap closure or motility under normoxic or hypoxic conditions. 
Representative scratch wound assay videos of UW402 cells treated with LDHA siRNA, 
control siRNA and vehicle control and untreated UW402 cells under normoxic and hypoxic 
conditions are included in the PowerPoint file on the supplementary CD. 
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Figure 6. 5 UW402 gap closure with LDHA siRNA under normoxic and hypoxic conditions 
Percentage of scratch in a monolayer of UW402 cells remaining open under normoxic (A) 
and hypoxic (B) conditions. Cells were untreated, treated with LDHA siRNA and jet prime 
transfection reagent, treated with control siRNA and jet prime transfection reagent, or 
treated with only jet prime transfection reagent (vehicle control). The scratch was created, 
and the live cell imaging initiated, 72h after transfection. Images were analysed every 6 
hours using live cell imaging and Tscratch software. Graphs show mean with SEM. A) The 
mean percentage of gap remaining open under normoxic conditions at each time point is 
listed in Table 8. 15. B) The mean percentage of gap remaining open under hypoxic 
conditions at each time point is listed in Table 8. 16. LDHA siRNA treatment was compared 
to all other conditions at each time point; not significant P > 0.05. 
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Figure 6. 6 UW402 LDHA siRNA gap closure images under normoxic conditions 
A series of still images taken at 0, 24 and 48h time points from representative UW402 live 
cell imaging scratch wound assays. Cells were untreated, treated with LDHA siRNA and jet 
prime transfection reagent, treated with control siRNA and jet prime transfection reagent, 
or treated with only jet prime transfection reagent (vehicle control). The scratch was 
created, and the live cell imaging initiated, 72h after transfection under normoxic 
conditions. Images taken at x 5, scale bar = 250.00 µm. 
  
240 
 
 
Figure 6. 7 UW402 LDHA siRNA gap closure images under hypoxic conditions 
A series of still images taken at 0, 24 and 48h time points from representative UW402 live 
cell imaging scratch wound assays. Cells were untreated, treated with LDHA siRNA and jet 
prime transfection reagent, treated with control siRNA and jet prime transfection reagent, 
or treated with only jet prime transfection reagent (vehicle control). The scratch was 
created, and the live cell imaging initiated, 72h after transfection under hypoxic conditions. 
Images taken at x 5, scale bar = 250.00 µm. 
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6.5 LDHB and LDHC expression in normal CNS and MB tissue and 
UW402 cell line 
Oxamate was successful at inhibiting MB cell line glycolysis, proliferation and motility 
however knock down of LDHA expression by LDHA siRNA was not. One possibility for these 
results is that oxamate also inhibits other members of the LDH family; LDHB and LDHC, 
which are very structurally similar to LDHA, as described in Chapter 1. It is possible that 
when LDHA is knocked down by siRNA, LDHB or LDHC compensate for the loss and take 
over the role of LDHA. This possibility was investigated further by data mining using the R2 
data base and by Western blotting. 
 
6.5.1 R2 database; expression of LDHB and LDHC mRNA in normal CNS tissues 
and MB subgroups 
LDHB (Figure 6. 8) and LDHC (Figure 6. 9) mRNA expression were examined and compared 
between the Gilbertson MB dataset and Roth normal tissue dataset using the R2 database 
as described previously with LDHA.  
The mean expression of LDHB within the MB subgroups was as follows; Shh > Wnt > Group 
3 > Group 4. Interestingly the Shh subgroup expressed significantly more LDHB than all the 
other MB subgroups (Wnt P ≤ 0.01, Group 3 P ≤ 0.001 and Group 4 P ≤ 0.0001). The Wnt 
subgroup and Group 3 also expressed significantly more LDHB than Group 4 MBs (P ≤ 
0.0001). Moreover the Shh and Wnt subgroups both expressed significantly more LDHB 
than non-neoplastic cerebellum (P ≤ 0.0001 and P ≤ 0.05 respectively) and the Shh 
subgroup also expressed significantly more LDHB than  non-neoplastic spinal cord (P ≤ 
0.001). However Group 4 expressed significantly less LDHB than non-neoplastic cerebellum 
and spinal cord (P ≤ 0.05 and P ≤ 0.001 respectively). 
242 
 
The mean expression of LDHC within the MB subgroups was as follows; Group 3 > Group 4 
> Wnt > Shh. However there was no significant difference in LDHC expression between the 
MB subgroups. Furthermore the Wnt, Shh and Group 3 subgroups expressed significantly 
less LDHC than the cerebellum. 
In summary LDHB is significantly upregulated in two MB subgroups (Wnt and Shh). 
Furthermore the Shh subgroup expressed significantly more LDHB and significantly less 
LDHA than all the other MB subgroups and (Figure 3. 2). 
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Figure 6. 8 LDHB expression in non-neoplastic CNS tissues and MB subgroups 
LDHB expression in a range of non-neoplastic CNS tissues and MB subgroups, mined using 
the R2 data base and the following datasets: Tumor Medulloblastoma - Gilbertson - 76 - 
MAS5.0 - u133p2 and Normal Various - Roth - 504 – MAS5.0 - u133p2 271. The number of 
samples per tissue is stated in brackets. Mean LDHB values: Wnt 4424, Shh 6482, Group 3 
4190, Group 4 1711, Cerebellum 3015, Spinal cord3828, foetal brain 2330. LDHB expression 
was compared between MB subgroups and compared to normal cerebellum and spinal 
cord. Graphs show box plots (highest value, lowest value, upper quartile, lower quartile, 
interquartile range and median). Ordinary one-way ANOVA; not significant P > 0.05, * P ≤ 
0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 
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6.4.1.2 LDHC expression 
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Figure 6. 9 LDHC expression in non-neoplastic CNS tissues and MB subgroups 
LDHC expression in a range of non-neoplastic CNS tissues and MB subgroups, mined using 
the R2 data base and the following datasets: Tumor Medulloblastoma - Gilbertson - 76 - 
MAS5.0 - u133p2 and Normal Various - Roth - 504 – MAS5.0 - u133p2 271. The number of 
samples per tissue is stated in brackets. Mean LDHC values: Wnt 8.863 Shh 6.320, group 3 
13.93, group 4 12.22, cerebellum 23.77, spinal cord 16.12, foetal brain 4.9. LDHC expression 
was compared between MB subgroups and compared to normal cerebellum and spinal 
cord. Graphs show box plots (highest value, lowest value, upper quartile, lower quartile, 
interquartile range and median). Ordinary one-way ANOVA; not significant P > 0.05, * P ≤ 
0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 
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6.5.2 Effect of LDHA knock down on MB cell line UW402 LDHB and LDHC protein 
expression. 
In order to investigate further, Western blots probing for LDHB and LDHC were performed 
on UW402 cell lysates which had been treated with LDHA siRNA, control siRNA and vehicle 
control under normoxic conditions (Figure 6. 10).  
LDHA siRNA caused no detectable knockdown of LDHB at 72h; however there was a minor 
decrease in LDHB expression at 96h. Interestingly, LDHA siRNA did down-regulate LDHC 
expression considerably at 72h and 96h. 
 
 
 
Figure 6. 10 LDHB and LDHC expression in UW402 cells treated with LDHA siRNA under 
normoxic conditions 
Western blots of lysates prepared from UW402 cells treated with jet prime transfection 
reagent (vehicle control), UW402 cells treated with LDHA siRNA and jet prime transfection 
reagent and UW402 cells treated with control siRNA and jet prime transfection reagent 
72h-96h after transfection. 25 µg of protein was loaded into each well and the blot was 
probed for LDHB (A) or LDHC (B) (37 kDa) and cyclophillin A (18 kDa) as a loading control. 
Blots shown are representative of two independent experiments. 
  
A 
B 
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Chapter 7: Discussion 
MB is a terrible disease which is in dire need of improved therapeutics that are less 
damaging to non-neoplastic cells and more effective at reducing the tumour burden and 
associated metastases. The aerobic glycolysis pathway enables rapid cell proliferation 
which is why it is utilised by cancer cells considerably more than non-neoplastic cells. Here 
LDHA has been investigated as a therapeutic target for MB because it is an enzyme known 
to be integral to the aerobic glycolysis pathway. In this study LDHA activity was inhibited 
using oxamate and LDHA expression was inhibited using LDHA siRNA. 
 
7.1 LDHA RNA expression in MB subgroups and non-neoplastic CNS tissue 
I used the R2 database for data mining and compared the expression of LDHA in non-
neoplastic cerebellum to other non-neoplastic CNS tissues. I found that non-neoplastic 
cerebellum expressed low levels of LDHA compared to other non-neoplastic CNS tissue, and 
significantly less than the midbrain, parietal lobe and frontal lobe. This correlates with 
previous studies which used MRI and PET scans in neurologically normal young adults and 
found that aerobic glycolysis was significantly elevated in the medial and lateral parietal 
and prefrontal cortices however the cerebellum had significantly lower levels of aerobic 
glycolysis than the rest of the brain 74. 
I also examined the differences in LDHA expression between the four MB subgroups. I 
found that LDHA expression was as follows; Group 3 > Wnt > Group 4 > Shh. Group 3 and 
Wnt MBs also expressed significantly more LDHA than non-neoplastic cerebellum and 
spinal cord tissue. As C-myc is a transcription factor for LDHA 24, it is not surprising that 
Group 3 and Wnt MBs express significantly higher levels of LDHA than non-neoplastic 
cerebellum and spinal cord, as Group 3 is known to over-express c-Myc and c-Myc is also a 
downstream target of the Wnt signalling pathway. Considering that previous studies have 
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shown that Shh promotes aerobic glycolysis 256,257, it was surprising that Shh had a lower 
mean level of LDHA expression than non-neoplastic cerebellum and spinal cord tissue 
however it had significantly higher LDHB levels than the other MB subgroups. It is possible 
that in the Shh subgroup LDHB is undertaking the role normally expected of LDHA and is 
worth investigating further. Group 3 is the most metastatic subgroup of MB and carries the 
poorest prognosis. Furthermore, both of these features are also commonly associated with 
LDHA and lactate concentrations in other tumours. Moreover Group 3 MBs expressed 
significantly higher levels of LDHA than all the other MB subgroups which would indicate 
that LDHA could be a promising therapeutic target against Group 3 MB. 
 
7.2 LDHA protein expression in MB 
Our studies have shown that the LDHA protein was abundantly expressed in all tested MB 
cell lines. The cerebellum has significantly lower levels of aerobic glycolysis than the rest of 
the brain 74 and although LDHA expression in the MB cell lines was lower compared to 
astrocyte cell lines, it was elevated in all MB cell lines compared to adult and foetal 
cerebellum tissue lysates, suggesting LDHA is being abnormally over-expressed and 
promoting an aerobic glycolysis phenotype in MB cell lines.  
The metabolic functions of LDHA are carried out in the cytoplasm and, as mentioned in 
chapter one, LDHA can bind to ssDNA and RNA suggesting that LDHA may have a role in 
transcription or translation of mRNA in the nucleus. Numerous metabolic enzymes are 
known to “moonlight” as RNA-binding proteins 285. Furthermore, He et al (2012) have 
suggested a link between the metabolic sate of a cell (such as its redox sate and changes in 
NAD+ / NADH ratio) and its ability to progress through S-phase 64. As described previously in 
other cancer tissues and cell lines 57,60, we found evidence of cytoplasmic and nuclear 
expression of LDHA in MB tissue and cell lines suggesting glycolytic and nuclear activity.  
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I also found that LDHA expression in MB cell lines was significantly elevated under hypoxic 
conditions, consistent with previous studies in other cell lines and HIF1 acting as a 
transcription factor for LDHA 22. Western blot analysis showed that UW402 and DAOY cells 
express similar amounts of LDHA and that Res256 cells express a slightly lower amount of 
LDHA. Flow cytometry analysis showed that Res256 and DAOY cells had a similar mean 
percentage of LDHA expressed in the population and per cell under normoxic and hypoxic 
conditions, although DAOY had a slightly higher mean expression than Res256. UW402 cells 
had a much lower mean percentage of cells expressing LDHA than the other MB cell lines 
under normoxic conditions, however the mean amount of LDHA expressed per UW402 cell 
was higher than the other two MB cell lines in both normoxic and hypoxic conditions. It has 
previously been suggested that the UW402 cell line is comprised of two cell populations, 
one characteristically small and spindle shaped and another which is a large pyramidal 
shape with multiple nuclei 283 (which I also observed in live cell imaging analysis). It is 
possible that one of these cell populations expresses much higher levels of LDHA than the 
other and this would account for less of the population expressing LDHA but a greater 
amount of LDHA expression overall. This would also account for the two peaks seen in the 
UW402 flow cytometry analysis under normoxic and hypoxic conditions. 
 
7.3 LDHA expression in non-neoplastic astrocyte cell line CC2565 
As expected, our studies revealed that CC2565 cells expressed high levels of LDHA protein 
under normoxic and hypoxic conditions. It is not surprising that LDHA expression was higher 
in the astrocyte cell line CC2565 than the MB cell lines as they are specialised cells which 
have evolved to export large amounts of lactate to fulfil their role in the astrocyte-neuron 
lactate shuttle 286. There was no significant elevation of LDHA expression in the CC2565 cell 
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line under hypoxic conditions which suggests that CC2565 cells express the maximum 
amount of LDHA under normoxic conditions.  
 
7.4 Medulloblastoma under hypoxic conditions 
Although the presence of a hypoxic microenvironment in MBs in vivo is unknown, the 
hypoxic conditions used (1% O2) are much closer to the oxygen concentrations likely to be 
found in MBs in vivo than the oxygen concentration of air (approximately 21%), as the 
mean oxygen concentration in tissues is 3% and oxygen concentrations in the interstitial 
tissue of the mammalian brain ranges between 1 and 5% 287,288. Solid tumours, like MB, 
typically contain regions of hypoxia which increase as the tumour grows with restricted 
blood vessel supplies. Hypoxia can also promote tumour angiogenesis in order to prevent 
tumour necrosis 289 and it has recently been reported that different medulloblastoma 
subgroups relate to different vascular profiles 290. Despite the lack of hypoxic studies on MB 
in vivo and in vitro, it is critical to continue studying MB under lower oxygen concentrations 
which are undeniably closer to in vivo environmental conditions as this will help predict 
responses to therapies more accurately.  
I chose to conduct all experiments in parallel under normoxic and hypoxic conditions 
wherever possible. Most of the studies in this project showed that when compared to 
untreated cells under the same oxygen conditions, inhibition of LDHA activity by oxamate, a 
structural analogue of pyruvate, had a more significant effect under hypoxic conditions 
than normoxic conditions. Under hypoxic conditions cells become more reliant on the 
glycolysis pathway to generate ATP 291, so when it was inhibited by oxamate the functional 
effects were more pronounced.  
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7.5 Oxamate and medulloblastoma metabolism 
I hypothesised that MB metabolism would be dependent on aerobic glycolysis and aimed to 
inhibit this pathway by targeting LDHA. As a structural analogue of pyruvate, oxamate 
competes with pyruvate and inhibits LDHA activity and lactate production. Lactate assays 
showed that MB cells produced more ng lactate/ µg total protein than the non-neoplastic 
astrocyte cell line CC2565 despite MB cell lines expressing significantly less LDHA than the 
CC2565 cell line. This suggests that LDHA in MB cell lines could be more active but, as only 
intracellular lactate concentrations were measured, a more likely explanation is that 
CC2565 cells are better adapted to exporting lactate due to their role in the astrocyte-
neuron lactate shuttle (Figure 7. 3) 292. The abundant expression of LDHA and lactate in the 
MB cell lines suggests they, like most cancers, have switched to an abnormal aerobic 
glycolysis phenotype 13. As shown previously in other cell lines 55,142,266, I found that 
oxamate successfully inhibited LDHA activity, the glycolytic phenotype and lactate 
production in all MB cell lines.  
All oxamate treatments significantly inhibited lactate concentrations in MB cell lines at 
every time point under normoxic and hypoxic conditions (with the exception of 25 mM and 
50 mM oxamate at 24h under normoxic conditions in the DAOY cell line), indicating 
successful inhibition of LDHA activity. Although the lactate concentrations with oxamate 
treatments in MB cell lines were similar under normoxic and hypoxic conditions, the 
differences were more significant compared to the untreated control under hypoxic 
conditions as glycolysis, and therefore LDHA and lactate production, is upregulated under 
hypoxia. 
Oxamate treatments also caused a significant reduction of pyruvate concentrations in all 
MB cell lines at 24h and 48h time points under normoxic and hypoxic conditions. This can 
be explained as follows; by reducing LDHA activity, NAD+ regeneration is also reduced. NAD+ 
251 
 
is required for the reactions which synthesise pyruvate form glucose; therefore a reduction 
in NAD+ would lead to a reduction in pyruvate (Figure 7. 1). Although the concentrations of 
pyruvate in MB cell lines with oxamate treatment were similar at each time point, the 
differences became less significant at longer time points as the concentrations of pyruvate 
in the untreated cells decreases over time. In vitro, as the control cell population continues 
to grow and the energy resources are finite, over time the amount of surplus pyruvate 
decreases and is diverted more rapidly into alternative energy pathways. 
 
Figure 7. 1 A schematic diagram of aerobic glycolysis 
Glycolsis requires NAD+ to create pyruvate from glucose. NAD+ is regenerated from NADH 
by LDHA. If LDHA is inhibited by oxamate, NAD+ regeneration and threfore pyruvate 
synthesised is also inhibited. 
 
The inhibition of LDHA activity and aerobic glycolysis by oxamate was further confirmed by 
glycolysis stress tests under normoxic conditions in the UW402 cell line. All oxamate 
treatments significantly reduced UW402 cell glycolysis, glycolytic capacity and glycolytic 
reserve. Furthermore, the mito stress test in the UW402 cell line under normoxic conditions 
showed that all oxamate treatments caused a significant increase in UW402 cell basal 
respiration, ATP production and maximal respiration, suggesting an increase in oxidative 
phosphorylation metabolism. Together these studies confirm oxamate significantly altered 
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MB metabolism, reduced LDHA activity, aerobic glycolysis and lactate production in Res256, 
UW402 and DAOY MB cell lines and also increased OXPHOS in UW402 cells. 
Out of all the MB cell lines, Res256 expressed the least amount of LDHA which would 
suggest it was less reliant upon aerobic glycolysis, however it was the most sensitive cell 
line to the oxamate treatments. It is possible that because Res256 had a lower expression 
of LDHA, lower concentrations of oxamate were able to have a more significant effect. 
Despite expressing a similar amount of LDHA to the UW402 cell line, the DAOY cell line was 
generally less sensitive to oxamate treatments than the other two cell lines. It is possible 
that the DAOY cell line was better than the other MB cell lines at adapting to use oxidative 
phosphorylation when aerobic glycolysis was obstructed. Additional investigations into the 
use of oxidative phosphorylation by these cell lines would be useful in further exploring and 
understanding these differences. 
 
7.6 Oxamate and medulloblastoma viability and growth 
As shown by previous studies in other cell lines 55,142,266, I found that oxamate significantly 
inhibited MB cell line growth under normoxic and hypoxic conditions in a time and 
concentration dependent manner, with the results more significant under hypoxic 
conditions (with the exception of Res256 cells). However, the Res256 cell line was the most 
sensitive and DAOY the least sensitive cell line. Also, by using MTS assays, I found that 
oxamate significantly decreased the amount of viable, metabolically active MB cells under 
normoxic and hypoxic conditions in a time and concentration dependent manner and the 
results were more significant under hypoxic conditions. The UW402 and DAOY cell lines 
were similarly sensitive but the Res256 cell line was the most sensitive.  
Further investigations were conducted into the effects of oxamate on the cell cycle to 
examine the potential mechanism in which oxamate reduced MB growth. Results indicated 
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that, as soon as 24h after treatment, under normoxic and hypoxic conditions, oxamate 
treatments significantly reduced the percentage of MB cells in G0/G1 and significantly 
increased the percentage of MB cells in G2/M in a concentration dependent manner (with 
the exception of DAOY cells under normoxic conditions) and the results were more 
significant under hypoxic conditions. Res256 and UW402 cells were similarly sensitive 
whereas DAOY cells were somewhat less sensitive. Furthermore, these results were 
consistent after 48h. Together, these experiments suggest that oxamate caused a G2/M cell 
cycle arrest in MB cells, as reported previously in nasopharyngeal carcinoma cells by Zhai et 
al 55 (2013). It is likely that by inhibiting LDHA and aerobic glycolysis, oxamate reduces the 
rate at which ATP can be generated and therefore rate at which MB cells can proliferate. 
Additionally oxamate may also affect the function of LDHA in the OCA-S complex. As 
discussed in chapter one, L-LDH is part of the OCA-S transcription complex which regulates 
H2B transcription and H2B contributes to the cell cycle regulation, specifically S-phase 
timing and progression 64. 
 
7.7 Oxamate and medulloblastoma motility 
Approximately 30% of MBs are metastatic at diagnosis and are associated with a much 
poorer prognosis 219. Previous studies in other cancers have shown that lactate is a 
prognostic factor for metastasis in patients and responsible for cell migration in vivo 85,86,113. 
I found that oxamate significantly inhibited MB cell line gap closure under normoxic and 
hypoxic conditions in a concentration dependent manner. However as I had previously 
shown that oxamate caused a decrease in MB cell proliferation, it was not clear whether 
the reduction in the rate of gap closure was due to a decrease in cell proliferation alone or 
also caused by a decrease in cell motility. Cell tracking analysis confirmed that oxamate 
significantly inhibited individual MB cell migratory velocity under normoxic and hypoxic 
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conditions, suggesting that the decrease in the rate of gap closure was due to both reduced 
cell proliferation and individual cell migratory velocity. Interestingly, I found that MB cells 
treated with oxamate and untreated MB cells were more motile under hypoxic conditions 
however, oxamate treatments still significantly reduced MB cell motility under hypoxic 
conditions. As discussed previously in chapter one, studies have shown that extracellular 
lactate promotes wound closure and aids cell motility 120. In vivo lactate lowers the pH of 
the microenvironment, activating cathepsins and MMPs which degrade the ECM, 
promoting migration (Figure 7. 2) 111-113,124. Together these studies show that by inhibiting 
the activity of LDHA and lactate production, MB motility is significantly reduced; a finding 
which could be of great benefit when developing therapies to reduce the devastatingly 
metastatic nature of the disease. 
 
Figure 7. 2 A schematic figure showing mechanisms in which LDHA and lactate promote 
cell migration 
LDHA promotes the conversion of pyruvate to lactate. Lactate is exported from the cell, 
lowering the extracellular pH and activating signalling pathways which upregulate the 
expression of MMPs and cathepsins, which degrade the ECM, and VEGF-A and IL-8, which 
promote angiogenesis, all of which promote cell migration. 
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7.8 CC2565 as a “control” cell line 
The CC2565 cell line is a commercially available, non-neoplastic, foetal, astrocyte cell line 
used as our control cell line, however as mentioned previously it is not an ideal control. It 
would have been more appropriate to use a cell line of the MB cell of origin, however the 
cell of origin for each subgroup is likely to be different, indeed this is still a matter of 
conjecture for most groups, not known for certain (as discussed in chapter one), and not 
been established as a cell line in vitro 213. Despite being unsuitable for direct comparison to 
MB cell lines, it was still of benefit to explore the response of this non-neoplastic astrocyte 
cell line to LDHA inhibition by oxamate, in order to foresee any potential negative side 
effects.  
 
Figure 7. 3 The astrocyte-neuron lactate shuttle model 
Astrocytes supply neurons with lactate which they can convert into pyruvate using LDHB 293 
 
It has long been known that astrocytes are able to secrete large amounts of lactate 292 and 
furthermore that neurons are able to use lactate produced by astrocytes as an energy 
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substrate 294. It has also been previously reported that LDHA is abundant in astrocytes 
whereas LDHB is more prominent in neurons 295. These observations along with many other 
studies led to the astrocyte-neuron lactate shuttle theory (Figure 7. 3); whereby astrocytes 
use LDHA to convert glucose, obtained from the blood stream, to lactate which is 
transported to neurons, neurons (which have no direct access to glucose from the blood 
stream) are then able to use lactate as an energy source by using LDHB to convert lactate 
back to pyruvate which can be used to generate ATP via oxidative phosphorylation 286.  
 
7.9 Effects of oxamate on CC2565 
Our studies also showed that, as observed in the MB cell lines, all oxamate treatments 
significantly decreased CC2565 lactate concentrations under normoxic and hypoxic 
conditions (with the exception of 25 mM oxamate at 24h under normoxic conditions) which 
was also expected as oxamate is an inhibitor of LDHA activity and therefore lactate 
production. Again, as previously described in the MB cell lines, oxamate treatments also 
caused a significant reduction of CC2565 pyruvate concentrations under normoxic and 
hypoxic conditions (Figure 7. 1). 
Although astrocytes are known to use aerobic glycolysis, they are also known to use 
oxidative phosphorylation so they may be more capable of switching to OXPHOS which 
could be why they were not as significantly affected by oxamate as the MB cell lines 296,297. 
This indicates a degree of cancer specificity which is hugely beneficial when considering 
therapeutic targets. By using MTS assays, I found that none of the oxamate treatments 
significantly decreased the amount of viable, metabolically active CC2565 cells under 
normoxic and hypoxic conditions after 24h treatment. Whereas 75 mM oxamate 
significantly inhibited the amount of viable, metabolically active cells in every MB cell line 
after 24h of treatment under at least one of the oxygen conditions tested. After 48h 
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treatment, only 75 mM oxamate significantly decreased the amount of viable, metabolically 
active CC2565 cells under normoxic and hypoxic conditions and the results were more 
significant under hypoxic conditions. After 72h treatment, 50 mM and 75 mM oxamate 
significantly decreased the amount of viable, metabolically active CC2565 cells under 
normoxic and hypoxic conditions and the results were more significant under hypoxic 
conditions.  
Astrocytes are known to have significant structural plasticity and are able to undergo rapid 
remodelling and rearrange their highly dynamic processes, a function which is thought to 
help control synapse function 298. In addition, in response to injury, astrocytes are known to 
fill the empty spaces as neuronal cells die (astrogliosis) and are also involved in glial scar 
formation 299,300. Therefore it was not surprising that the CC2565 cell line was significantly 
more motile than the MB cell lines. Unlike the MB cell lines, I found that 25 mM oxamate 
did not significantly inhibit CC2565 cell line gap closure under normoxic or hypoxic 
conditions. However, CC2565 gap closure was affected by 75 mM oxamate between 6h and 
24h and by 50 mM oxamate at 12h under normoxic conditions but only at 18h by 50 mM 
and 75 mM oxamate under hypoxic conditions. Together these results indicate that LDHA 
and lactate are not critical for astrocyte motility. 
Although current therapies are also toxic to non-neoplastic cells, it is desirable for new 
therapies to target MB in a way which is not as toxic to non-neoplastic cells but still 
damaging to MB cells. Our results are promising as they show that low concentrations of 
oxamate had cytostatic effects on MB cell lines but no significant effect on the amount of 
viable, metabolically active CC2565 cells or their motility under normoxic or hypoxic 
conditions. At earlier time points, even the higher concentrations of oxamate had 
considerably less significant effects on the amount of viable, metabolically active CC2565 
cells and their motility than MB cells under normoxic and hypoxic conditions.  
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7.10 Oxamate as a therapeutic LDHA inhibitor for MB 
I have shown that oxamate significantly inhibits MB cell LDHA activity, lactate production, 
aerobic glycolysis, proliferation and motility under normoxic and hypoxic conditions and 
also upregulates OXPHOS under normoxic conditions (in UW402 cells). Furthermore, 
although 25 mM oxamate inhibited LDHA activity and lactate production in the non-
neoplastic paediatric astrocyte cell line CC2565, it had no significant effects on the amount 
of viable, metabolically active cells or their motility at any time point tested, under 
normoxic or hypoxic conditions. A possible explanation is that astrocytic cells are able to 
adapt to utilising an OXPHOS metabolic phenotype far more easily than MB cells, a trait 
which could be used as an advantage when designing therapies for MB. Although the data 
presented here, and by others, using oxamate to target cancer is promising, unfortunately 
oxamate is not approved for clinical use.  As mentioned in chapter one, oxamate does not 
penetrate cells very well and as a result the concentration of oxamate required to have any 
significant effects on MB cells are far too high to be considered for clinical use. 
Development of a more efficient LDHA inhibitor based on the structure of oxamate that 
could be effective at lower concentrations would be desirable for future studies and clinical 
trials. 
 
7.11 LDHA siRNA studies 
In our study I chose to inhibit LDHA expression by using a single siRNA sequence to target 
LDHA instead of a pool of multiple siRNA sequences targeting LDHA. The two methods have 
been compared and published by Thermo Fisher Scientific and they reported that pooled 
siRNA gave false positive rates of >50% and false negative rates of >40% whereas using a 
single siRNA sequence gave slightly lower false negative and positive rates 301. This method 
was also explored by Jackson et al (2003), who found that some of the off target transcripts 
259 
 
that were silenced by siRNAs, contained just a limited amount of sequence similarity to 
siRNA duplexes 302. Therefore, the more siRNA sequences used in a transfection, the more 
off targets are likely to be affected. As most siRNA studies only screen for inhibition of the 
target gene, it is often difficult to know what the true cause of any phenotypic changes 
seen is. A more reliable method would be to conduct multiple single siRNA transfections for 
the same target. 
Previous studies in other cell lines have found that knockdown of LDHA expression reduced 
tumour cell migration, growth and maintenance 94,95,115,133. However, I found that despite 
showing high levels of LDHA knock down, LDHA siRNA transfection did not have any 
significant downstream effects on MB cell metabolism, growth or motility under normoxic 
or hypoxic conditions. It is possible that as LDHA was not completely knocked down, the 
remaining LDHA became more active and was able to compensate for the loss. However, 
previous studies which had not achieved a complete knock down either still observed 
functional consequences. Another possibility is that, when LDHA was knocked down by 
siRNA, other LDH family members were able to compensate for the loss of LDHA. As LDH-1 
and LDH-5 have identical active site regions and only differ in 81 out of 332 amino acid 
positions 7, it is likely that oxamate inhibits all LDH isoenzymes which is why it was more 
effective than LDHA siRNA. Previous studies have shown that oxamate can bind to LDHB 
and furthermore LDHB is inhibited by high concentrations of pyruvate therefore as an 
analogue of pyruvate oxamate may further promote inhibition of LDHB activity 7,303. Other 
groups which describe a reduction in tumour cell migration, growth and maintenance when 
LDHA is knocked down used a different LDHA siRNA sequence from our study but did not 
verify whether LDHB and LDHC were also knocked down. So it is possible that the functional 
effects observed in these studies were due to knock down of more than one LDH gene 
94,95,115,133. I investigated these possibilities further by examining the expression of LDHB and 
LDHC protein in the lysates treated with LDHA siRNA and found that LDHC was also 
260 
 
markedly down-regulated. This off target effect could be due to LDHC sequence similarity 
to LDHA, as mentioned previously; LDHC is thought to have evolved later than LDHA and 
LDHB from a duplication of the LDHA gene. The human LDHC and LDHA amino acid 
sequences show 76% homology 304 however there is also 75% homology between the 
human LDHB and LDHA amino acid sequences 305 but interestingly LDHB expression 
remained relatively unchanged.  
Together these results suggest that oxamate may inhibit LDHA, LDHB and possibly LDHC 
activity and that LDHA, LDHB and possibly LDHC must be inhibited in order to reduce MB 
lactate concentrations, MB growth and MB motility. However further studies are required 
to confirm this hypothesis. 
 
7.12 LDHA as a therapeutic target for MB and clinical implications 
As non-neoplastic cells do not proliferate as rapidly as MB, they do not have such high 
energy demands. This is what makes MB and other tumours vulnerable to therapies which 
target aerobic glycolysis. I have shown that LDHA expression was significantly elevated in 
Group 3 and Wnt MB subgroups compared to non-neoplastic cerebellar tissue, furthermore 
other groups have shown that elevated lactate levels were associated with a Group 3 /4 MB 
subgroup profile 169 and Shh, which is over expressed in the Shh MB subgroup, is known to 
stimulate aerobic glycolysis 256. Although MB is made up of four distinct subgroups, 
together these studies indicate that aerobic glycolysis is a common feature of most, if not 
all MBs. By developing drugs to target this pathway we can exploit this weakness without 
causing too much damage to non-neoplastic cells.  
Although previous studies have shown that oxamate, an analogue of pyruvate, inhibited 
glycolysis and lactate production suggesting that LDHA is the primary site of its action 268, 
our LDHA knock down studies did not result in the same functional observations as 
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oxamate treatments. Other groups have found that knock down of LDHA inhibits tumour 
progression in other cancers, however they did not verify the specificity of the LDHA knock 
down 94,95,115,133. It is possible that in these cases LDHB and LDHC were also knocked down. 
Within our studies I verified that LDHC was knocked down considerably as well as LDHA but 
LDHB was not.  
Unfortunately our stuides alone are inconclusive as to whether LDHA alone is a suitable 
therapeutic target for MB, further investigation is necessary to clarify whether the 
differences in functional effects of oxamate and LDHA siRNA on MB cells was due to 
inhibition of other LDH family members by oxamate or insufficient knock down of LDHA. 
The results of these future investigations will be critical as LDHA may prove to be an 
inadequate target for MB and a broarder LDH family inhibitor which inhibits lactate 
production may be more apropriate.  
Although our studies have no direct clinical implications for current MB patients, this 
research supports the concept and provides proof of principle that targeting aerobic 
glycolysis and lactate production in MB cells is worthwhile therapeutic avenue worth 
pursuing further. However, the current major hindrance is the lack of therapies which 
target this pathway approved for clinical use. Although, as discussed in chapter one, there 
are several groups working on developing novel LDHA inhibitors but they require 
refinement in terms of potency and specificity.  
 
7.13 Summary of key findings 
 LDHA is significantly over expressed in Group 3 and Wnt MB subgroups compared 
to non-neoplastic cerebellar tissue 
 Group 3 MB expresses significantly more LDHA than the other MB subgroups 
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 LDHA is expressed in all MB cell lines tested and MB tissue.  
 LDHA is upregulated in MB cell lines under hypoxic conditions. 
 Oxamate inhibits LDHA activity and lactate concentrations in MB cell lines under 
normoxic and hypoxic conditions. 
 Oxamate inhibits aerobic glycolysis and promotes oxidative phosphorylation in MB 
cell lines. 
 Oxamate inhibits MB cell line proliferation under normoxic and hypoxic conditions 
 Oxamate inhibits MB cell line motility under normoxic and hypoxic conditions 
 LDHA is highly expressed in a non-neoplastic astrocyte cell line (CC2565) 
 25 mM oxamate did not significantly affect the amount of viable, metabolically 
active CC2565 cells under normoxic or hypoxic conditions. 
 25 mM oxamate did not significantly affect the motility of CC2565 cells under 
normoxic or hypoxic conditions. 
 Significant knock down of LDHA did not significantly affect MB metabolism, 
viability, proliferation or motility. 
 LDHB is significantly over expressed in SHH and Wnt MB subgroups compared to 
non-neoplastic cerebellar tissue. 
 
7.14 Conclusions to experimental studies 
These studies combined with extensive research into the literature suggest that reducing 
MB lactate concentrations using a broad LDH inhibitor could be more important than 
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targetting LDHA alone as oxamate significantly decreased lactate concentrations and had 
significant functional effects on MB proliferation and migration whereas LDHA siRNA did 
not, despite succsessful LDHA knockdown. 
 
7.15 Limitations to the programme of study 
As with many scientific studies, this one had many limitations, some of which have been 
discussed previously including MB and control cell line availability.  One limitation was that 
there were only three MB cell lines available for this project; it would have been 
advantageous to screen more cell lines initially and take forward a selection which 
represented a broader range of LDHA expressions and different metabolic phenotypes. 
Also, the MB cell lines that were available have been cultured in vitro for over a decade so 
have adapted to in vitro selection pressures, are very homogenous and are far removed 
from a MB growing in a patient. Moreover the MB cell lines and tissue section used in this 
study have not been sub-grouped, so we can only speculate which sub-group they belong 
to and which patients will benefit from findings of this study. Additional tissue sections 
from MB patients would also have been beneficial to provide more extensive IHC analysis. 
Furthermore, due to limited access to the Seahorse extracellular flux analyser, I was only 
able to analyse the metabolic profile of one MB cell line in detail. Ideally to make this study 
more clinically relevant, this study would have included a selection of MB cell lines and 
tissue sections from Wnt, SHH, Group 3 and Group 4 MB subgroups. Furthermore, as 
discussed previously, there is no control cell line available which truly represents any of the 
hypothesised MB cells of origin. Another limitation was that hypoxic chambers were 
unavailable for bench work. Once cells were ready to be used in an assay they were 
removed from the hypoxic environment. The relative increase in oxygen concentration 
would have an effect on gene transcription and cell response which would differ from a 
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true hypoxic environment. The size of this effect would also depend on the time taken for 
cell fixation or analysis to occur after removal of the cells from the hypoxic environment. 
We have learnt from these studies and as a result will establish a new hypoxic suite with 
hypoxic work stations. A further limitation was that all the studies were carried out in vitro 
in an environment without variable oxygen concentrations, variable nutrient availability 
and no interaction with chemical signals from surrounding cells found in an in vivo 
microenvironment.  
 
7.16 Future work 
This project provides a firm foundation for future work which could combat the terrible 
prognosis for MB. Additional assays to measure the concentration of ROS, ATP, NAD+ and 
NADH would be beneficial to provide further information about the metabolic response of 
the MB and astrocyte cell lines to oxamate and LDHA knockdown.  To follow this study, it 
would also be of interest to screen and compare all the available broad LDH inhibitors, 
which are more potent than oxamate, such as Galloflavin, (LDHA and LDHB inhibitor), and 
gossypol (LDHA and LDHC inhibitor) as therapeutic agents for MB using in vitro assays and 
MB mouse models of each MB subgroup 203,218. It would be of particular interest if gossypol 
was effective and well tolerated in combination with current therapies as it has already 
been used in human clinical trials for recurrent malignant glioma patient, so could be 
incorporated into MB clinical trials relatively quickly.  
As discussed previously in this chapter, an important next step is to establish whether the 
functional differences between the oxamate studies and LDHA siRNA studies were due to 
inhibition of LDHA, LDHB and LDHC activity by oxamate or incomplete knock down of LDHA. 
Once this has been established in vitro, future studies should also incorporate the mouse 
models of each MB subgroup 203,218. 
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As mentioned in chapter one, lactate plays a key role in tumour progression, including 
metastasis, evasion of the immune response and it has also been shown to enhance DNA 
repair 86,132,306. Further work should investigate lactate as a key modulator of MB 
progression and metastasis. 
New hypotheses which could be tested are: 
1. Inhibition of LDHA, LDHB and LDHC is required to decrease MB lactate 
production, cell proliferation, and migration. 
2. Lactate is fundamental for MB migration 
To test hypothesis 1, LDHA, LDHB and LDHC should be knocked down in MB cell lines 
individually and in combination. siRNAs which specifically target the non-homologous 
regions between the LDH family members should be used. Also, multiple single siRNA 
transfections for the same target should be used, and the effect on all LDH enzymes 
examined to reveal any off target effects and false positive results. The use of shRNA to 
create stable knockdown cell lines could also be investigated as this may improve the total 
knockdown of LDH protein expression. Western blot and qRT-PCR could be used to verify 
LDH knockdown, lactate assays to measure intracellular lactate production, growth curves 
or BrdU assays to measure proliferation, and live cell imaging gap closure assays, cell 
tracking and Boyden chamber assays to measure migration. If the hypothesis is accepted 
with these in vitro experiments, xenografts of MB cell lines with LDHA, LDHB and LDHC 
knocked down could be implanted and migration and growth studied in mouse models. 
 
To test hypothesis 2, lactate expression can be measured using lactate assays and cell 
migration can be measured using live cell imaging gap closure assays, cell tracking and 
Boyden chamber assays. As we have already shown, oxamate decreases MB lactate 
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expression, gap closure and cell velocity. Exogenous lactate can then be added to oxamate 
treated and untreated samples to see if the effect is reversed or migration even enhanced. 
As a control the effect of cell migration when the pH of the media is decreased in the 
presence and absence of oxamate should also be investigated.  
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Chapter 8: Appendices 
8.1 Cell culture 
Table 8. 1 Cell culture media concentrations 
The concentration of all components of DMEM (Gibco) and EMEM (ATCC) media. The 
concentration and components of ABM media (Lonza) is not publically available. 
Components DMEM Concentration 
(mg/L) 
EMEM concentration 
(mg/L) 
Glycine 30.0 7.50 
L-Alanyl-L-Glutamine 862.0  
L-Alanine   8.90 
L-Arginine hydrochloride 84.0 126.40 
L-Asparagine·H2O   15.0 
L-Aspartic Acid   13.3 
L-Cystine 2HCl 63.0 31.20 
L-Glutamic Acid   14.70 
L-Glutamine   292.00 
L-Histidine hydrochloride-H2O 42.0 41.90 
L-Isoleucine 105.0 52.50 
L-Leucine 105.0 52.50 
L-Lysine hydrochloride 146.0 72.50 
L-Methionine 30.0 15.00 
L-Phenylalanine 66.0 32.50 
L-Proline   11.50 
L-Serine 42.0 10.50 
L-Threonine 95.0 47.60 
L-Tryptophan 16.0 10.00 
L-Tyrosine 72.0  
L-Tyrosine·2Na·2H2O   51.90 
L-Valine 94.0 46.80 
Choline chloride 4.0 1.00 
D-Calcium pantothenate 4.0  
Folic Acid 4.0 1.00 
Niacinamide 4.0  
Pyridoxine hydrochloride 4.0  
Riboflavin 0.4 0.10 
Thiamine hydrochloride 4.0 1.00 
i-Inositol 7.2  
myo-Inositol   2.00 
Nicotinamide   1.00 
D-Pantothenic Acid  1.00 
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(hemicalcium) 
Pyridoxine·HCl   1.00 
Calcium Chloride (CaCl2-2H2O) 264.0 200.00 
Ferric Nitrate (Fe(NO3)3"9H2O) 0.1  
Magnesium Sulfate (MgSO4-
7H2O) 
200.0 97.67 
Potassium Chloride (KCl) 400.0 400.00 
Sodium Bicarbonate (NaHCO3) 3700.0 1500.00 
Sodium Chloride (NaCl) 6400.0 6800.00 
Sodium Phosphate monobasic 
(NaH2PO4-2H2O) 
141.0 140.00 
D-Glucose (Dextrose) 4500.0 1000.00 
Sodium Pyruvate   110.00 
Phenol Red 15.0 10.00 
 
 
As cell lines grow at different rates, different seeding densities were used for each cell line 
depending on the method and size of plate required. 
 
Table 8. 2 Cell line seeding densities 
A list of seeding densities used for each cell line and each method. 
Method Res256 UW402 DAOY CC2565 
Flow cytometry 175,000 200,000 175,000 220,000 
Immunocytochemistry 150,000 200,000 175,000 200,000 
Glycolysis assays 175,000 200,000 175,000 220,000 
Trypan blue growth curve 100,000 100,000 100,000 - 
MTS 10,000 10,000 10,000 10,000 
Cell cycle analysis 175,000 200,000 175,000 - 
Live cell imaging 90,000 110,000 105,000 120,000 
Seahorse assays - 5,000 - - 
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8.2 Antibodies and controls 
All antibodies were verified for specificity and dilutions were optimised using suitable 
positive controls. Isotype and peptide controls were used to show background non-specific 
antibody binding. 
Table 8. 3 Primary antibodies and controls 
A list of all primary antibodies, isotope controls and peptide controls used throughout this 
project including supplier, dilution and concentration details. 
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LD
H
A
 A
b
 
Novus 
Biologicals, UK: 
NBP1-48336 
Rabbit IgG Polyclonal 1.25 
mg/ml 
FC 
1:175 7.13 µg/ml 
ICC 
1:200 6.25 µg/ml 
WB 
1:10000 0.125 µg/ml 
LD
H
A
 A
b
 Abcam, UK: 
Ab9002 
Rabbit IgG Polyclonal 8 
mg/ml 
IHC 
1:200 40 µg/ml 
LD
H
B
 A
b
 
Novus 
Biologicals, UK:  
NB110-57160 
Rabbit IgG Monoclonal 1.192
mg/ml 
WB 
1:10000 0.1192 µg/ml 
LD
H
C
 A
b
 
Novus 
Biologicals, UK: 
NBP1-92065 
Rabbit IgG Polyclonal 0.1 
mg/ml 
WB 
1:10000 0.01 µg/ml 
C
yc
lo
p
h
ili
n
 A
 A
b
 Abcam, UK: 
ab41684 
Rabbit IgG Polyclonal 1 
mg/ml 
WB 
1:10000 0.1 µg/ml 
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Vector 
laboratories, 
UK: I-1000-5 
Rabbit IgG - 5 
mg/ml 
FC 
1:704 7.13 µg/ml 
ICC 
1:800 6.25 µg/ml 
LD
H
A
 P
e
p
ti
d
e Abcam, UK: 
ab77945 
- - - 2.9 
mg/ml 
IHC 
1:72 40 µg/ml 
 
Table 8. 4 Secondary antibodies 
A list of all secondary antibodies used throughout this project including supplier and 
dilution details. 
 
 
8.3 General reagents 
Ethanol dilutions were prepared from 100% ethanol (VWR Chemicals, UK) diluted with 
dH2O. 
Phosphate buffered saline (PBS) was prepared from 1 tablet (Gibco, UK) per 200 ml of 
dH2O. 
Secondary Antibody Supplier Dilution Technique 
Goat anti-rabbit IgG horseradish peroxidase-
conjugated antibody 
Promega, UK 1:10000 WB 
Goat anti-Rabbit IgG (H+L) Secondary 
antibody, Alexa Fluor® 488 conjugate  
Life 
technologies 
1:500 FC, ICC 
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8.4 Data tables 
 
Table 8. 5 UW402 glycolysis stress test ECAR values 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. 6 UW402 mito stress test OCR values 
 
 
 
 
 
 
 
 
 
 
 
 Oxamate concentration 
Time (minutes) 0 mM 25 mM 50 mM 75 mM 
1.316667 6.724002 5.079524 4.497735 3.348864 
7.883333 7.256867 6.148384 5.168 4.578109 
14.43333 7.688091 6.938797 5.825496 5.541783 
21.03333 20.70037 16.586 13.64747 11.2747 
27.78333 22.19029 16.34788 13.46975 11.41566 
34.33333 22.7791 16.10369 13.1581 11.44669 
40.93333 22.73546 15.52508 12.73053 11.09326 
47.48333 35.9423 24.77401 21.59535 17.67479 
54.21667 35.74357 24.42041 21.15665 18.06985 
60.78333 36.50943 25.27379 22.16012 19.13307 
67.33334 36.27774 25.25635 22.39841 19.13992 
73.900 12.92261 9.393786 8.269613 7.638348 
80.63333 8.906661 6.531011 5.60541 5.187985 
87.18333 6.787064 4.815057 4.13556 3.962328 
93.73333 5.742267 3.992441 3.395508 3.428574 
 Oxamate concentration 
Time (minutes) 0 mM 25 mM 50 mM 75 mM 
1.333793 34.76488 49.29679 47.88701 48.63081 
7.881901 31.81346 45.1576 43.30449 44.83168 
14.38709 31.23689 44.66371 42.76516 44.36759 
21.07856 17.47309 22.04477 20.81876 21.48061 
27.73829 16.03476 20.66394 19.27546 20.58977 
34.33002 14.70289 19.5867 18.28577 19.37666 
40.99344 14.12049 19.72562 18.04759 19.04017 
47.53249 37.63488 54.78997 54.1822 56.00465 
54.13707 35.27684 48.70515 48.35283 51.21973 
60.80385 33.09218 43.30798 43.29364 46.83463 
67.40776 31.31124 39.7234 39.92777 44.29288 
73.98987 9.189533 10.95291 10.28108 12.19311 
80.56021 8.841138 10.64142 9.771804 11.77515 
87.13837 8.263593 10.17809 9.186115 11.24815 
93.73035 8.122819 9.798483 8.556439 10.62132 
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Table 8. 7 Normoxic percent of UW402 gap open 
 
 
 
 
 
Table 8. 8 Hypoxic percent of UW402 gap open  
 
 
 
 
 
 
Table 8. 9 Normoxic percent of DAOY gap open 
 
 
 
 
 
 
Table 8. 10 Hypoxic percent of DAOY gap open 
 
 
 
 
 
  
Time (h) 0 mM 25 mM  50 mM 75 mM 
0 100.000 100.000 100.000 100.000 
12 72.95761 89.91592 90.76428 91.97936 
24 42.38092 75.37322 79.20071 81.6711 
36 22.13576 58.49208 68.41945 71.51654 
48 17.90879 39.7434 57.21005 62.2495 
60 12.85765 24.32674 48.27337 51.38609 
72 7.109293 14.25498 40.85857 43.87694 
Time (h) 0 mM 25 mM  50 mM 75 mM 
0 100.000 100.000 100.000 100.000 
12 72.69926 83.64594 85.13503 83.67969 
24 43.94141 65.63462 71.46614 69.12875 
36 22.15325 51.66134 53.28716 53.79872 
48 10.25202 37.58967 37.75329 42.1322 
60 4.278386 24.70683 23.00809 29.49649 
72 2.371606 12.08672 11.53279 18.01334 
Time (h) 0 mM 25 mM  50 mM 75 mM 
0 100.000 100.000 100.000 100.000 
12 56.70525 81.95163 83.81173 85.9054 
24 8.485645 53.58157 62.92254 68.59153 
36 0.000 39.93432 46.46189 50.91193 
48 0.000 25.45584 34.47672 36.71042 
60 0.000 15.63237 26.12859 30.0057 
72 0.000 8.048264 17.1291 24.86508 
Time (h) 0 mM 25 mM  50 mM 75 mM 
0 100.000 100.000 100.000 100.000 
12 45.62992 57.33262 69.8831 80.74903 
24 4.41449 16.68871 39.47671 58.70528 
36 0.000 0.8040317 11.4825 36.59418 
48 0.000 0.000 2.401348 17.95455 
60 0.000 0.000 0.000 6.555222 
72 0.000 0.000 0.000 1.936975 
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Table 8. 11 Normoxic percent of Res256 gap open 
 
 
 
 
 
 
 
 
Table 8. 12 Hypoxic percent of Res256 gap open 
  
 
 
 
 
 
 
Table 8. 13 Normoxic percentage of CC2565 gap open  
  
 
 
 
 
 
 
 
  
Time (h) 0 mM 25 mM 50 mM 75 mM 
0 100.000 100.000 100.000 100.000 
12 55.00558 79.72887 82.48143 83.95345 
24 21.55746 59.96629 62.71621 74.91957 
36 11.3959 40.57842 45.09589 65.24271 
48 2.897128 32.61958 34.85702 52.45018 
60 0.000 27.97503 29.57534 43.03582 
72 0.000 24.56827 22.94283 34.81963 
Time (h) 0 mM 25 mM  50 mM 75 mM 
0 100.000 100.000 100.000 100.000 
12 52.43987 74.3714 80.76254 86.14623 
24 14.27358 48.70612 65.14007 76.12798 
36 1.54345 26.56783 48.1868 68.77906 
48 0.075690 16.27405 37.55336 61.44084 
60 0.000 8.675204 26.71829 53.96623 
72 0.000 4.968843 14.98444 46.35791 
Time (h) 0 mM 25 mM  50 mM 75 mM 
0 100.000 100.000 100.000 100.000 
6 69.19373 65.46073 75.03381 80.68515 
12 33.79786 31.52891 42.99265 54.19223 
18 12.20321 7.18689 14.00064 29.00503 
24 5.452414 0.3257226 6.033094 14.74581 
30 4.102195 0.000 1.146512 5.216505 
36 2.5761 0.000 0.6364642 0.4182535 
42 2.498393 0.000 0.000 0.000 
48 0.6901008 0.000 0.000 0.000 
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Table 8. 14 Hypoxic percentage of CC2565 gap open  
  
 
 
 
 
 
 
 
 
Table 8. 15 Normoxic percent of UW402 LDHA siRNA gap open   
 
 
 
 
 
 
 
 
 
Table 8. 16 Hypoxic percent of UW402 LDHA siRNA gap open 
 
 
 
  
Time (h) 0 mM 25 mM  50 mM 75 mM 
0 100.000 100.000 100.000 100.000 
6 70.62749 82.20891 80.89485 87.69934 
12 48.77015 51.11961 62.67442 66.56536 
18 15.7706 33.33271 37.68022 43.27621 
24 8.26133 21.68873 26.43617 27.19167 
30 3.26639 15.89336 19.14224 21.23448 
36 2.70953 8.397049 14.45318 18.29422 
42 0.000 0.6303083 7.434309 14.07136 
48 0.000 0.000 6.415485 12.71045 
Time (h) Negative control Vehicle control Control siRNA LDHA siRNa 
0 100.000 100.000 100.000 100.000 
6 84.4853 78.91177 80.46989 80.31812 
12 66.24067 63.73087 62.70222 59.00372 
18 46.97665 48.74174 45.2886 39.14405 
24 24.28519 32.25374 35.15003 22.76333 
30 12.68252 20.01812 23.79796 15.73813 
36 5.38238 9.600607 17.01422 10.67853 
42 1.946037 4.263647 13.42926 5.177388 
48 0.4426023 1.004167 11.46002 2.683384 
Time (h) Negative control Vehicle control Control siRNA LDHA siRNa 
0 100.000 100.000 0.000 100.000 
6 91.12971 87.21796 3.682739 85.50527 
12 78.3047 71.18248 6.313004 68.33607 
18 63.80817 52.79757 7.944815 51.39471 
24 47.65376 37.30763 9.46837 30.34858 
30 32.81597 24.11273 10.26284 20.89192 
36 22.74322 18.41777 9.140515 13.15849 
42 15.14103 12.71772 7.254413 8.777395 
48 11.83009 8.682903 7.053405 7.029913 
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